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Abstract 
Stem  cells  are  defined  by  their  ability  to  make  more  stem  cells,  a  property  known  
as   self-­‐‑renewal   and   their   ability   to   generate   cells   that   enter   differentiation.   One  
mechanism  by  which  fate  decisions  can  be  effectively  controlled  in  stem  cells  is  through  
asymmetric   division   and   the   correct   partitioning   and   inheritance   of   cell   fate  
determinants.   While   hematopoietic   stem   cells   have   the   capacity   to   divide   through  
asymmetric   division,   the  molecular  machinery   that   regulates   this   process   is   unknown  
and  whether   its  activity   is  required   in  vivo   remains  unclear.  Here  we  show  that  Lis1,  a  
dynein-­‐‑binding  protein   and   regulator   of   asymmetric  division,   is   critically   required   for  
blood  development  and   for  hematopoietic   stem  cell   renewal   in   fetal  and  adult   life.      In  
particular,   conditional   deletion   of   Lis1   led   to   a   severe   bloodless   phenotype   and  
embryonic  lethality   in  vivo.     In  both  fetal  and  adult  mice,  loss  of  Lis1  led  to  a  failure  of  
normal   self-­‐‑renewal,   which   included   impaired   colony-­‐‑forming   ability   in   vitro   and  
defects   in   long-­‐‑term   reconstitution   ability   following   transplantation.   As   a   possible  
mechanism,  we  find  that   the  absence  of  Lis1   in  hematopoietic  cells,   in  part,  accelerates  
differentiation  linked  to  the  incorrect  inheritance  of  cell  fate  determinants.  Furthermore,  
using   a   live   cell   imaging   strategy,   we   find   that   the   incorrect   inheritance   of   cell   fate  
determinants   observed   following   the   loss   of   Lis1   is   due  defects   in   spindle  positioning  
and   orientation.      Finally,   using   two   animal   models   of   undifferentiated   myeloid  
leukemia,  we  show  that  Lis1  is  critical  for  the  aberrant  cell  growth  that  occurs  in  cancer.    
Deletion   of   Lis1   both   at   the   early   and   late   stages   of   myeloid   leukemia   blocked   its  
propagation  in  vivo  and  led  to  a  marked  improvement  in  survival.    Together,  these  data  
identify  Lis1  and  the  directed  control  of  asymmetric  division  as  key  regulators  of  normal  
and  malignant  hematopoietic  development.    
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1. Introduction  
1.1 Hematopoiesis and hematopoietic stem cells  
The  hematopoietic  system  is  a  regulated  developmental  cascade  that  produces  
distinct  cell  lineages  that  differentiate  into  the  mature  cell  types  of  the  blood  and  
generates  roughly  100  billion  blood  cells  every  day  (Orkin  2000).  This  process  is  
maintained  throughout  the  lifetime  of  an  individual  by  hematopoietic  stem  cells  (HSC).  
HSCs  are  defined  by  their  unique  ability  to  make  more  stem  cells,  a  property  known  as  
self-­‐‑renewal  and  their  ability  to  differentiate  into  all  blood  cell  lineages  (Weissman  2000).  
The  ability  of  HSCs  to  balance  self-­‐‑renewal  with  differentiation  is  critical  not  only  when  
the  body  replaces  cells  to  maintain  homeostasis,  but  also  during  development  when  a  
substantial  increase  in  HSC  numbers  is  required  to  ensure  enough  HSCs  are  generated  
for  postnatal  life  and  for  the  essential  geometric  expansion  of  differentiated  blood  cells  
that  are  immediately  required  for  embryonic  growth  and  development  (Lessard  et  al.  
2004).  In  addition,  the  capacity  of  HSCs  to  balance  self-­‐‑renewal  with  differentiation  is  
also  important  after  acute  injury  when  an  exponential  rise  in  the  HSC  population  is  
needed  for  rapid  and  effective  regeneration  (Morrison  2009).    
1.1.1 Hematopoietic stem cell development  
Blood  cell  production  during  embryonic  development  manifests  in  numerous  
anatomical  sites  that  are  separated  both  temporally  and  spatially.  The  first  definitive  
HSCs  appear  in  mice  around  embryonic  day  (E)  10.5  in  very  low  numbers  in  the  aorta-­‐‑
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gonad  mesonephros  region,  which  is  composed  of  the  dorsal  aorta,  its  surrounding  
mesenchyme  and  the  urogenital  ridges  (Cumano  et  al.  1996;  Godin  et  al.  1999;  
Medvinsky  and  Dzierzak  1996;  Muller  et  al.  1994).  Additionally,  HSCs  are  generated  in  
the  vitelline  and  umbilical  arteries  that  connect  the  dorsal  aorta  with  the  yolk  sac  and  the  
placenta,  respectively  (de  Bruijn  et  al.  2000).  The  placenta  also  has  the  capacity  for  de  
novo  generation  of  HSCs  and  accrues  a  reservoir  of  HSCs  during  mid-­‐‑gestation  (Alvarez-­‐‑
Silva  et  al.  2003;  Gekas  et  al.  2005;  Ottersbach  and  Dzierzak  2005).  However,  HSCs  
derived  from  the  aorta-­‐‑gonad  mesonephros  region,  placenta  and  yolk  sac  eventually  
colonize  the  fetal  liver,  which  serves  as  the  main  site  for  HSC  expansion  and  
differentiation  during  mid-­‐‑gestation  (Ema  and  Nakauchi  2000).  In  late  gestation,  
however,  hematopoietic  activity  moves  to  the  bone  marrow,  which  supports  both  self-­‐‑
renewal  and  differentiation  of  HSCs  in  specialized  microenvironmental  niches,  
including  well-­‐‑defined  endothelial/perivascular  and  osteoblastic  niches  (Orkin  and  Zon  
2008).    
1.1.2 Properties of fetal and adult hematopoietic stem cells   
During  development,  the  HSC  pool  expands  rapidly  in  the  fetal  liver  and  
therefore,  most  HSCs  in  the  fetal  liver  are  actively  cycling  (Morrison  et  al.  1995).  
However,  the  movement  of  hematopoietic  activity  from  the  fetal  liver  to  the  bone  
marrow  is  accompanied  by  a  shift  from  a  proliferative  fetal  HSC  to  a  quiescent,  
conservatively  self-­‐‑renewing  adult  HSC  (Mikkola  and  Orkin  2006;  Orkin  and  Zon  2008).  
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In  addition  to  differences  in  proliferative  capacity  between  fetal  and  adult  HSCs,  there  
are  several  phenotypic  and  functional  differences  between  fetal  and  adult  HSCs.    Fetal  
liver  HSCs  differ  from  adult  bone  marrow  HSCs  in  the  expression  of  specific  surface  
markers,  in  their  gene  expression  profiles  and  in  their  self-­‐‑renewal  and  developmental  
potential  (Harrison  et  al.  1997;  Ikuta  et  al.  1990;  Ivanova  et  al.  2002;  Kantor  et  al.  1992;  
Kim  et  al.  2005;  Morrison  et  al.  1995;  Phillips  et  al.  2000).  Several  genes  including  Rae28  
(Kim  et  al.  2004;  Ohta  et  al.  2002),  Meis1  (Azcoitia  et  al.  2005;  Hisa  et  al.  2004;  Kirito  et  al.  
2004),  c-­‐‑myb  (Mucenski  et  al.  1991;  Sandberg  et  al.  2005)  and  Cbp  (Rebel  et  al.  2002)  
regulate  the  maintenance  of  HSCs  throughout  fetal  and  adult  life.  In  contrast,  a  number  
of  transcriptional  regulators  including  Gfi-­‐‑1  (Hock  et  al.  2004a),  Tel/Etv6  (Hock  et  al.  
2004b)  and  Bmi1  (Park  et  al.  2003)  maintain  adult  but  not  fetal  HSCs,  whereas  the  
transcription  factor  and  endodermal  marker  Sox17  is  required  for  fetal  and  neonatal,  but  
not  adult  HSCs  (Kim  et  al.  2007).            
1.2 Asymmetric cell division 
Both  during  embryogenesis  and  in  adult  life,  stem  cells  are  defined  by  their  
ability  to  make  more  stem  cells,  a  property  known  as  self-­‐‑renewal  and  their  ability  to  
generate  cells  that  undergo  differentiation.  One  attractive  strategy  stem  cells  employ  to  
accomplish  these  two  tasks  is  asymmetric  division,  whereby  a  stem  cell  divides  and  
gives  rise  to  one  daughter  cell  that  maintains  the  stem  cell  fate  and  one  daughter  cell  
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that  differentiates  (Morrison  and  Kimble  2006).  By  contrast,  a  symmetric  division  
generates  daughter  cells  that  are  destined  to  acquire  the  same  fate.    
1.2.1 Principle mechanisms that govern asymmetric cell division 
Two  principle  mechanisms  govern  asymmetric  division:  intrinsic  or  extrinsic.  
During  an  “intrinsic”  asymmetric  division,  a  dividing  cell  asymmetrically  segregates  
fate  determinants  so  that  the  daughter  cells  inherit  different  levels,  thus  generating  
daughter  cells  that  adopt  distinct  cell  fates.  For  an  intrinsic  asymmetric  division  to  occur,  
a  cell  must  initially  set  up  an  axis  of  polarity  via  extrinsic  and/or  intrinsic  cues  and  
subsequently  use  this  axis  of  polarity  to  partition  fate  determinants  to  one  side  of  the  cell  
(Knoblich  2008).  Finally,  the  dividing  cell  must  orient  the  mitotic  spindle  along  the  axis  
of  asymmetry  to  facilitate  differential  inheritance  of  fate  determinants  into  the  two  
incipient  daughter  cells  (Congdon  and  Reya  2008).    
Alternatively,  an  “extrinsic”  mechanism  can  promote  an  asymmetric  division  
however,  unlike  an  intrinsically-­‐‑motivated  division,  an  extrinsic  mechanism  relies  on  the  
asymmetric  placement  of  daughter  cells  relative  to  external  cues  (Morrison  and  Kimble  
2006).  In  this  context,  the  stem  cell  is  in  close  contact  with  the  stem  cell  niche  and  
depends  on  localized  niche-­‐‑derived  signals  to  maintain  stem  cell  identity.  Importantly,  
regulated  orientation  of  the  mitotic  spindle  during  division  retains  only  one  of  the  two  
daughter  cells  in  the  stem  cell  niche  and  thus  only  one  of  the  daughter  cells  is  
adequately  exposed  to  extrinsic  cues  necessary  to  maintain  stem  cell  identity.  Thus,  an  
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extrinsic  mechanism  attains  an  asymmetric  outcome  even  though  the  division  itself  is  
intrinsically  symmetric.          
1.2.2 Asymmetric cell division in invertebrates 
The  fruitfly  Drosophila  melanogaster  is  a  model  system  for  asymmetric  division  
(Neumuller  and  Knoblich  2009).  Neuroblasts,  which  are  stem  cell-­‐‑like  progenitor  cells  of  
the  Drosophila  central  nervous  system,  divide  asymmetrically  to  generate  one  daughter  
cell  that  retains  neuroblast  properties  and  one  ganglion  mother  cell  (GMC),  which  
further  divides  to  generate  two  differentiating  neurons  (Neumuller  and  Knoblich  2009).  
During  an  asymmetric  division,  apical-­‐‑basal  polarity  is  established  and  maintained  by  
an  evolutionarily  conserved  protein-­‐‑complex,  the  Par  complex,  which  consists  of  
Bazooka/Par-­‐‑3  (Schober  et  al.  1999;  Wodarz  et  al.  1999),  Par-­‐‑6  (Petronczki  and  Knoblich  
2001)  and  atypical  protein  kinase  C  (aPKC)  (Rolls  et  al.  2003;  Wodarz  et  al.  2000).  Apical  
positioning  of  the  Par  complex  first  occurs  in  the  neurogenic  ectoderm  of  the  Drosophila  
embryo  and  is  maintained  during  neuroblast  delamination  (Betschinger  and  Knoblich  
2004).  This  apical  localization  of  the  Par  complex  is  required  to  drive  the  segregation  of  
cell  fate  determinants  to  the  opposite,  basal  side  of  the  cell  and  to  direct  the  orientation  
of  the  mitotic  spindle.    
Basal  localization  of  the  cell  fate  determinant  Numb  is  driven  by  a  cascade  of  
phosphorylation  events  triggered  by  the  mitotic  kinase  Aurora  A  (Wirtz-­‐‑Peitz  et  al.  
2008).  Specifically,  at  the  onset  of  mitosis,  Aurora  A  phosphorylates  Par-­‐‑6,  which  is  
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initially  in  complex  with  aPKC  and  lethal  (2)  giant  larvae  (Lgl).  This  phosphorylation  
event  leads  to  the  phosphorylation  of  Lgl  by  aPKC.    Phosphorylated  Lgl  no  longer  binds  
aPKC,  and  this  allows  for  the  exchange  of  Lgl  for  Par-­‐‑3  into  the  Par  complex.  This  
complex  remodeling  permits  aPKC  to  now  phosphorylate  Numb  which  triggers  its  
release  from  the  apical  neuroblast  cortex  and  its  subsequent  accumulation  on  the  
opposite,  basal  side  of  the  cell  (Smith  et  al.  2007;  Wirtz-­‐‑Peitz  et  al.  2008).    This  
mechanism  may  also  explain  how  other  segregating  determinants,  including  Brain  
Tumor  (Brat)  and  Prospero  (Pros)  localize  asymmetrically.  Once  inherited  by  the  
differentiated  daughter  cell,  Numb  represses  Notch  signaling  (Knoblich  2008)  and  Pros  
acts  as  both  a  transcriptional  activator  and  inhibitor  to  promote  a  differentiated  state  
(Choksi  et  al.  2006).  The  molecular  function  of  Brat  in  neuroblasts  is  currently  unknown,  
however,  recent  evidence  suggest  Brat  may  serve  as  a  transcriptional  activator  of  Pros  or  
influence  cell  fate  by  regulating  microRNAs  (Bello  et  al.  2006;  Knoblich  2008).      
Proper  orientation  of  the  mitotic  spindle  is  required  to  ensure  unequal  
inheritance  of  cell  fate  determinants.  Two  pathways  are  known  to  control  neuroblast  
spindle  orientation:  the  Gα-­‐‑Pins-­‐‑Mud  pathway  and  the  Pins-­‐‑Dlg-­‐‑Khc73  pathway  (Siller  
and  Doe  2009).  The  Gα-­‐‑Pins-­‐‑Mud  pathway  involves  an  adaptor  protein  called  
Inscuteable  (Insc),  which  localizes  apically  and  associates  with  the  Par  complex  by  
binding  to  Par-­‐‑3  and  recruits  a  GoLoco  domain  protein  called  Pins.  The  GoLoco  
domains  of  Pins  serve  as  binding  sites  for  the  heterotrimeric  G  protein  subunit  Gαi,  
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which  when  bound  leads  to  a  conformational  change  in  Pins  that  allows  for  its  
subsequent  interaction  with  mushroom  body  defective  (Mud).  The  mammalian  
orthologue  of  Mud  (NuMA)  interact  with  the  dynein-­‐‑dynactin  complex,  which  includes  
Lis1  (Merdes  et  al.  1996).  This  association  is  required  for  spindle  rocking  movements  and  
spindle  orientation  in  Drosophila  larval  neuroblasts  (Siller  and  Doe  2008b).  Although  
definitive  evidence  is  lacking,  it  is  thought  that  the  Gα-­‐‑Pins-­‐‑Mud  pathway  regulates  
spindle  orientation  by  recruiting  the  dynein-­‐‑dynactin-­‐‑Lis1  complex  to  the  apical  cortex.  
The  dynenin-­‐‑dynactin-­‐‑Lis1  complex  is  intimately  associated  with  astral  microtubules  
emanating  from  the  centrosome,  and  thus,  the  recruitment  of  this  complex  to  the  apical  
cortex  generates  a  pulling  force  to  lock  one  centrosome  at  the  apical  pole,  which  
subsequently  leads  to  the  proper  alignment  of  the  mitotic  spindle  along  the  apical/basal  
polarity  axis  (Siller  and  Doe  2009).  A  second  spindle  orientation  pathway  requires  Pins,  
the  membrane-­‐‑bound  guanylate  kinase  Dlg  (disc  large)  and  its  interaction  partner  Khc-­‐‑
73,  a  microtubule  plus-­‐‑end-­‐‑directed  kinesin  motor  heavy  chain  (Siegrist  and  Doe  2005).  
Implementation  of  this  pathway  involves  the  localization  of  Khc73  to  microtubule  plus-­‐‑
ends  where  it  binds  to  Dlg,  which  associate  with  Pins  to  facilitate  cortical  microtubule  
anchoring  and  subsequent  stabilization  of  the  mitotic  spindle  (Siegrist  and  Doe  2005).    
1.2.2 Asymmetric cell division in the Hematopoietic System 
Although  the  intricate  molecular  machineries  controlling  asymmetric  division  
are  well  characterized  in  Drosophila,  a  comprehensive  understanding  of  asymmetric  
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division  and  its  regulation  in  the  blood  system  is  lacking.    Pioneering  studies  in  the  
hematopoietic  system  using  a  clone-­‐‑splitting  technique  demonstrated  that  the  progeny  
of  hematopoietic  precursor  cells  could  adopt  asymmetric  fates  (Ema  et  al.  2000;  Punzel  et  
al.  2003).  However,  these  earlier  studies  did  not  provide  constitute  evidence  of  an  
intrinsically-­‐‑driven  asymmetric  cell  division.  That  is,  following  an  intrinsically  
symmetric  division,  two  identical  daughter  cells  could  be  differentially  exposed  to  an  
extrinsic  cue,  thus  changing  the  fate  of  one  of  the  two  daughter  cells  without  being  
linked  to  the  mitosis  itself.    The  challenge  of  definitively  showing  that  hematopoietic  
stem  cells  can  asymmetric  divide  via  an  intrinsic  mechanism  is  that,  for  the  most  part,  
dependable  markers  for  the  prospective  and  noninvasive  discrimination  of  
differentiating  and  immature  hematopoietic  cells  is  lacking.  This  obstacle  was  overcome  
by  using  transgenic  notch  reporter  (TNR)  mice,  in  which  GFP  expression  indicates  notch  
pathway  activation  (Mizutani  et  al.  2007).  The  TNR  system  revealed  that  hematopoietic  
stem  cells  (HSC)  highly  express  GFP  and  that  GFP  expression  is  down-­‐‑regulated  as  
HSCs  differentiate  (Duncan  et  al.  2005).  Thus,  these  data  indicate  that  GFP  expression  
could  serve  as  a  surrogate  marker  for  HSC  identity  and  that  the  fate  of  daughter  cells  
could  be  determined  by  tracking  dividing  GFP-­‐‑positive  HSCs  in  real-­‐‑time  via  time-­‐‑lapse  
microscopy.  This  approach  convincingly  demonstrated  that  HSCs  could  undergo  both  
symmetric  division  (two  GFP+  progeny)  and  asymmetric  division  (one  GFP+  and  one  
GFP-­‐‑  daughter)  (Wu  et  al.  2007).    
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1.2.2.1  Numb  is  an  important  cell  fate  determinant  in  the  hematopoietic  system  
Following  the  observation  that  HSCs  could,  in  fact,  undergo  both  symmetric  and  
asymmetric  division  came  the  discovery  that  the  balance  between  asymmetric  and  
symmetric  division  of  HSCs  is  responsive  to  intrinsic  cues  linked  to  mitosis.  Specifically,  
the  cell  fate  determinant  Numb  was  shown  to  be  selectively  partitioned  into  the  
differentiating  daughter  cell  during  an  asymmetric  division  (Wu  et  al.  2007).  
Mechanistically,  Numb  induces  differentiation  by  inhibiting  Notch  signaling,  most  likely  
by  controlling  the  intracellular  trafficking  of  Notch  intermediates  (Berdnik  et  al.  2002).  In  
line  with  this,  Notch  reporter  activity  in  HSCs  was  increasingly  more  repressed  with  
increasing  levels  of  Numb  (Wu  et  al.  2007).  Furthermore,  ectopic  expression  of  Numb  
enhances  the  differentiation  of  HSCs  in  vitro  (Wu  et  al.  2007).  These  data  support  a  role  
for  Numb  as  a  cell  fate  determinant  in  the  hematopoietic  system,  in  part  by  inhibiting  
Notch  signaling.    
1.2.2.1  Regulators  of  asymmetric  division  implicated  in  hematopoietic  stem  cell  
function  
In  addition  to  Numb,  several  polarity  proteins  and  cell  fate  determinants  
implicated  in  asymmetric  cell  division  in  other  stem  cell  model  systems  have  recently  
been  shown  to  play  a  role  in  HSC  activity.  Genetic  deletion  or  shRNA-­‐‑mediated  
knockdown  of  the  cell  fate  determinant  Musashi2  (Msi2)  leads  to  a  reduction  in  the  
frequency  and  absolute  number  of  HSC-­‐‑enriched  cells  (de  Andres-­‐‑Aguayo  et  al.  2011;  
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Ito  et  al.  2010).  Furthermore,  Msi2-­‐‑deficient  HSCs  have  impaired  repopulation  ability  in  
vivo  and  undergo  premature  differentiation  in  vitro  (de  Andres-­‐‑Aguayo  et  al.  2011;  Hope  
et  al.  2010;  Kharas  et  al.  2010).  An  RNAi  screen  identified  Pard6a,  one  of  the  four  
mammalian  pard6  proteins  that  are  homologs  of  the  C.  elegans  PARD6,  and  Prkcz,  one  of  
the  two  mammalian  homologs  of  aPKC,  as  necessary  for  the  maintenance  of  HSCs  in  
adult  life  (Hope  et  al.  2010).  In  addition,  Prox1,  the  vertebrate  cognate  of  Drosophila  
Prospero,  was  shown  to  promote  differentiation  at  the  expense  of  HSC  maintenance  
(Hope  et  al.  2010).  The  cell  polarity  gene  Llgl1  (lethal  giant  larvae  homolog  1)  plays  an  
important  role  in  regulation  of  HSCs.  Conditional  deletion  of  Llgl1  leads  to  expansion  of  
HSCs  and  increased  cell  fitness  (Heidel  et  al.  2013).  Interestingly,  recent  studies  suggest  
fatty  acid  oxidation  (FAO)  plays  a  role  in  the  regulation  of  asymmetric  HSC  division.  
Specifically,  genetic  deletion  of  the  FAO  regulator  Pml,  induced  the  differentiation  of  
HSCs  in  part  due  to  an  increase  in  symmetric,  differentiating  divisions  (Ito  et  al.  2012).  
Collectively,  these  data  suggest  that  several  previously  identified  asymmetric  division  
regulators  play  a  critical  functional  role  in  normal  HSC  activity.  
1.2.2.2  Balance  of  the  modes  of  hematopoietic  stem  cell  division  depends  on  the  
microenvironment  
Along  with  data  showing  HSCs  can  asymmetrically  divide  via  intrinsic  
mechanisms,  it  has  also  been  shown  that  the  balance  between  symmetric  and  
asymmetric  division  in  part,  depends  on  the  microenvironment.  Studies  driven  largely  
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by  the  utilization  of  the  clone-­‐‑splitting  technique  demonstrated  that  the  type  of  stroma  
or  cytokines  used  in  culture  influence  the  frequencies  of  division  patterns  (Ema  et  al.  
2000;  Punzel  et  al.  2003;  Takano  et  al.  2004).  Later  work,  using  the  transgenic  notch  
reporter  system,  which  did  not  require  any  micromanipulation  of  progeny  cells,  further  
showed  that  when  HSCs  were  cultured  on  a  pro-­‐‑differentiation  osteoblastic  cell  line,  
HSCs  predominately  undergo  asymmetric  division.  In  contrast,  HSCs  placed  on  a  
stromal  cell  line  previously  shown  to  maintain  HSCs  fate  in  vitro,  preferentially  divide  
symmetrically  (Wu  et  al.  2007).    Collectively,  these  data  suggest  that  the  balance  between  
modes  of  division  is  not  hardwired  in  HSCs,  but  instead  is  responsive  to  extrinsic  cues.    
1.2.2.3  Asymmetric  cell  division  during  activation  of  the  immune  system    
In  addition  to  HSCs,  certain  differentiated  hematopoietic  cells,  under  the  right  
conditions,  can  undergo  asymmetric  division  as  well.  Following  antigenic  stimulation,  
naïve  T  and  B  cell  of  the  adaptive  immune  system  respond  by  generating  terminally  
differentiated  effector  and  stem  cell-­‐‑like  memory  daughter  cells.    In  context  of  T  
lymphocytes,  a  naïve  T  cell  becomes  activated  when  it  engages  with  an  antigen-­‐‑
presenting  cell  via  the  immunological  synapse  (Saito  and  Yokosuka  2006).  The  formation  
of  the  immunological  synapse  results  in  facultative  polarity  of  the  lymphocyte,  which  
permits  the  T  cell  to  direct  its  mitotic  spindle  perpendicular  to  the  synapse.  
Subsequently,  several  molecules  asymmetrically  distribute  to  one  side  of  the  cell  
including  the  immune  receptors  leukocyte  function-­‐‑associated-­‐‑1  (LFA-­‐‑1),  CD8  and  CD3.  
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In  addition,  the  cell  fate  determinant  Numb  and  members  of  the  aPKC-­‐‑Par3-­‐‑Par6  
complex  and  the  Scrib-­‐‑Dlg-­‐‑Lgl  family  of  polarity  proteins  polarize  in  the  T  cell,  
indicating  that  previously  defined  mechanisms  of  asymmetric  division  were  most  likely  
conserved  in  lymphocytes  (Chang  et  al.  2007).  As  the  naïve  T  cell  divides,  the  incipient  
daughter  cells  inherit  unequal  amounts  of  several  of  these  proteins.  Phenotypic  and  
functional  analyses  indicated  that  the  daughter  “proximal”  to  the  antigen-­‐‑presenting  cell  
undergoes  transit  amplification  and  eventually  terminally  differentiates  into  an  effector  
cell,  whereas  the  daughter  “distal”  to  the  contact  site  becomes  a  self-­‐‑renewing  memory  
cell  that  maintains  the  capacity  to  asymmetrically  divide  if  re-­‐‑challenged  (Chang  et  al.  
2007).  Collectively,  these  data  indicate  that  asymmetric  division  of  activated  T  cells  was  
responsible  in  part,  for  the  production  of  functionally  distinct  daughter  cells  and  that  
previously  defined  mechanisms  of  asymmetric  division  were  most  likely  conserved  in  
lymphocytes.  
1.2.3 Dysregulation of asymmetric division in cancer 
In  context  of  oncogenesis,  stem  cells  play  a  crucial  role  in  the  formation  and  
maintenance  of  human  tumors  (Clarke  and  Fuller  2006;  Reya  et  al.  2001).  The  
observation  that  only  a  small  population  of  tumor  cells,  which  have  stem  cell-­‐‑like  
properties,  can  reinitiate  tumor  formation  in  immunocompromised  mice  has  led  to  the  
cancer  stem  cell  hypothesis,  which  predicts  that  tumors  are  maintained  by  so-­‐‑called  
cancer  stem  cells  that  give  rise  to  all  the  other  tumor  cell-­‐‑types  (Bonnet  and  Dick  1997;  
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Lapidot  et  al.  1994;  Reya  et  al.  2001).  Furthermore,  this  hypothesis  raises  the  possibility  
that  stem  cells  might  even  be  at  the  origin  of  a  tumor,  and  therefore,  defects  in  stem  cells  
might  be  among  the  earliest  events  that  induce  tumor  formation  (Clarke  and  Fuller  
2006).  In  homeostasis,  asymmetric  cell  division  is  one  mechanism  stem  cells  employ  to  
properly  control  self-­‐‑renewal  activity  and  ensure  normal  stem  cell  maintenance.  Since  
uncontrolled  self-­‐‑renewal  can  be  a  hallmark  of  oncogenesis  (Reya  et  al.  2001),  
dysregulation  of  asymmetric  cell  division  may  account  for  this  aberrant  self-­‐‑renewal  
activity  in  cancer.    
1.2.3.1  Asymmetric  division  regulators  implicated  in  tumor  formation  
In  Drosophila,  defects  in  asymmetric  cell  division  can  transform  neural  stem  cells  
into  tumor-­‐‑initiating  cells  and  thus,  several  of  the  critical  regulators  of  asymmetric  cell  
division,  including  Brat,  Numb  and  Pros,  act  as  tumor  suppressors  (Bello  et  al.  2006;  
Betschinger  et  al.  2006;  Caussinus  and  Gonzalez  2005;  Gonzalez  2007;  Lee  et  al.  2006a;  
Lee  et  al.  2006b;  Wang  et  al.  2007;  Wang  et  al.  2006).  When  any  of  these  genes  are  
mutated,  neuroblasts,  in  part,  begin  dividing  symmetrically  which  leads  to  the  
production  of  excess  neuroblasts  at  the  expense  of  differentiating  neurons.  Importantly,  
vertebrate  homologs  of  genes  regulating  asymmetric  cell  division  in  Drosophila  have  
been  shown  to  be  dysregulated  in  human  malignancies.  For  example,  loss  of  Numb  is  
responsible  for  the  hyperactivation  of  Notch  signaling  observed  in  breast  cancer  (Pece  et  
al.  2004).  Atypical  PKCι  is  overexpressed  in  non-­‐‑small  cell  lung  cancer  (Regala  et  al.  
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2005),  human  Lgl  (Hugl-­‐‑1)  and  atypical  PKCζ  fail  to  asymmetrically  localize  in  ovarian  
epithelial  cancers  (Grifoni  et  al.  2007),  and  both  human  Scrib  and  Dlg  mislocalize  in  
colon  cancer  (Gardiol  et  al.  2006).  Recently  it  was  shown,  in  a  mouse  mammary  tumor  
model,  that  transformed  mammary  stem  cells  mislocalized  Numb  and  therefore,  loss  the  
ability  to  effectively  divide  asymmetrically  (Cicalese  et  al.  2009).  Instead,  these  cells  
perpetually  underwent  symmetric  renewal  divisions,  which  lead  to  the  formation  of  a  
tumor.    
1.2.3.2  Dysregulation  of  asymmetric  cell  division  in  malignant  hematopoietic  
development  
In  context  of  hematopoietic  malignancy,  it  was  recently  shown  that  certain  
leukemia-­‐‑associated  oncogenes  could  influence  the  balance  of  symmetric  and  
asymmetric  division.  While  the  tyrosine  kinase  BCR-­‐‑ABL,  which  is  the  hallmark  genetic  
abnormality  in  chronic  myelogenous  leukemia  (CML)  has  a  specific  and  profound  
impact  on  cell  proliferation  and  survival,  NUP98-­‐‑HOXA9,  an  oncogene  associated  with  
late  stage  CML  and  some  de  novo  AMLs,  does  not  influence  proliferation  and  survival  
and  instead,  shifts  the  normal  balance  of  asymmetric  and  symmetric  division  towards  
symmetric  renewal  divisions  (Wu  et  al.  2007).  This  may  explain  why  the  acquisition  of  
certain  oncogenes,  such  as  NUP98-­‐‑HOXA9,  leads  to  the  preferential  growth  of  immature  
cells  and  reduced  differentiation.    Since  CML  is  known  to  progress  from  a  slow  growing  
chronic  phase  where  the  ability  to  differentiate  is  maintained  (Witte  2001)  to  an  
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aggressive,  blast  crisis  stage  where  the  capacity  to  differentiate  is  nearly  eliminated  
(Calabretta  and  Perrotti  2004),  the  observation  that  secondary  translocations  such  as  
NUP98-­‐‑HOXA9  can  cause  a  significant  shift  in  the  pattern  of  division  suggest  that  
dysregulation  of  HSC  division  pattern  may,  in  part,  be  responsible  for  disease  
progression.      
Whether  known  regulators  of  asymmetric  division  play  a  role  in  hematological  
malignancies  is  largely  unknown,  however,  recently  it  was  shown  that  repression  of  the  
polarity  protein  Lgl1  is  associated  with  human  leukemia  development  and  an  adverse  
prognosis  in  cytogentically  normal  acute  myelogenous  leukemia  (AML)  (Heidel  et  al.  
2013).  Furthermore,  mutations  of  Llgl2,  a  close  human  homologue  of  Llgl1,  have  been  
identified  in  progression  from  congenital  neutropenia  to  AML  (Beekman  et  al.  2012).  
Although  the  functional  consequences  of  expression  changes  of  Llgl1,2  has  not  be  
shown,  these  data,  nevertheless,  suggest  dysregulation  of  asymmetric  cell  division  may  
play  a  role  in  malignant  hematopoietic  development.  
1.3 Lis1 (Pafah1b)   
The  LIS1  gene  encodes  a  45-­‐‑kDA  protein  that  contains  a  N-­‐‑terminal  Lis-­‐‑H  
domain,  followed  by  a  coiled-­‐‑coil  region  and  a  C-­‐‑terminal  series  of  WD  repeats.  These  
seven  WD  repeats  form  a  propeller-­‐‑like  structure  that  serves  as  a  platform  for  LIS1  to  
engage  in  numerous  protein-­‐‑protein  interactions  (Cahana  et  al.  2001;  Caspi  et  al.  2000;  
Gerlitz  et  al.  2005;  Neer  et  al.  1994;  Reiner  et  al.  1993;  Sapir  et  al.  1997;  Sasaki  et  al.  2000;  
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Smith  et  al.  2000;  Tai  et  al.  2002;  Tarricone  et  al.  2004).  LIS1  was  first  identified  as  a  non-­‐‑
catalytic  subunit  of  the  brain  cytosolic  platelet-­‐‑activating  factor  acetylhydrolase  
(PAFAH)  isoform  1b,  an  enzyme  involved  in  the  deactivation  of  platelet-­‐‑activating  
factor  (PAF),  a  lipid  messenger  that  has  a  critical  role  in  the  inflammatory  response  
(Hattori  et  al.  1994;  Reiner  et  al.  1993).  Thus,  the  formal  gene  name  for  LIS1  is  PAFAH1b.  
The  1b  isoform  of  this  enzyme,  which  is  composed  of  LIS1  and  two  catalytic  alpha  
subunits  (α1  and  α2),  is  specific  to  the  brain  cytosol  and  evidence  to  date  has  not  
revealed  a  definitive  role  for  LIS1  in  PAFAH  enzymatic  regulation.  A  non-­‐‑enzymatic  
function  of  LIS1  was  first  identified  in  the  filamentous  fungus  Aspergillus  nidulans.  
Mutations  in  nudF,  the  fungal  homologue  of  LIS1,  caused  a  severe  defect  in  
nucleokinesis,  a  process  that  involves  the  migration  of  nuclei  into  and  within  the  
growing  tip  of  hyphae  (Xiang  et  al.  1995).  The  nudF  phenotype  was  identical  to  that  
generated  by  mutations  in  genes  encoding  subunits  of  the  microtubule  motor  protein  
cytoplasmic  dynein  (Willins  et  al.  1997).  This,  along  with  studies  in  Saccharomyces  
cerevisiae  and  Drosophila,  identified  LIS1  as  part  of  an  evolutionarily  conserved  pathway  
that  regulates  the  microtubule  motor  protein  dynein  (Lee  et  al.  2003;  Lei  and  Warrior  
2000).  LIS1  does,  in  fact,  bind  to  verterbrate  cytoplasmic  dynein  (Faulkner  et  al.  2000;  
Sasaki  et  al.  2000;  Smith  et  al.  2000)  as  well  as  to  other  proteins  including  CLIP-­‐‑70  
(Coquelle  et  al.  2002;  Tai  et  al.  2002),  NDEL  (Kitagawa  et  al.  2000),  NDEL1  (Niethammer  
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et  al.  2000),  and  mNudC  (Morris  et  al.  1998).  Each  of  these  Lis1-­‐‑interacting  proteins,  in  
turn,  dynamically  associates  with  dynein  (Aumais  et  al.  2001;  Sasaki  et  al.  2000).    
In  cultured  mammalian  cells,  it  was  shown  that  LIS1  co-­‐‑localizes  with  
cytoplasmic  dynein  at  the  cell  cortex  and  at  the  mitotic  kinetochores.  Functionally,  
elevated  or  reduced  levels  of  LIS1  results  in  a  pronounced  delay  of  mitotic  progression  
accompanied  with  a  chromosomal  alignment  defect  in  metaphase  (Faulkner  et  al.  2000).  
Supporting  a  role  for  Lis1  in  cell  division,  following  either  shRNA-­‐‑mediated  knockdown  
or  the  controlled  genetic  deletion  of  Lis1  in  neural  progenitor  cells  impaired  cell  cycle  
progression  (Tsai  et  al.  2005;  Yingling  et  al.  2008).    Lis1  also  has  an  important  function  in  
spermatogenesis.  Using  a  gene  trap  mouse  line  with  selective  disruption  of  a  testis-­‐‑
specific  Lis1  transcript,  it  was  shown  that  loss  of  Lis1  leads  to  a  blockade  of  spermatid  
differentiation  (Nayernia  et  al.  2003).  Recently  it  was  demonstrated  that  Lis1  regulates  
BMP  signaling  and  E-­‐‑cadherin-­‐‑mediated  adhesion  to  control  germline  stem  cell  (GSC)  
self-­‐‑renewal  and  proliferation  in  the  Drosophila  ovary  (Chen  et  al.  2010).    Importantly,  
complete  loss  of  Lis1  results  in  peri-­‐‑implantation  lethality,  indicating  that  Lis1  is  a  critical  
gene  (Cahana  et  al.  2001;  Hirotsune  et  al.  1998).        
1.3.1 Role of the Lis1 gene in lissencephaly 
The  PAFAH1b  gene  is  designated  as  LIS1,  because  heterozygous  mutations  of  
this  gene  cause  a  severe  brain  developmental  disorder  known  as  lissencephaly  (Lo  Nigro  
et  al.  1997;  Reiner  et  al.  1993).  Unlike  the  conspicuous  convolutions  of  the  normal  brain,  
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the  brain  surface  of  individuals  with  lissencephaly  is  completely  devoid  of  the  normal  
sulci  and  gyri,  which  accounts  for  the  name  of  the  disease,  which  translates  from  Greek  
to  “smooth  brain”  (Dobyns  et  al.  1993).  During  normal  cortical  development,  neurons  
migrate  in  an  “inside-­‐‑out”  fashion  to  establish  the  neuronal  layers  of  the  cerebral  cortex  
(Gupta  et  al.  2002).  As  a  result  of  proper  implementation  of  this  process  the  brain  
appears  normal.  However,  during  cortical  development  in  individuals  with  
lissencephaly,  migratory  neurons  fail  to  reach  their  final  cortical  position  within  the  
cerebral  cortex  This,  consequently,  leads  to  a  paucity  of  gyri  and  sulci  on  the  brain  
surface,  which  accounts  for  the  overall  “smooth  brain”  phenotype  (Wynshaw-­‐‑Boris  
2007).  Studies  in  mice  have  confirmed  that  a  defect  in  Lis1-­‐‑mediated  neuronal  migration  
is  primarily  responsible  for  this  gross  phenotype.  Mice  with  graded  reduction  in  Lis1  
dosage  exhibited  a  LIS1  dose-­‐‑dependent  disorganization  of  the  cortical  layers,  the  
hippocampus  and  the  olfactory  bulb  (Fleck  et  al.  2000;  Hirotsune  et  al.  1998;  Paylor  et  al.  
1999),  and  thus,  faithfully  recapitulated  the  human  disorder.    Importantly,  mice  with  
reduced  levels  of  Lis1  display  migrational  defects  (Hirotsune  et  al.  1998).  Furthermore,  a  
requirement  for  Lis1  in  neuronal  migration  was  demonstrated  by  time-­‐‑lapse  
videomicroscopy  of  neuronal  migration  in  slice  cultures  from  embryonic  cortex  (Shu  et  
al.  2004;  Youn  et  al.  2009).  Mechanistically,  LIS1  is  required  for  nuclear  movement  
during  neuronal  migration  by  coupling  the  nucleus  to  the  centrosome  in  a  dynein-­‐‑
dependent  manner  (Tanaka  et  al.  2004).    
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1.3.2 Lis1 in regulation of spindle orientation 
A  role  for  Lis1  in  spindle  orientation  and  positioning  has  been  demonstrated  in  
the  budding  yeast  Saccharomyces  cerevisiae  (Lee  et  al.  2003),  C.  elegans  (Cockell  et  al.  2004),  
Drosophila  neuroblasts  (Siller  and  Doe  2008a),  in  cultured  epithelial  cells  (Faulkner  et  al.  
2000)  and  in  the  mammalian  neuroepithelium  (Yingling  et  al.  2008).  In  S.  cerevisiae,  Pac1  
(related  to  mammalian  Lis1)  is  required  for  polarized  transport  of  the  astral  microtubule  
plus  ends  into  the  mother-­‐‑bud  neck  of  dividing  yeast  cells  (Lee  et  al.  2003).  Likewise,  in  
C.  elegans,  a  membrane-­‐‑anchored  protein  complex  containing  Lis1  and  dynein  generates  
pulling  forces  on  the  astral  microtubules  to  properly  position  the  mitotic  spindle  
(Cockell  et  al.  2004).  In  this  system,  the  protein  LIN-­‐‑5  (Mud  in  flies;  NuMA  in  mammals)  
regulates  the  interaction  of  the  Lis1/dynein  complex  with  the  cell  cortex  (Srinivasan  et  al.  
2003).  In  cultured  mammalian  epithelial  cells,  the  mitotic  spindles  of  dividing  cells  
normally  lie  parallel  to  the  epithelial  plane.  However,  overexpression  of  LIS1  
randomized  spindle  orientation  (Faulkner  et  al.  2000).    These  data  suggest  Lis1  regulates  
spindle  orientation  in  epithelial  cells.    
Recently,  a  role  for  Lis1  in  spindle  orientation  has  extended  to  the  mammalian  
nervous  system.  During  development,  neuroepithelial  stem  cells  (NESCs)  perpetually  
undergo  symmetrical  renewal  divisions  until  the  onset  of  neurogenesis  when  NESCs  
switch  to  an  asymmetric  mode  of  division  to  generate  one  radial  glial  progenitor  cell  
(RGPCs)  and  one  migratory  post-­‐‑mitotic  neuron.  In  order  for  a  NESC  to  undergo  a  
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symmetric  renewal  division,  it  must  precisely  align  its  mitotic  spindle  in  such  a  way  to  
facilitate  equal  distribution  of  asymmetrically  localized  determinants  such  as  β-­‐‑catenin,  
aPKC,  Numb  and  cadherins  into  the  incipient  daughter  cells.  However,  in  the  absence  of  
Lis1,  spindle  cleavage  planes  of  NESCs  and  RGPCs  become  randomized  and  as  a  result  
Lis1  mutant  NESCs  and  RGPCs  predominantly  divide  asymmetrically  thereby  reducing  
the  progenitor  pool  population  and  decreasing  the  total  number  of  cortical  neurons  
(Yingling  et  al.  2008).  Randomization  of  spindle  orientation  occurs  in  Lis1  mutant  cells  
because  in  the  absence  of  Lis1,  cortical  microtubule  capture  and  stability  is  impaired  and  
thus,  Lis1-­‐‑deficient  cells  cannot  effectively  rotate  the  mitotic  spindle  to  a  precise  
orientation  that  facilitates  symmetric  division  (Yingling  et  al.  2008).  Collectively,  these  
studies  underscore  Lis1  as  a  core  component  of  the  spindle-­‐‑positioning  machinery  
regulating  asymmetric  cell  division  in  a  variety  of  organisms  and  cell  types.    
  
  21  
2. Materials and Methods 
2.1 Generation and analysis of mice 
Hypomorphic  conditional  knockout  mice  (Lis1f/f,  also  Lis1-­‐‑loxP  or  Pafah1b1-­‐‑loxP;  
Strain:  129-­‐‑Pafah1b1tm2awb/J)  (Hirotsune  et  al.  1998)  were  mated  with  either  Rosa26-­‐‑
CreERT2  mice  (Strain:  B6;129-­‐‑Gt(ROSA)26Sortm1(cre/Esr1)Tyj)  (Ventura  et  al.  2007)  or  Vav-­‐‑Cre  
transgenic  mice(de  Boer  et  al.  2003).    Vav-­‐‑Cre  reporter  mice  were  generated  by  crossing  
Vav-­‐‑Cre  mice  to  Rosa26-­‐‑stop-­‐‑tdTomato  mice  (Stain:  B6.Cg-­‐‑Gt(ROSA)26Sortm9(CAG-­‐‑
tdTomato)Hze/J;  Stock  #:  007909).  B6-­‐‑CD45.1  (Strain:  B6.SJL-­‐‑PtprcaPepcb/BoyJ)  mice  were  used  
as  transplant  recipients.  All  mice  were  6-­‐‑16  weeks  of  age.  Mice  were  bred  and  
maintained  in  the  animal  care  facilities  at  Duke  University  Medical  Center  and  the  
University  of  California,  San  Diego.  Tamoxifen  treatment  of  mice  was  done  as  
previously  described  (Yang  et  al.  2008).  Briefly,  adult  mice  were  administered  tamoxifen  
(Sigma)  in  corn  oil  (20  mg/ml)  daily  by  oral  gavage  at  ~114  µμg  tamoxifen  per  gram  of  
body  weight  per  day  for  five  consecutive  days.  For  leukemia  experiments,  all  recipient  
mice  weighed  ~17.5-­‐‑20  grams  and  were  administered  2  mg  of  tamoxifen  per  day  for  five  
consecutive  days.  Embryos  were  suspended  in  phosphate-­‐‑buffered  saline  and  visualized  
with  a  Leica  MZ16  FA  Fluorescence  Stereomicroscope.  Embryos  were  fixed  in  4%  
paraformaldehyde  and  embedded  in  paraffin  according  to  standard  protocols.  Sections  
(5  µμm)  were  obtained  for  hematoxylin  and  eosin  (H&E)  staining.  All  animal  experiments  
were  performed  according  to  protocols  approved  by  the  Duke  University  Institutional  
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Animal  Care  and  Use  Committee  and  the  University  of  California,  San  Diego  
Institutional  Animal  Care  and  Use  Committee.    
2.2 Cell isolation and FACS analysis 
Cells  were  suspended  in  Hanks’  balanced  salt  solution  (HBSS)  (Gibco,  Life  
Technologies)  containing  5%  (vol/vol)  fetal  bovine  serum  and  2  mM  EDTA  and  
prepared  for  FACS  analysis  and  sorting  as  previously  described  (Domen  et  al.  2000).  The  
following  antibodies  were  used  to  define  lineage  positive  cells:  145-­‐‑2C11  (CD3ε),  GK1.5  
(CD4),  53-­‐‑6.7  (CD8),  RB6-­‐‑8C5  (Ly-­‐‑6G/Gr1),  M1/70  (CD11b/Mac-­‐‑1),  TER119  (Ly-­‐‑
76/TER119),  6B2  (CD45R/B220),  and  MB19-­‐‑1  (CD19).  Red  blood  cells  were  lysed  using  
RBC  Lysis  Buffer  (eBioscience)  before  staining  for  lineage  markers.  For  fetal  liver  cell  
isolation  and  FACS  analysis,  single-­‐‑cell  suspensions  were  prepared  by  disaggregation  
and  passing  through  a  74-­‐‑µμm-­‐‑nylon  mesh  (Corning).  Placentas  were  prepared  as  
described  previously  (Gekas  et  al.  2008).  Yolk  sacs  were  prepared  as  described  
previously  (Yoder  et  al.  1997).  For  fetal  HSC  cell  population  analysis,  the  lineage  
antibody  cocktail  was  used  without  anti-­‐‑Mac-­‐‑1.  The  following  additional  antibodies  
were  used  to  define  HSC  populations:  2B8  (CD117/c-­‐‑kit),  D7  (Ly-­‐‑6A/E/Sca-­‐‑1),  AA4.1  
(CD93/C1qRp),  HM48-­‐‑1  (CD48/BCM1),  TC15-­‐‑12F12.2  (CD150),  A2F10  (CD135/Flt3)  and  
RAM34  (CD34).  Fetal  HSCs  were  defined  as  c-­‐‑Kit+  Lin-­‐‑  AA4.1+  (KL  AA4.1+).  Yolk  sac  
HSCs/progenitors  were  defined  as  CD34+.  Placenta  HSCs/progenitors  were  defined  as  c-­‐‑
Kit+  CD34+.  Adult  HSCs  were  defined  as  either  c-­‐‑Kit+  Lin-­‐‑  Sca1+  CD48-­‐‑  CD150+  (KLS  
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CD48-­‐‑  CD150+)  or  c-­‐‑Kit+  Lin-­‐‑  Sca1+  Flt3-­‐‑  (KLSF).  To  determine  donor-­‐‑derived  chimerism  
in  transplantation-­‐‑based  assays,  peripheral  blood  cells  of  transplant  recipients  were  
obtained  by  the  submandibular  bleeding  method  and  prepared  for  analysis  as  
previously  described(Ito  et  al.  2010).  All  antibodies  were  purchased  from  BD  Pharmigen,  
eBioscience  or  BioLegend.  Apoptosis  assays  were  performed  by  staining  cells  with  
Annexin-­‐‑V  and  7AAD  (BD  Pharmingen).  Analysis  of  in  vivo  BrdU  incorporation  was  
performed  using  the  FITC  BrdU  Flow  Kit  (BD  Pharmingen)  after  a  single  intraperitoneal  
injection  of  BrdU  (2  mg).    Analysis  and  cell  sorting  were  carried  out  on  FACSVantage  
SE,  FACStar,  FACSCantoII,  FACSDiva  and  FACSAria  III  machines  (all  from  Becton  
Dickinson)  and  data  were  analyzed  with  FlowJo  software  (Tree  Star  Inc.).    
2.3 Retro- and Lentiviral constructs and production 
MIG-­‐‑BCR-­‐‑ABL  was  a  gift  from  Warren  Pear  and  Ann  Marie  Pendergast  and  was  
cloned  into  MSCV-­‐‑IRES-­‐‑YFP  retroviral  vector.  MSCV-­‐‑NUP98-­‐‑HOXA9-­‐‑IRES-­‐‑YFP  was  a  
gift  from  Gary  Gilliland  and  was  cloned  into  the  MSCV-­‐‑IRES-­‐‑GFP  vector.  MSCV-­‐‑MLL-­‐‑
AF9-­‐‑IRES-­‐‑GFP  was  generously  provided  by  Scott  Armstrong.  NRASG12V  cDNA  was  a  
gift  from  Christopher  Counter  and  was  cloned  into  MSCV-­‐‑IRES-­‐‑YFP  retroviral  vector.  
pCXLIS1-­‐‑RFP-­‐‑IAP  vector  (Tanaka  et  al.  2004),  encoding  a  full-­‐‑length  human  LIS1  cDNA,  
was  obtained  from  Joseph  Gleeson  and  the  protein  coding  region  was  cloned  into  
MSCV-­‐‑IRES-­‐‑truncated  hNGFR  retroviral  vector.  Numb  cDNA  (p65  isoform,  accession  
number  BC033459,  NCBI)  was  either  cloned  into  the  MSCV-­‐‑IRES-­‐‑GFP  vector  or  fused  to  
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CFP  in  the  MSCV-­‐‑CFP  vector  following  the  removal  of  IRES.  H2B-­‐‑GFP  (pEGFPN1)  
vector  (Kanda  et  al.  1998)  was  a  gift  from  Geoffrey  Wahl  and  the  H2B-­‐‑GFP  chimeric  
gene  was  cloned  into  MSCV-­‐‑IRES-­‐‑GFP  retroviral  vector  following  the  removal  of  IRES-­‐‑
GFP.  mCherry-­‐‑alpha-­‐‑tubulin  fusion  construct  (Day  et  al.  2009)  was  generously  provided  
by  John  Chang  and  Sarah  Russell.      
Lentiviral  short  hairpin  RNA  (shRNA)  constructs  were  cloned  in  FG12  as  
described  previously  (Qin  et  al.  2003).  The  target  sequences  are  5′-­‐‑
AGATGAACTAAATCGAGC-­‐‑3′  for  shLIS1-­‐‑(592),  5′-­‐‑TGTCTGCCTCAAGGGATA-­‐‑3′  for  
shLIS1-­‐‑(1191)  and  5′-­‐‑TGCGCTGCTGGTGCCAAC-­‐‑3′  for  luciferase  as  a  negative  control.  
LIS1  mutant  cDNA  resistant  to  shLIS1-­‐‑(592)  was  constructed  by  inverse  PCR  strategy  
using  a  primer  designed  to  include  silent  mutations  (underlined)  in  the  shLIS1-­‐‑(592)  
target  sequence:  5′  -­‐‑  AGACGAGCTTAACCGTGC  -­‐‑3′.  The  protein-­‐‑coding  region  of  
mutated  human  LIS1  cDNA  was  cloned  into  MSCV-­‐‑IRES-­‐‑truncated  hNGFR  retroviral  
vector.  Virus  was  produced  in  293T  cells  transfected  using  the  FuGENE®6  or  X-­‐‑
tremeGENE  HP  (Roche)  with  viral  constructs  along  with  VSV-­‐‑G  and  gag-­‐‑pol.  For  
lentivirus  production  Rev  was  also  co-­‐‑transfected.  Viral  supernatants  were  collected  for  
three  to  five  days  followed  by  ultracentrifugal  concentration  at  50,000x  g  for  3h.    
2.4 Cell culture and methylcellulose colony formation 
For  liquid  culture,  freshly  isolated  adult  KLS  (cKit+  Lin-­‐‑  Sca-­‐‑1+)  bone  marrow  cells  
were  plated  into  a  96-­‐‑well  U  bottom  plate  in  X-­‐‑Vivo15  (with  Gentamicin  and  Phenol  
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Red)  (Lonza)  supplemented  with  50  µμM  2-­‐‑mercaptoethanol,  10%  (vol/vol)  fetal  bovine  
serum,  stem  cell  factor  (SCF;  100  ng/ml,  R&D  Systems)  and  thrombopoietin  (TPO;  20  
ng/ml,  R&D  Systems).  4-­‐‑OH  tamoxifen  (Sigma)  was  dissolved  in  ethanol  at  1  mg/ml  
(1000X),  and  a  1X  solution  was  made  immediately  before  treatment.  For  certain  
immunofluorescence  experiments,  cells  were  treated  for  24  hrs  with  either  10  µM  
Cytochalasin  B  (Sigma)  or  10  nM  Nocodazole  (Sigma).    
For  fetal  liver  methylcellulose  assays,  individual  fetal  livers  (FL)  from  embryonic  
day  12.5  (E12.5)  embryos  were  dissected  in  cold  phosphate-­‐‑buffered  saline,  
disaggregated  and  passed  through  a  74-­‐‑µμm  nylon  mesh  (Corning)  to  generate  single-­‐‑cell  
suspensions.  5,000  FL  cells  were  plated  in  triplicate  in  Iscove’s  modified  medium-­‐‑based  
methylcellulose  medium  (Methocult  M3434,  StemCell  Technologies).  Erythroid  (BFU-­‐‑E)  
hematopoietic  progenitors  were  scored  by  morphological  criteria  on  day  7  and  myeloid  
(CFU-­‐‑GM)  and  multilineage  (CFU-­‐‑GEMM)  colonies  were  scored  on  day  10.    
For  yolk  sac  and  placenta  methylcellulose  assays,  sorted  yolk  sac  or  placenta  cells  
were  plated  (300-­‐‑500  cells/well)  in  triplicate  in  Methocult  M3434.  Colonies  generated  
from  yolk  sac  cells  were  counted  on  day  8  and  colonies  formed  from  placenta  cells  were  
scored  on  day  14.  For  methylcellulose  assays  performed  with  leukemia  cells,  5,000  
lineage-­‐‑negative  (Lin-­‐‑)  bcCML  cells  (BCR-­‐‑ABL+,  NUP98-­‐‑HOXA9+)  were  plated  in  
triplicated  and  scored  on  day  8.    
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2.5 In vivo transplantation assays 
For  fetal  liver  transplants,  5,000  Lin-­‐‑  AA4.1+  fetal  liver  cells  (derived  from  E14.5  
embryos  expressing  CD45.2)  or  3  x  105    whole  fetal  liver  cells  (derived  from  E12.5  
embryos  expressing  CD45.2)    along  with  3  x105  competitive  bone  marrow  cells  derived  
from  an  unirradiated  recipient  mouse  were  transplanted  by  retro-­‐‑orbital  i.v.  injections  
into  lethally  irradiated  (9.5  Gy)  congenic  recipient  mice  (expressing  CD45.1).  Recipient  
mice  received  donor  cells  derived  from  one  individual  embryo  of  a  given  genotype.  
Peripheral  blood  of  recipient  mice  was  collected  at  4,  8,  12  and  16  weeks  after  
transplantation.  Donor  and  recipient  cells  were  distinguished  by  expression  of  CD45.1  
(A20;  eBioscience)  and  CD45.2  (104;  eBioscience).  For  bone  marrow  transplants,  500  LT-­‐‑
HSCs  (cKit+  Lin-­‐‑  Sca-­‐‑1+  CD150+  CD48-­‐‑)  isolated  from  bone  marrow  of  mice  expressing  
CD45.2  were  transplanted  into  lethally  irradiated  (9.8  Gy)  congenic  recipient  mice  
(expressing  CD45.1)  along  with  3  x  105  Sca1-­‐‑depleted  bone  marrow  cells  derived  from  an  
unirradiated  recipient  mouse.  Peripheral  blood  of  recipient  mice  was  collected  at  4,  8  
and  28  weeks  after  transplantation.    For  Lis1  chimera  bone  marrow  transplants,  3  x  105  
whole  bone  marrow  cells  isolated  from  Lis1  chimera  mice  (expressing  CD45.2)  were  
transplanted  into  lethally  irradiated  (9.8  Gy)  recipient  mice  (expressing  CD45.1)  along  
with  3  x  105  Sca1-­‐‑depleted  bone  marrow  cells  derived  from  an  unirradiated  recipient  
mouse.  Peripheral  blood  of  recipient  mice  was  collected  at  16  weeks  after  
transplantation.    
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2.6 Determining Numb inheritance 
For  experiments  involving  fixed  cells,  dividing  cells  in  late  telophase  or  
undergoing  cytokinesis  were  identified  by  pronounced  cytoplasmic  cleft  by  brightfield  
or  visualized  by  staining  cells  for  alpha-­‐‑tubulin  plus  the  presence  of  dual  nuclei  using  
DAPI.  ImageJ  1.46r  was  used  to  determine  fluorescence  intensity  of  pixels  following  
Numb  staining.  The  fluorescence  intensity  of  Numb  was  on  average  ~2.4-­‐‑fold  higher  in  
the  Numbhigh  daughter  cell  relative  to  the  Numblow  daughter  cell  during  an  asymmetric  
division.  Based  on  immunofluorescence  data,  Numb  is  ~1.8-­‐‑fold  higher  in  progenitors  
than  in  HSCs  and  thus,  incipient  daughters  that  expressed  at  least  a  1.8-­‐‑fold  difference  in  
Numb  expression  were  scored  as  an  asymmetric  Numb  inheritance.    
For  live  imaging  experiments,  KLS  cells  isolated  from  Lis1f/f;  Rosa26-­‐‑creER/Rosa26-­‐‑
creER  and  Lis1+/+;  Rosa26-­‐‑creER/Rosa26-­‐‑creER  mice  were  co-­‐‑infected  with  mCherry-­‐‑α-­‐‑
tubulin  and  Numb-­‐‑CFP  fusion  constructs  and  doubly-­‐‑infected  cells  were  subsequently  
plated  in  methylcellulose  medium  (Methocult  M3434,  StemCell  Technologies)  and  
treated  with  4-­‐‑OH  tamoxifen  (Sigma).  Dividing  cells  identified  in  movie  replay  were  
visualized  in  spectrum  color  format  (where  red  indicates  pronounced  α-­‐‑tubulin  
expression  and  centrosome  location)  to  readily  identify  the  centrosomes.  Using  ImageJ  
1.46r  software,  a  line  connecting  the  two  centrosomes  of  a  cell  was  drawn  (Line  1;  
dotted).  Subsequently,  an  additional  line  (Line  2;  solid)  was  drawn  perpendicular  to  
Line  1,  which  marked  the  cleavage  furrow  and  partitioned  the  mother  cell  into  incipient  
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daughter  cell  1  (D1)  and  daughter  cell  2  (D2).  Using  the  criteria  described  above  and  our  
immunofluorescence  data,  incipient  daughters  that  expressed  at  least  a  1.8-­‐‑fold  
difference  in  Numb  expression  were  scored  as  an  asymmetric  Numb  inheritance.      
2.7 Analysis of spindle orientation and mitotic events 
Bone  marrow  KLS  cells  were  isolated  and  sorted  from  age-­‐‑gender  matched  Lis1f/f;  
Rosa26-­‐‑creER/Rosa26-­‐‑creER  and  Lis1+/+;  Rosa26-­‐‑creER/Rosa26-­‐‑creER  mice  and  cultured  
overnight  in  X-­‐‑Vivo™15  media  (Lonza)  supplemented  with  50  µμM  2-­‐‑mercaptoethanol,  
10%  (vol/vol)  fetal  bovine  serum,  SCF  (100  ng/ml,  R&D  Systems)  and  thrombopoietin  (20  
ng/ml,  R&D  Systems).  Cells  were  retrovirally-­‐‑infected  with  MSCV-­‐‑H2B-­‐‑GFP  and  
mCherry-­‐‑α-­‐‑tubulin,  harvested  48  hrs  after  infection  and  re-­‐‑sorted  for  GFP+  mCherry+  
KLS  cells.  Sorted  cells  were  either  cultured  in  96-­‐‑well  U-­‐‑bottomed  plates  (BD  
Biosciences)  for  48  hrs  with  4-­‐‑OH  tamoxifen  (Sigma)  and  subsequently  placed  on  
chambered  coverglass  slides  (Lab-­‐‑Tek  II®,  Thermo  Scientific)  coated  with  0.1  µμg/µμl  
Retronectin®  (Takara  Bio  Inc.)  in  the  continual  presence  of  4-­‐‑OH  tamoxifen  or  plated  in  
Iscove’s  modified  medium-­‐‑based  methycellulose  medium  (Methocult  M3434,  StemCell  
Technologies)  supplemented  with  4-­‐‑OH  tamoxifen.    Images  were  collected  every  3-­‐‑4  
minutes  with  xyzt  acquisition  mode  using  an  Axio  Observer.Z1  microscope  with  the  
LSM  700  scanning  module  (Zeiss).  Cultures  were  maintained  at  37°C,  5%  CO2  using  a  
Heating  Insert  P  Lab-­‐‑Tek  S1  with  an  Incubator  PM  S1  (Zeiss).  Mitotic  cells  were  
identified  in  movie  replay.  To  measure  spindle  orientation,  a  concatenation  of  Z-­‐‑stack  
  29  
images  of  each  cell  at  every  measured  time  point  from  the  start  of  metaphase  to  early  
telophase  was  generated  and  displayed  orthogonally  using  Zen  2010  software.  
Subsequently,  the  angle  formed  between  the  substratum  plane  (Retronectin  base)  and  
the  virtual  line  passing  through  spindle  poles  was  measured  using  ImageJ  1.44.  To  
quantify  mitosis  duration,  the  time  between  nuclear  envelope  breakdown  and  chromatin  
condensation  until  the  beginning  of  telophase  was  determined.  For  chromosome  counts,  
KLS  cells  were  cultured  in  X-­‐‑Vivo™15  media  (Lonza)  supplemented  with  50  µμM  2-­‐‑
mercaptoethanol,  10%  (vol/vol)  fetal  bovine  serum,  SCF  (100  ng/ml,  R&D  Systems)  and  
TPO  (20  ng/ml,  R&D  Systems)  for  48  hrs,  and  then  arrested  in  metaphase  by  a  2h  
incubation  with  100  ng/ml  colcemid  (KaryoMAX  solution,  Gibco).  Cells  were  treated  
with  hypotonic  solution  (0.56%  KCl)  for  15  min  at  37°C,  then  fixed  with  3:1  
methanol:glacial  acetic  acid  and  spread  on  a  slide  to  prepare  metaphase  spreads.  
Karyotyping  was  performed  by  Cell  Line  Genetics,  Inc.  (www.clgenetics.com).      
2.8 Generation and analysis of leukemic mice 
Bone  marrow  KLS  cells  were  isolated  and  sorted  from  age-­‐‑gender  matched  Lis1f/f;  
Rosa26-­‐‑creER/Rosa26-­‐‑creER  and  Lis1+/+;  Rosa26-­‐‑creER/Rosa26-­‐‑creER  mice  and  cultured  
overnight  in  X-­‐‑Vivo15  media  (Lonza)  supplemented  with  50  µμM  2-­‐‑mercaptoethanol,  
10%  (vol/vol)  fetal  bovine  serum,  SCF  (100  ng/ml,  R&D  Systems)  and  TPO  (20  ng/ml,  
R&D  Systems).  Cells  were  retrovirally-­‐‑infected  with  MSCV-­‐‑BCR-­‐‑ABL-­‐‑IRES-­‐‑YFP  and  
MSCV-­‐‑NUP98-­‐‑HOXA9-­‐‑IRES-­‐‑GFP  to  generate  myeloid  blast  crisis  phase  CML  (bcCML)  
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or  MSCV-­‐‑MLL-­‐‑AF9-­‐‑IRES-­‐‑GFP  and  MSCV-­‐‑NRASG12V-­‐‑IRES-­‐‑YFP  to  generate  de  novo  AML.  
Subsequently,  cells  were  harvested  48  hours  after  infection.  Doubly-­‐‑infected  cells  (for  
bcCML  experiments)  or  unsorted  cells  (for  AML  experiments)  were  transplanted  retro-­‐‑
orbitally  into  cohorts  of  B6-­‐‑CD45.1  mice.  Before  transplantation,  for  de  novo  AML  
transplants,  infected  cells  regardless  of  donor  genotype  displayed  similar  infection  
efficiency.  All  recipients  were  sub-­‐‑lethally  (6-­‐‑7  Gy)  irradiated.  For  secondary  bcCML  
transplantations,  cells  recovered  from  terminally  ill  primary  recipients  were  sorted  for  
lineage-­‐‑negative  (Lin-­‐‑),  MSCV-­‐‑BCR-­‐‑ABL-­‐‑IRES-­‐‑YFP  and  MSCV-­‐‑NUP98-­‐‑HOXA9-­‐‑IRES-­‐‑
GFP  and  transplanted  into  secondary  recipients.  Analysis  of  diseased  mice  was  
conducted  as  previously  described  (Ito  et  al.  2010).    
2.9 Human leukemia patient samples and cell lines 
Patient  samples  were  obtained  from  either  Singapore  General  Hospital  
(Singapore),  the  Fred  Hutchinson  Cancer  Research  Center  or  from  the  Duke  Adult  Bone  
Marrow  Transplant  Clinic  from  Institutional  Review  Board-­‐‑approved  protocols  with  
written  informed  consent  in  accordance  with  the  Declaration  of  Helsinki.  Primary  
bcCML  cells  were  imatinib,  nilotinib  and  dasatinib-­‐‑resistant.  Primary  AML  cells  
harbored  the  MLL-­‐‑AF9  translocation.  Leukemia  cells  were  cultured  in  Iscove’s  modified  
Dulbecco  medium  (IMDM)  with  10%  fetal  bovine  serum  (FBS),  100  IU/ml  penicillin  and  
100 µμg/ml  streptomycin,  55  µμM  2-­‐‑mercaptoethanol  and  supplemented  with  SCF,  IL-­‐‑3,  
IL-­‐‑6,  Flt3L,  and  TPO.  The  human  chronic  myeloid  leukemia  cell  line  K562  was  
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maintained  in  Roswell  Park  Memorial  Institute  medium  (RPMI-­‐‑1640)  with  10%  FBS,  100  
IU/ml  penicillin  and  100 µμg/ml  streptomycin.  The  human  acute  myeloid  leukemia  cell  
line  MV4-­‐‑11  was  maintained  in  IMDM  with  10%  FBS,  100  IU ml−1  penicillin  and  
100 µμg/ml  streptomycin.    
For  colony  forming  assays,  human  cell  lines  or  sorted  hCD34+  cells  from  primary  
patient  samples  were  transduced  with  lentiviral  shRNA  (cloned  in  FG12-­‐‑UbiC-­‐‑GFP),  
and  GFP-­‐‑positive  cells  were  sorted  at  48  hrs  and  plated  in  complete  methylcellulose  
medium  (MethoCult  Express,  StemCell  Technologies).  For  certain  colony-­‐‑forming  
experiments,  K562  cells  were  co-­‐‑transduced  with  lentiviral  shRNA  (FG12-­‐‑UbiC-­‐‑GFP)  
and  retroviral  constructs  (MSCV-­‐‑IRES-­‐‑hNGFR)  and  doubly-­‐‑infected  cells  were  sorted  
and  plated  in  methylcellulose.  All  knockdown  experiments  were  conducted  with  the  
construct  shRNA-­‐‑LIS1-­‐‑(592)  except  those  involving  human  primary  CML  cells,  which  
were  instead  transduced  with  an  alternative  shLIS1  construct:  shRNA-­‐‑LIS1-­‐‑(1191).  This  
construct  represents  an  independent  hairpin  shRNA  targeting  LIS1  that  more  effectively  
knockdowns  LIS1  in  these  cells.  Colony  numbers  were  counted  10-­‐‑14  days  after  plating.      
2.10 Gene expression microarray and data analysis 
Control  (Lis1+/+;  Rosa-­‐‑creER)  or  Lis1f/f;  Rosa-­‐‑creER  mice  were  treated  with  
tamoxifen  for  five  consecutive  days.  Three  days  after  the  final  tamoxifen  administration,  
KLS  bone  marrow  cells  were  FACS-­‐‑sorted  and  total  cellular  RNAs  were  purified.    RNAs  
were  amplified,  labeled,  hybridized  onto  Affymetrix  GeneChip  Mouse  Genome  430  2.0  
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Arrays  and  raw  hybridization  data  were  collected  (Asuragen  Inc.,  Austin,  TX).  
Expression  level  data  were  normalized  using  a  multiple-­‐‑loess  algorithm  as  previously  
described  (Sasik  et  al.  2004).  Probes  whose  expression  level  exceeds  a  threshold  value  in  
at  least  one  sample  were  considered  detected.  The  threshold  value  is  found  by  
inspection  from  the  distribution  plots  of  log2  expression  levels.  Detected  probes  were  
sorted  according  to  their  q-­‐‑value,  which  is  the  smallest  false  discovery  rate  (FDR)  
(Benjamini  and  Hochberg  1995)  at  which  the  gene  is  called  significant.  An  FDR  value  of  
α  is  the  expected  fraction  of  false  positives  among  all  genes  with  q  ≤α.  FDR  was  
evaluated  using  Significance  Analysis  of  Microarrays  and  its  implementation  in  the  
official  statistical  package  samr  (Tusher  et  al.  2001).  To  prevent  unwarranted  variances,  
the  percentile  of  standard  deviation  values  used  for  the  exchangeability  factor  s0  in  the  
regularized  t-­‐‑statistic  was  set  to  50.    
The  probe  list,  sorted  by  q-­‐‑value  in  ascending  order,  was  translated  into  Entrez  
gene  ID'ʹs  and  parsed  so  that  where  several  different  probes  represent  the  same  gene,  
only  the  highest-­‐‑ranking  probe  was  kept  for  further  analysis.  The  sorted  list  of  genes  
was  subjected  to  a  non-­‐‑parametric  variant  of  the  Gene  Set  Enrichment  Analysis  (GSEA)  
(Subramanian  et  al.  2005),  in  which  the  p-­‐‑value  of  a  gene  set  was  defined  as  the  minimal  
rank-­‐‑order  p-­‐‑value  of  a  gene  in  the  gene  set  (Arnold  et  al.  1992)  rather  than  the  
Kolmogorov-­‐‑Smirnov  statistic  as  in  GSEA.  Briefly,  let  rk  be  the  k-­‐‑th  highest  rank  among  a  
gene  set  of  size  N.  The  rank-­‐‑order  p-­‐‑value  pk  of  this  gene  is  the  probability  that  among  N  
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randomly  chosen  ranks  without  replacement,  the  k-­‐‑th  highest  rank  will  be  at  least  rk.  The  
p-­‐‑value  of  a  gene  set  was  defined  as  the  smallest  of  all  pk.  Finding  the  p-­‐‑value  of  a  gene  
set  of  size  N  requires  calculation  of  N  rank-­‐‑order  p-­‐‑values;  however,  there  is  no  need  to  
adjust  the  p-­‐‑values  for  the  number  of  genes  tested  as  the  tests  are  highly  statistically  
dependent.  A  Bonferroni  adjustment  of  gene  set  p-­‐‑values  for  the  number  of  gene  sets  
tested  was  performed.  Gene  sets  with  adjusted  p-­‐‑values  ≤  0.01  were  reported.  For  the  
analysis  of  stem  cell  signature  sets  published  (Eppert  et  al.  2011;  Metzeler  et  al.  2008;  
Somervaille  et  al.  2009;  Venezia  et  al.  2004;  Wong  et  al.  2008;  Yagi  et  al.  2003),  all  
detected  genes  in  the  Lis1-­‐‑/-­‐‑  (Lis1f/fcreER  +tamoxifen)  to  control  (Lis1+/+creER  +tamoxifen)  
comparison  were  sorted  according  to  their  q-­‐‑values  as  above  and  gene  set  enrichment  
analysis  for  each  signature  gene  set  was  performed.  Each  gene  signature’s  p-­‐‑value  is  
Bonferroni-­‐‑adjusted  by  a  factor  of  9  (number  of  signature  gene  sets  tested).  Heat  maps  
were  created  using  in-­‐‑house  hierarchical  clustering  software  and  the  colors  qualitatively  
correspond  to  fold  changes.  Microarray  data  reported  have  been  deposited  in  the  
ArrayExpress  Database  (accession  number  E-­‐‑MEXP-­‐‑3855)  (European  Bioinformatics  
Institute  2013).      
2.11 PCR genotyping and RT-PCR analysis 
For  genotyping  by  PCR,  the  reaction  mixture  contained  MangoMix  (Bioline),  
genomic  DNA  and  0.5  µμM  of  each  primer.  PCR  conditions  for  genotyping  were  as  
follows:  3  min  at  94°C,  followed  by  35  cycles  at  94°C  for  30  s,  60°C  for  1  min,  and  72°C  
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for  1  min.  To  detect  the  wild-­‐‑type,  floxed,  and  deleted  floxed  mouse  Lis1  allele,  the  
following  primer  sequences  were  used:  Lis1-­‐‑Common-­‐‑R,  5′-­‐‑
GCTTGTTCATCAAGCTTGCAC-­‐‑3′;  Lis1-­‐‑F_VI,  5′-­‐‑GCTTCCTGTTCA  GCAGATATG-­‐‑3′;  
Lis1-­‐‑F_II,  5′-­‐‑GGCGATGATAACCACTGAGTC-­‐‑3′.  RNA  was  isolated  using  RNAqueous-­‐‑
Micro  (Ambion)  or  RNeasy  Mini  kit  (Qiagen).  cDNA  was  prepared  from  equal  amounts  
of  RNAs  using  Superscript  II  reverse  transcriptase  (Invitrogen).  The  following  primer  
sequences  were  used  for  standard  RT-­‐‑PCR  reactions:  Lis1-­‐‑F,  5′-­‐‑
TGGATTCCCCGTCCACCTGA-­‐‑3′;  Lis1-­‐‑R,  5′-­‐‑TTGGCCGCACCATACGTACC-­‐‑3′;  
GAPDH-­‐‑F,  5′-­‐‑CAATGACCCCTTCATTGACC-­‐‑3′;  GAPDH-­‐‑R,  5′-­‐‑
TTGATTTTGGAGGGATCTCG-­‐‑3′.  Quantitative  real-­‐‑time  PCRs  were  performed  using  
iQ  SYBR  Green  Supermix  (Bio-­‐‑Rad)  on  a  CFX  96  C1000™  Thermal  cycler  (Bio-­‐‑Rad).  
Results  were  normalized  to  the  level  of  β2  microglobulin  (B2M,  human;  B2m,  mouse)  or  
TATA-­‐‑binding  protein  (Tbp,  mouse).  Primer  sequences  are  as  follows  for  mouse:  Numb-­‐‑
F,  5′-­‐‑ATGAGTTGCCTTCCACTATGCAG-­‐‑3′;  Numb-­‐‑R,  5′-­‐‑
TGCTGAAGGCACTGGTGATCTGG-­‐‑3′;  Tbp-­‐‑F,  5′-­‐‑GTATCTACCGTGAATCTTGGCTG-­‐‑
3′;  Tbp-­‐‑R,  5′-­‐‑AGTTGTCCGTGGCTCTCTTATTC-­‐‑3′;  Socs3-­‐‑F,  5′-­‐‑
GGGTGGCAAAGAAAAGGAG-­‐‑3′;  Socs3-­‐‑R,  5′-­‐‑GTTGAGCGTCAAGACCCAGT-­‐‑3′;  Brd4-­‐‑
F,  5′-­‐‑CCATGGACATGAGCACAATC-­‐‑3′;  Brd4-­‐‑R,  5′-­‐‑TGGAGAACATCAATCGGACA-­‐‑3′;  
Pml-­‐‑F,  5′-­‐‑CCAGAGGAACCCTCCGAAGA-­‐‑3′;  Pml-­‐‑R,  5′-­‐‑
GGCAGCGCAGAAACTGAAAT-­‐‑3′;  Msi2-­‐‑F,  5′-­‐‑TGCCATACACCATGGATGCGT-­‐‑3′;  
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Msi2-­‐‑R,  5′-­‐‑GTAGCCTCTGCCATAGGTTGC-­‐‑3′.  B2m-­‐‑F,  5′-­‐‑
ACCGGCCTGTATGCTATCCAGAA-­‐‑3′;  B2m-­‐‑R,  5′-­‐‑AATGTGAGGCGGGTGGAACTGT-­‐‑
3′.  Mouse  Lis1  (Mm01253377_mH)  gene  levels  were  analyzed  with  TaqMan  Gene  
Expression  Assays.  Primer  sequences  are  as  follows  for  human:  LIS1-­‐‑F,  5′-­‐‑
CATGAGCATGTGGTAGAATGC-­‐‑3′;  LIS1-­‐‑R,  5′-­‐‑GGCCCAGGTTTACCACTTTT-­‐‑3′;  B2M-­‐‑
F,  5′-­‐‑ATGAGTATGCCTGCCGTGTGA-­‐‑3′;  B2M-­‐‑R,  5′-­‐‑GGCATCTTCAAACCTCCATG-­‐‑3′.  
2.12 Immunofluorescence staining 
Cells  were  allowed  to  settle  briefly  on  poly-­‐‑L-­‐‑lysine  coated  coverslips  (BD  
Biosciences)  at  37°C,  fixed  with  4%  paraformaldehyde  (USB  Corporation)  or  methanol,  
permeabilized  with  1X  Dako  wash  buffer  (Dako)  and  blocked  with  20%  normal  goat  
serum  (Invitrogen)  or  donkey  serum  (Abcam)  in  1X  Dako  wash  buffer.  Bones  were  
removed  and  fixed  in  4%  paraformaldehyde  for  24  hrs  at  4°C,  saturated  with  20%  
sucrose  in  1X  PBS  overnight  and  embedded  in  O.C.T.  Compound  (Sakura).  Bones  were  
cut  to  sections  using  a  Cyrojane  Tape  Transfer  System  and  a  Leica  CM3050  S  cryostat  
(Leica  Microsystems).  All  bone  sections  were  permeablized  with  100%  acetone  for  5  min  
at  -­‐‑20°C.  Primary  antibody  incubation  was  overnight  at  4°C.  The  following  primary  
antibodies  were  used:  rabbit  anti-­‐‑Numb  1:50  or  1:100  (Abcam),  goat  anti-­‐‑LIS1  1:500  
(Santa  Cruz  Biotechnology),  mouse  anti-­‐‑alpha-­‐‑tubulin  1:200  (Abcam),  rabbit  anti-­‐‑
Sp7/Osterix  1:100  (Abcam),  rat  anti-­‐‑α-­‐‑tubulin  1:1000  (Abcam),  mouse  anti-­‐‑α-­‐‑tubulin  
conjugate  FITC  1:200  (Sigma).  Primary  antibody  incubation  for  Osterix  was  3  hr  at  room  
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temperature.  Secondary  antibody  incubation  was  performed  for  1  hr  at  room  
temperature.  DAPI  (Molecular  Probes)  was  used  to  detect  DNA.  Images  were  obtained  
with  a  Confocal  Leica  TCS  SP5  II  (Leica  Microsystems)  or  an  Axio  Observer.Z1  
microscope  with  the  LSM  700  scanning  module  (Zeiss).  ImageJ  1.46r  was  used  to  
determine  fluorescence  intensity.  For  VE-­‐‑cadherin  analysis,  Alexa  Fluor  647  anti-­‐‑mouse  
VE-­‐‑Cadherin  (50µμg;  BioLegend)  was  administered  per  mouse  and  imaged  30  minutes  
post-­‐‑injection.  Images  were  acquired  using  an  upright  Leica  TCS  SP5  II  confocal  system  
with  a  Leica  DM  6000  CFS  microscope  and  Leica  LAS  AF  software  (Leica  Microsystems).  
Z-­‐‑stack  images  were  sequentially  captured  in  1024x1024  format  with  line  averaging  and  
max  projection.    
2.13 Western Blot 
Cell  lysates  were  prepared  by  lysing  cells  in  NP-­‐‑40  lysis  buffer  (Boston  
BioProducts)  or  RIPA  lysis  buffer  (Sigma  Aldrich)  with  protease  inhibitor  (Thermo  
Scientific),  incubated  for  15-­‐‑30  min.  on  ice  and  centrifuged  at  15,000  rpm  for  10  minutes  
at  4°C.  Before  electrophoresis,  lysates  were  diluted  in  sample  buffer  (10%  glycerol,  1.5%  
SDS,  60  mM  Tris/HCl,  pH  6.8,  2.5%  beta-­‐‑mercaptoethanol,  0.0025%  bromophenol  blue)  
and  heated  at  95°C  for  5  min.  Proteins  were  separated  by  SDS-­‐‑PAGE,  transferred  to  
either  Immobilon  polyvinylidene  difluoride  membranes  (Millipore)  or  Hybond-­‐‑ECL  
nitrocellulose  membranes  (GE  Healthcare).  Primary  antibodies  used:  goat  anti-­‐‑LIS1  
(1:100;  Santa  Cruz  Biotechnology),  rabbit  anti-­‐‑Numb  (1:1000;  Abcam),  rabbit  anti-­‐‑beta  
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tubulin  (1:2000;  Abcam)  and  anti-­‐‑alpha  tubulin  (1:5000;  Abcam).  Secondary  antibodies  
used:  IRDye  800CW  anti-­‐‑goat  IgG  (1:20000;  LI-­‐‑COR),  IRDye  680RD  anti-­‐‑rabbit  IgG  
(1:20000;  LI-­‐‑COR),  IRDye  800CW  anti-­‐‑rabbit  IgG  (1:10000;  LI-­‐‑COR)  and  IRDye  680RD  
anti-­‐‑mouse  IgG  (1:10000;  LI-­‐‑COR).  Membranes  were  developed  using  the  Odyssey  CLx  
imaging  system  (LI-­‐‑COR).    
2.14 Statistical analysis 
Statistical  analyses  were  carried  out  using  GraphPad  Prism  software  version  5.0a  
or  5.0d  (GraphPad  software  Inc.).  Data  are  mean  ±  SEM.  Chi-­‐‑square  test  was  used  to  
determine  deviation  from  Mendelian  ratios.  Two-­‐‑tailed  unpaired  Student’s  t-­‐‑tests  with  
Welch’s  correction  when  appropriate  were  used  to  determine  statistical  significance  











3. Lis1 is required for hematopoietic stem cell self-
renewal activity during fetal development. 
3.1 Introduction 
During  embryonic  development,  the  hematopoietic  stem  cell  (HSC)  pool  
increases  substantially  to  ensure  a  sufficient  number  of  HSCs  are  produced  for  postnatal  
life  and  for  the  geometric  expansion  of  differentiated  blood  cells  that  are  imminently  
required  for  growth  and  development  (Lessard  et  al.  2004).  To  accomplish  this,  HSCs  
modulate  the  balance  between  self-­‐‑renewal  and  differentiation.  Recently,  it  has  been  
shown  that  HSCs  have  the  ability  to  undergo  both  symmetric  renewal  division  
(generating  two  daughter  stem  cells)  and  asymmetric  cell  division  (generating  one  
daughter  stem  cell  and  one  differentiating  daughter  cell)  (Wu  et  al.  2007).  Thus,  one  way  
HSCs  may  control  the  extent  at  which  they  either  self-­‐‑renewal  or  differentiate  is  by  
dynamically  changing  their  mode  of  division  (i.e.  from  an  asymmetric  mode  of  division  
to  a  symmetric  mode  of  division).    In  this  regard,  during  development,  HSCs  may  
predominately  undergo  symmetric  renewal  division  to  guarantee  that  the  required  
number  of  HSCs  are  generated.  Although  it  has  been  demonstrated  that  HSCs  have  the  
ability  to  undergo  both  modes  of  division,  the  intrinsic  regulators  of  this  process  are  
largely  unknown  in  the  hematopoietic  system.  The  dynein-­‐‑binding  protein  Lis1  has  
previously  been  shown  to  play  a  role  in  the  machinery  control  division  pattern  in  the  
nervous  system  (Yingling  et  al.  2008),  however,  whether  this  molecule  plays  a  role  in  the  
regulation  of  fetal  HSC  self-­‐‑renewal  was  unknown.    
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3.2 Results 
3.2.1 Vav-Cre-mediated deletion of Lis1 permits evaluation of Lis1’s 
role specifically in the hematopoietic system. 
To  enable  assessment  of  Lis1’s  role  in  establishment  of  the  hematopoietic  system  
and  self-­‐‑renewal  of  fetal  hematopoietic  stem  cells  (HSCs),  we  took  advantage  of  the  
Cre/loxP  recombination  system  to  genetically  delete  Lis1  specifically  in  the  
hematopoietic  system.  Mice  homozygous  for  the  null  Lis1  allele  die  during  
embryogenesis  before  embryonic  (E)  day  9.5  (Hirotsune  et  al.  1998).  Thus,  to  circumvent  
embryonic  lethality  and  to  spatially  and  temporally  control  the  deletion  of  Lis1,  we  
utilized  a  hypomorphic/conditional  Lis1  floxed  allele,  where  a  loxP-­‐‑flanked  PGK-­‐‑neo  
gene  was  placed  in  the  reverse  transcriptional  orientation  relative  to  Lis1  in  intron  2  and  
another  loxP  site  was  placed  in  intron  6  of  the  Lis1  gene  (Hirotsune  et  al.  1998).    
Conditional  Lis1  knockout  mice  were  generated  by  crossing  mice  carrying  the  
Lis1  floxed  allele  to  mice  in  which  Cre  recombinase  is  driven  by  vav  regulatory  elements  
(Vav-­‐‑Cre  mice).  Vav  is  an  adaptor  protein  expressed  in  all  adult  and  fetal  hematopoietic  
cell  types,  including  HSCs  derived  from  the  fetal  liver  (Adams  et  al.  1999;  Adams  et  al.  
1992;  Bustelo  et  al.  1993;  Katzav  et  al.  1989;  Ogilvy  et  al.  1999a;  Ogilvy  et  al.  1999b).  To  
confirm  Vav-­‐‑Cre-­‐‑mediated  recombination  occurs  within  the  fetal  HSC  population,  we  
crossed  Vav-­‐‑Cre  mice  with  Tomato  reporter  mice  (Rosa26-­‐‑stop-­‐‑tdTomato).  These  
fluorescent  reporter  mice  harbor  a  loxP-­‐‑flanked  STOP  cassette,  which  prevents  
transcription  of  the  downstream  fluorescent  Tomato  red  protein.  When  crossed  to  Vav-­‐‑
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Cre  mice,  the  STOP  cassette  is  deleted  only  in  Vav-­‐‑Cre-­‐‑expressing  cells,  resulting  in  
expression  of  Tomato  red.  Using  this  strategy,  we  found  that  ~98.7%  of  E11.5  fetal  liver  
HSCs  (c-­‐‑Kit+  Lin-­‐‑  AA4.1+)  and  ~99.4%  of  HSCs  at  E13.5  are  Tomato  positive,  indicating  
that  Vav-­‐‑Cre  is  effectively  expressed  and  functional  in  fetal  HSCs  (Figure  1).  
  
Figure  1:  Efficiency  of  Vav-­‐‑Cre-­‐‑mediated  recombination  in  fetal  HSCs.  
Figure  1:  Vav-­‐‑Cre-­‐‑mediated  recombination  in  fetal  HSCs  (c-­‐‑Kit+  Lin-­‐‑  AA4.1+;  KL  AA4.1+).  Vav-­‐‑Cre  
mice  were  crossed  to  Rosa26-­‐‑stop-­‐‑tdTomato  reporter  mice.  Representative  FACS  histogram  shows  
reporter  activity  (Tomato  expression)  in  KL  AA4.1+  cells  from  control  (Tomato+;  Vav-­‐‑Cre-­‐‑)  and  
Tomato+;  Vav-­‐‑Cre+  littermates  at  E11.5  and  E13.5;  n=2-­‐‑7  mice  for  each  genotype  for  each  
gestational  age.  
  
Following  the  generation  of  blood-­‐‑specific  Lis1  knockout  mice,  we  performed  
genomic  polymerase  chain  reaction  (PCR)  analysis  of  DNA  extracted  from  CD45-­‐‑
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expression  in  hematopoietic  cells  isolated  from  homozygous  mutants  (Lis1f/f;  Vav-­‐‑Cre;  
hereafter  referred  to  as  Lis1-­‐‑/-­‐‑  mice)  (Figure  2).      
  
Figure  2:  Vav-­‐‑Cre-­‐‑controlled  deletion  of  Lis1  in  fetal  hematopoietic  cells.    
Figure  2:  The  schematic  indicates  the  strategy  for  deletion  of  Lis1  in  hematopoietic  cells  using  
mice  homozygous  for  the  floxed  Lis1  allele  crossed  to  mice  heterozygous  for  the  floxed  Lis1  allele  
and  carrying  a  transgene  in  which  expression  of  the  Cre  recombinase  is  driven  by  the  Vav  
promoter  (top).  Analysis  of  deletion  efficiency  by  genomic  PCR  within  CD45+  PI-­‐‑  (Propidium  
iodide,  live)  fetal  liver  cells  from  E14.5  littermates  (bottom).  
  
3.2.2 Blood-specific deletion of Lis1 leads to a significant reduction in   
fetal liver HSCs and a striking bloodless phenotype. 
Using  our  Vav-­‐‑Cre-­‐‑based  genetic  approach,  we  found  that  out  of  a  total  of  344  
viable  progeny  produced  by  breeding  wild  type  mice  homozygous  for  the  Lis1  floxed  
allele  (Lis1f/f)  to  Vav-­‐‑positive  heterozygotes  (Lis1f/+;  Vav-­‐‑Cre),  0  Lis1-­‐‑/-­‐‑  mice  were  born,  
where  we  expected  86  Lis1-­‐‑/-­‐‑  mice  based  on  normal  Mendelian  ratios.  Subsequently,  the  





























Table  1:  Genotype  of  offspring  derived  from  the  cross  of  Lis1f/f  and  Lis1f/+;  Vav-­‐‑Cre  mice.  
Stage                                                                                                         Genotype             p-­‐‑value  
   Lis1f/+   Lis1f/f   Lis1f/+;  Vav-­‐‑Cre   Lis1f/f;  Vav-­‐‑Cre     
12.5  dpc   25   28   18   19   0.38  
14.5  dpc   8   9   5   11   0.52  
15.5  dpc   3   2   0   2   0.44  
18.5  dpc   9   7   8   0   *0.04  
Postnatal   140   94   110   0   ***2.02x10-­‐‑27  
  
In  a  retrospective  analysis,  we  found  that  during  gestation,  loss  of  Lis1  led  to  a  
strikingly  abnormal  phenotype  at  E14.5  (Figure  3).  Although  grossly  normal  in  form  and  
size,  Lis1-­‐‑/-­‐‑  embryos  are  nevertheless  quite  pale  in  color,  suggesting  severe  anemia.    
  
Figure  3:  Blood-­‐‑specific  deletion  of  Lis1  leads  to  a  bloodless  phenotype.    
Figure  3:  Representative  image  of  Control  (Lis1f/+,  upper  left)  and  Lis1-­‐‑/-­‐‑  (Lis1f/f;  Vav-­‐‑Cre,  upper  
right)  littermates  at  E14.5.  Representative  hematoxylin  and  eosin  (H&E)  stain  of  fetal  liver  from  





Histologically,  hematoxylin  and  eosin  (H&E)  stains  of  wild  type  and  Lis1-­‐‑/-­‐‑  fetal  
livers  at  E14.5  show  a  conspicuous  loss  of  total  hematopoietic  cells  within  the  fetal  liver  
of  Lis1-­‐‑/-­‐‑  mice  (Figure  3).  Most  noticeably,  erythropoietic  islands  are  numerous  in  wild  
type  but  not  readily  identifiable  in  Lis1-­‐‑/-­‐‑  fetal  livers.  Interestingly,  Lis1  deletion  led  to  a  
~13.5  fold  reduction  in  the  frequency  of  HSCs  (c-­‐‑Kit+  Lin-­‐‑  AA4.1+)  in  the  fetal  liver  at  
E14.5  (Figure  4a).  Importantly,  the  7-­‐‑fold  expansion  of  HSCs  that  occurs  between  E12.5-­‐‑
E15.5  and  leads  to  the  ultimate  generation  of  a  functional  hematopoietic  system  failed  to  
occur  in  the  absence  of  Lis1  (Figure  4b).  These  data  suggest  that  an  underlying  HSC  
defect  may  be  responsible  for  the  bloodless  phenotype  of  Lis1-­‐‑/-­‐‑  mice.  
  
Figure  4:  Failure  of  fetal  HSC  expansion  in  the  absence  of  Lis1.    
Figure  4:  a,  Fetal  liver  cells  from  Control  (Lis1f/+)  and  Lis1-­‐‑/-­‐‑  mice  were  analyzed  for  frequency  of  
fetal  HSCs  (cKit+  Lin-­‐‑  AA4.1+;  KL  AA4.1+).  Dot  plots  are  shown  for  one  representative  Control  
(left)  and  Lis1-­‐‑/-­‐‑  (right)  E14.5  embryo.  b,  Absolute  number  of  fetal  HSCs  (KL  AA4.1+)  from  Control  
(Lis1f/+  or  Lis1f/f;  solid  squares)  or  Lis1-­‐‑/-­‐‑  (squares)  mice  at  different  gestational  ages;  n=3-­‐‑5  mice  for  

















































3.2.3 Loss of Lis1 impairs fetal HSC self-renewal activity in vitro and 
in vivo. 
To  determine  whether  the  failure  of  fetal  HSC  expansion  in  vivo  was  linked  to  
functional  defects  in  self-­‐‑renewal  we  first  assessed  colony  formation  in  methylcellulose  
cultures.    An  identical  number  of  whole  fetal  liver  cells  from  wild  type  or  Lis1-­‐‑/-­‐‑  
littermates  were  cultured  in  methylcellulose  to  detect  colony  formation.  Loss  of  Lis1  led  
to  a  3-­‐‑fold  reduction  in  total  colony  formation  (Figure  5a).  Importantly,  the  fact  that  the  
types  of  colonies  formed  (erythroid,  BFU-­‐‑E;  myeloid,  CFU-­‐‑GM;  multi-­‐‑lineage,  CFU-­‐‑
GEMM)  were  similar  between  wild  type  and  Lis1-­‐‑deficient  cells  indicated  that  
differentiation  capacity  was  unaffected  in  the  absence  of  Lis1  (Figure  5b-­‐‑d).    
  
Figure  5:  Impaired  self-­‐‑renewal  capacity  of  Lis1-­‐‑deficient  fetal  HSCs  in  vitro.  
Figure  5:  a,  Total  number  of  colonies  generated  from  plating  5,000  whole  fetal  liver  cells  from  
Control  (Lis1f/+  or  Lis1f/f)  and  Lis1-­‐‑/-­‐‑  embryos.  b-­‐‑d,  Deconstruction  of  total  number  of  colonies  into  
the  number  of  individual  types  of  colonies  generated:  BFU-­‐‑E  (b),  CFU-­‐‑GM  (c)  and  CFU-­‐‑GEMM  
















































































































CFU-­‐‑GM  and  CFU-­‐‑GEMM  were  determined  on  Day  10  (*p=0.0194  for  BFU-­‐‑E,  *p=0.0305  for  CFU-­‐‑
GM,  *p=0.0132  for  CFU-­‐‑GEMM).  Error  bars  show  the  standard  error  of  mean  (SEM).    
 
 
To  test  the  self-­‐‑renewal  capacity  of  Lis1-­‐‑deficient  fetal  HSCs  in  vivo,  we  
transplanted  HSC-­‐‑enriched  cells  (Lin-­‐‑  AA4.1+)  from  either  wild  type  or  Lis1-­‐‑/-­‐‑  E14.5  
littermates  into  lethally  irradiated  congenic  recipients.  While  transplantation  of  wild  
type  HSC-­‐‑enriched  cells  led  to  ~53%  donor  chimerism  at  4  months  post-­‐‑transplant,  no  
chimerism  (0%)  was  detected  in  mice  reconstituted  with  Lis1-­‐‑deficient  cells,  suggesting  
that  loss  of  Lis1  affects  fetal  HSC  self-­‐‑renewal  in  vivo  (Figure  6a,  b).    
  
Figure  6:  Loss  of  Lis1  impairs  self-­‐‑renewal  of  fetal  HSCs  in  vivo.    
Figure  6:  a,  Representative  FACS  profile  of  donor  chimerism  (4  months)  in  CD45.1+  recipients  
transplanted  with  5,000  HSC-­‐‑enriched  cells  (Lin-­‐‑  AA4.1+)  from  either  Control  (Lis1f/+)  or  Lis1-­‐‑/-­‐‑    
E14.5  embryos.  b,  Average  donor  chimerism  at  different  times  post-­‐‑transplantation  (2-­‐‑4  donor  
mice  were  used  for  each  genotype  and  4-­‐‑6  recipient  mice  in  each  cohort).  Control  is  shown  with  
solid  squares  and  Lis1-­‐‑/-­‐‑  is  shown  with  open  squares.  Error  bars  show  the  standard  error  of  the  
mean  (SEM).      
  
In  support  of  a  requirement  for  Lis1  in  HSC  renewal  activity  in  vivo,  we  also  
performed  whole  fetal  liver  transplants  to  test  HSC  function  irrespective  of  phenotype.  







































While  transplantation  of  wild  type  whole  fetal  liver  cells  led  to  ~70.4%  donor  chimerism,  
transplantation  of  Lis1-­‐‑deficient  whole  fetal  liver  cells  led  to  a  chimerism  of  ~0.2%,  
indicating  that  the  loss  of  Lis1  affected  functional  HSCs  and  is  unlikely  to  have  simply  
led  to  changes  in  phenotype  (Figure  7).      
  
Figure  7:  Repopulation  ability  of  Lis1-­‐‑deficient  whole  fetal  liver  cells.  
Figure  7:  a,  Experimental  scheme  used  to  test  repopulation  ability  of  Lis1-­‐‑deficient  whole  fetal  
liver  cells.  300,000  whole  fetal  liver  cells  from  control  (Lis1f/f)  and  Lis1-­‐‑/-­‐‑  (Lis1f/f;  Vav-­‐‑Cre)  CD45.2+  
littermates  at  E12.5  were  transplanted  along  with  300,000  Sca1-­‐‑depleted  recipient-­‐‑type  (CD45.1+)  
whole  bone  marrow  cells  into  CD45.1+  recipient  mice.  b,  Representative  FACS  plot  shows  donor  
chimerism  (CD45.2+)  in  recipients  that  received  either  control  or  Lis1-­‐‑/-­‐‑  cells  at  8  weeks  post-­‐‑
transplantation.  c,  Average  donor  chimerism  at  8  weeks  post-­‐‑transplantation  (n=3-­‐‑4  recipients  
per  genotype;  **p=0.0041).  
  
Collectively,  these  data  demonstrate  Lis1  plays  an  essential  role  in  the  maintenance  of  
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3.2.4 Lis1 has a broad impact on HSC function at multiple sites during 
embryonic development. 
Although  HSCs  primarily  expand  and  differentiate  within  the  fetal  liver  during  
embryonic  development,  HSCs  emerge  and  are  found  in  other  anatomic  sites  including  
the  placenta,  which  accrues  a  reservoir  of  HSCs  during  mid-­‐‑gestation,  and  possibly  the  
yolk  sac  (Alvarez-­‐‑Silva  et  al.  2003;  Ema  and  Nakauchi  2000;  Gekas  et  al.  2005;  Ottersbach  
and  Dzierzak  2005).  In  this  regard,  we  tested  the  impact  of  Lis1  deletion  on  yolk  sac  and  
placental  hematopoiesis.  The  Vav-­‐‑Cre-­‐‑driver  led  to  a  partial  deletion  of  Lis1  in  CD34+  
stem/progenitor  yolk  sac  cells  at  E11.5  (Figure  8a).  Although  we  found  no  change  in  the  
frequency  of  CD34+  cells  (Figure  8b),  this  partial  deletion  of  Lis1  led  to  a  ~11-­‐‑fold  
reduction  in  total  colony  formation  (Figure  8c).      
  
Figure  8:  Analysis  of  colony-­‐‑forming  ability  of  HSCs/progenitors  from  yolk  sac.  
Figure  8:  a-­‐‑c,  Impact  of  loss  of  Lis1  on  colony-­‐‑forming  ability  of  stem/progenitor  cells  isolated  
from  the  yolk  sac  and  placenta.  a,  Analysis  of  deletion  efficiency  in  yolk  sac.  7AAD-­‐‑  CD34+  yolk  
sac  cells  were  isolated  from  control  (Lis1f/f)  and  Lis1-­‐‑/-­‐‑  (Lis1f/f;  Vav-­‐‑Cre)  littermates  at  E11.5  and  RT-­‐‑
PCR  analysis  performed  to  determine  expression  of  Lis1  mRNA  (water  was  used  as  a  negative  














































































Lis1f/+)  and  Lis1-­‐‑/-­‐‑  mice  (n=2-­‐‑4  mice  for  each  cohort).  c,  Total  number  of  colonies  generated  from  
plating  500  CD34+  yolk  sac  cells  from  control  (Lis1f/f  or  Lis1f/+)  and  Lis1-­‐‑/-­‐‑  embryos.  Data  are  
compiled  from  2-­‐‑4  embryos  of  each  genotype  in  triplicate  assay  wells;  ****p<0.0001.  Error  bars  
show  the  standard  error  or  mean  (SEM).  
  
Likewise,  we  found  that  Vav-­‐‑Cre-­‐‑mediated  deletion  of  Lis1  led  to  a  partial  
deletion  of  Lis1  in  c-­‐‑Kit+  CD34+  stem/progenitor  placenta  cells  at  E12.5,  which  had  no  
affect  on  the  frequency  of  this  population.  However,  c-­‐‑Kit+  CD34+  placenta  cells  from  
homozygous  mutants  failed  to  form  colonies  in  vitro.  This  data  suggest  Lis1  may  have  a  
significant  impact  on  hematopoietic  stem  cell  function  at  multiple  sites  during  
embryogenesis  (Figure  9).    
  
Figure  9:  Analysis  of  colony-­‐‑forming  ability  of  HSCs/progenitors  from  placenta.  
Figure  9:  a-­‐‑c,  Impact  of  loss  of  Lis1  on  colony-­‐‑forming  ability  of  stem/progenitor  cells  isolated  
from  the  placenta.  a,  Analysis  of  deletion  efficiency  in  placenta.  7AAD-­‐‑  c-­‐‑Kit+  CD34+  placenta  cells  
were  isolated  from  control  (Lis1f/f)  and  Lis1-­‐‑/-­‐‑  (Lis1f/f;  Vav-­‐‑Cre)  littermates  at  E12.5  and  RT-­‐‑PCR  
analysis  performed  to  determine  expression  of  Lis1  mRNA  (water  was  used  as  a  negative  
control).  b,  Average  frequency  of  c-­‐‑Kit+  CD34+  stem/progenitor  placenta  cells  from  control  (Lis1f/f  
or  Lis1f/+)  and  Lis1-­‐‑/-­‐‑  mice  (n=5-­‐‑6  mice  for  each  cohort).  c,  Total  number  of  colonies  generated  from  
plating  300  c-­‐‑Kit+  CD34+  placenta  cells  from  control  (Lis1f/f  or  Lis1f/+)  and  Lis1-­‐‑/-­‐‑  embryos.  Data  are  
compiled  from  5-­‐‑6  embryos  of  each  genotype  in  triplicate  assay  wells;  ***p=0.0001.  Error  bars  


















































































Self-­‐‑renewing  hematopoietic  stem  cells  (HSC)  are  at  the  apex  of  the  
hematopoietic  hierarchy  on  the  basis  of  their  ability  to  generate  all  cell  types  of  the  blood  
system  (Orkin  and  Zon  2008).  During  embryogenesis,  HSCs  are  generated  de  novo  in  
numerous  anatomical  sites  but  primarily  expand  and  differentiate  within  the  fetal  liver  
(Mikkola  and  Orkin  2006).  The  expansion  of  the  HSC  population  within  the  fetal  liver  is  
essential  to  ensure  that  enough  stem  cells  are  generated  to  sustain  postnatal  life  and  to  
permit  the  geometric  expansion  of  differentiated  cells  immediately  required  for  
embryonic  growth  and  development.  This  period  of  HSC  expansion  during  
development  depends  on  the  ability  of  HSCs  to  self-­‐‑renewal  (divide  and  make  more  
stem  cells).  Several  intrinsic  regulators  of  fetal  HSC  self-­‐‑renewal  have  been  identified  
including  Sox17,  Rae28,  Meis1  and  c-­‐‑myb  (Azcoitia  et  al.  2005;  Hisa  et  al.  2004;  Kim  et  al.  
2007;  Kim  et  al.  2004;  Kirito  et  al.  2004;  Mucenski  et  al.  1991;  Ohta  et  al.  2002;  Rebel  et  al.  
2002;  Sandberg  et  al.  2005).  These  intrinsic  factors  integrate  with  extrinsic  cues  to  
promote  self-­‐‑renewal  divisions  of  fetal  HSCs.    
Here,  we  show  that  the  dynein-­‐‑binding  protein,  Lis1  plays  a  role  in  fetal  
hematopoiesis.  Blood-­‐‑specific  deletion  of  Lis1  leads  to  a  strikingly  bloodless  phenotype  
that  comparably  mirrors  the  phenotypes  observed  following  the  genetic  deletion  of  
known  HSC  self-­‐‑renewal  regulators  such  as  Aml-­‐‑1/Runx1,  Gata-­‐‑2  and  MLL  (Okuda  et  
al.  1996;  Porcher  et  al.  1996;  Tsai  et  al.  1994;  Wang  et  al.  1996).  The  similarities  in  
  50  
phenotype  suggest  the  intriguing  possibility  that  events  controlled  by  Lis1  activity  may  
be  integrated  with  the  function  of  these  transcription  factors. Probing  into  Lis1’s  role  in  
fetal  hematopoiesis,  we  find  Lis1  is  critically  required  for  fetal  HSC  self-­‐‑renewal  activity.    
Specifically,  data  from  both  in  vitro-­‐‑based  experiments  and  transplantation-­‐‑based  in  vivo  
assays  convincingly  show  that  the  genetic  deletion  of  Lis1  leads  to  strong  defects  in  fetal  
HSCs.  Interestingly,  the  loss  of  Lis1  impairs  the  self-­‐‑renewal  ability  of  stem/progenitor  
cells  from  multiple  sites  of  blood  development  including  the  yolk  sac,  placenta  and  the  
fetal  liver.  To  date,  while  several  regulators  of  self-­‐‑renewal  of  fetal  liver  HSCs  have  been  
identified,  the  cell-­‐‑intrinsic  mediators  of  yolk  sac  and  placental  HSCs  are  largely  
unknown.    Thus,  the  identification  of  Lis1  as  an  important  regulator  of  HSC  function  in  
HSCs  from  non-­‐‑fetal  liver  sites  during  development  underscore  the  key  requirement  for  
Lis1  in  HSC  activity  broadly  during  embryogenesis.    
Interestingly,  a  role  for  Lis1  in  stem  cell  self-­‐‑renewal  has  also  been  shown  in  the  
mammalian  nervous  system.  During  neural  development,  neuroepithelial  stem  cells  
undergo  rapid  symmetric  renewal  divisions  to  expand  and  grow  the  neural  tube,  which  
is  fundamental  to  the  formation  of  the  brain.  Recently  it  was  shown  that  Lis1  is  critically  
required  for  the  maintenance  of  proliferative  neuroepithelial  stem  cells.  In  the  absence  of  
Lis1,  neuroepithelial  expansion  of  neuroepithelial  stem  cells  fails  to  occur  and  instead  
neuroepithelial  stem  cells  undergo  apoptotic  cell  death  (Yingling  et  al.  2008).  Thus,  these  
data  implicating  Lis1  in  the  self-­‐‑renewal  of  neural  stem  cells  along  with  our  finding  that  
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Lis1  is  essential  for  blood  stem  cell  renewal  during  development  highlight  the  
significance  of  Lis1  function  to  the  regulation  and  maintenance  of  stem  cell  identity.      
  52  
4. Critical requirement for Lis1 in the self renewal of 
adult HSCs 
4.1 Introduction 
Intrinsic  regulators  of  hematopoietic  stem  cell  (HSC)  self-­‐‑renewal  might  be  
distinct  or  shared  between  HSCs  derived  from  the  fetal  liver  and  from  that  of  the  adult  
bone  marrow.  A  number  of  genes  including  Sox17  regulate  the  maintenance  of  fetal  but  
not  adult  HSCs  (Kim  et  al.  2007).  In  contrast,  a  number  of  genes  including  Gfi-­‐‑1,  Tel/Etv6  
and  Bmi-­‐‑1  maintain  adult  but  not  fetal  HSCs  (Hock  et  al.  2004a;  Hock  et  al.  2004b;  Park  
et  al.  2003).  In  addition  to  differences  in  transcriptional  regulation,  fetal  and  adult  HSCs  
differ  in  terms  of  gene  expression  profile,  surface  marker  expression,  developmental  
potential  and  self-­‐‑renewal  capacity  (Ikuta  et  al.  1990;  Ivanova  et  al.  2002;  Morrison  et  al.  
1995;  Phillips  et  al.  2000).    
Although  there  are  clear  differences  between  fetal  and  adult  HSCs,  several  genes  
appear  to  regulate  the  maintenance  of  HSCs  throughout  fetal  and  adult  including  Rae28,  
Meis1  and  c-­‐‑myb,  suggesting  key  players  implicated  in  the  regulation  of  fetal  HSCs  may  
have  a  conserved  functional  role  in  the  adult  system.  (Azcoitia  et  al.  2005;  Hisa  et  al.  
2004;  Kim  et  al.  2004;  Kirito  et  al.  2004;  Mucenski  et  al.  1991;  Ohta  et  al.  2002;  Rebel  et  al.  
2002;  Sandberg  et  al.  2005).    Determining  whether  Lis1  plays  a  role  in  the  adult  blood  
system  and  in  particular  adult  HSC  self-­‐‑renewal  will  provide  further  insight  into  the  
similarities  and  differences  between  fetal  and  adult  HSCs.  
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4.2 Results 
4.2.1 Use of a tamoxifen-inducible cre system leads to effective 
deletion of Lis1 in adult HSCs. 
To  determine  if  Lis1  has  a  conserved  functional  role  in  the  adult  blood  system,  
we  took  a  genetic  approach  and  crossed  floxed  Lis1  mice  to  mice  harboring  a  Cre-­‐‑
recombinase-­‐‑O-­‐‑estrogen-­‐‑Receptor-­‐‑T2  (Cre-­‐‑ERT2)  allele  targeted  to  the  ubiquitously  
expressed  ROSA26  locus  (denoted  hereafter  as  Lis1f/f;  Rosa-­‐‑creER  mice)  (Ventura  et  al.  
2007).  In  these  mice,  the  ERT2  moiety  fused  to  Cre  retains  the  recombinase  inactive  in  the  
cytosol  until  tamoxifen  administration  releases  this  inhibition.  Thus,  tamoxifen  delivery  
allows  effective  temporal  control  over  Lis1  deletion.    
To  induce  Lis1  deletion  in  adult  mice,  both  Lis1f/f;  Rosa-­‐‑creER  and  Lis1+/+;  Rosa-­‐‑
creER  control  mice  were  administered  tamoxifen  daily  for  five  consecutive  days  (Figure  
10a).  Three  days  post-­‐‑tamoxifen  treatment,  we  performed  genomic  polymerase  chain  
reaction  (PCR)  analysis  and  showed  that  in  tamoxifen-­‐‑treated  Lis1f/f;  Rosa-­‐‑creER  mice,  the  
floxed  allele  was  effectively  deleted  and  the  undeleted  allele  could  no  longer  be  detected  
in  adult  bone  marrow  HSC-­‐‑enriched  cells  (c-­‐‑Kit+  Lin-­‐‑  Sca-­‐‑1+  or  KLS)  (Figure  10b).  
Furthermore,  real-­‐‑time  (RT)-­‐‑PCR  analysis  indicated  a  clear  reduction  in  Lis1  mRNA  
expression  in  KLS  cells  (Figure  10b).  In  support  of  this,  quantitative  PCR  showed  a  
92.4%  reduction  of  Lis1  mRNA  expression  in  these  cells  (Figure  10c).  To  further  confirm  
that  our  tamoxifen  regiment  effectively  led  to  Lis1  deletion,  we  immunostained  highly  
enriched  HSCs  (KLS  CD48-­‐‑)  for  Lis1  and  found  that  Lis1  protein  expression  is  markedly  
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reduced  in  HSCs  after  tamoxifen  administration  (Figure  10d,e).  Collectively,  these  data  
demonstrate  that  we  could  effectively  delete  Lis1  in  adult  HSCs  using  our  tamoxifen-­‐‑
inducible  cre  system  and  that  this  model  could  be  used  to  test  the  requirement  of  Lis1  in  
adult  HSC  renewal.    
 
Figure  10:  Tamoxifen-­‐‑inducible  cre  activity  effectively  leads  to  Lis1  deletion  in  adult  
hematopoietic  stem  cells.    
Figure  10:  a,  Schematic  shows  strategy  for  deletion  of  Lis1  in  adult  mice.  Both  control  (Lis1+/+;  
Rosa26-­‐‑creER/Rosa26-­‐‑creER,  indicated  as  Lis1+/+;  Rosa-­‐‑creER)  and  Lis1f/f;  Rosa26-­‐‑creER/Rosa26-­‐‑creER  
(indicated  as  Lis1f/f;  Rosa-­‐‑creER)  mice  were  administered  tamoxifen  daily  for  5  days.  Analyses  and  
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genomic  PCR  analysis  (top)  and  RT-­‐‑PCR  (bottom).  Genomic  DNA  from  HSC-­‐‑enriched  cells  (c-­‐‑
Kit+  Lin-­‐‑  Sca1+  or  KLS)  isolated  from  tamoxifen-­‐‑treated  control  (Lis1+/+;  Rosa-­‐‑creER,  indicated  as  
+/+),  corn  oil-­‐‑treated  control  (Lis1f/f;  Rosa-­‐‑creER,  indicated  as  f/f)  and  tamoxifen-­‐‑treated  Lis1f/f;  Rosa-­‐‑
creER  (indicated  as  -­‐‑/-­‐‑)  mice.  For  RT-­‐‑PCR  analysis,  KLS  cells  were  isolated  from  control  (+/+)  and  
(-­‐‑/-­‐‑)  mice  and  RT-­‐‑PCR  analysis  was  performed  to  determine  expression  of  Lis1  mRNA  (water  was  
used  as  a  negative  control).  c,  Analysis  of  Lis1  deletion  efficiency  by  quantitative  PCR.  For  qPCR,  
KLS  cells  were  isolated  from  control  and  Lis1f/f;  Rosa-­‐‑creER  mice  and  realtime  PCR  analysis  
performed  to  determine  expression  of  Lis1  mRNA  (n=2;  ***p=0.0004).  Expression  levels  were  
normalized  and  displayed  relative  to  the  control  TATA-­‐‑binding  protein  (TBP).  All  error  bars  
show  the  standard  error  of  the  mean  (SEM).  d,  Analysis  of  Lis1  deletion  efficiency  by  
immunofluorescence.  HSCs  (KLS  CD48-­‐‑)  isolated  from  control  and  Lis1f/f;  Rosa-­‐‑creER  mice  3  days  
post-­‐‑tamoxifen  treatment  were  immunostained  with  anti-­‐‑Lis1  antibody  (green)  and  4′,  6-­‐‑
diamidino-­‐‑2-­‐‑phenylindole  (DAPI,  blue)  and  fluorescence  intensity  was  quantified,  ****p<0.0001.  
a.u.,  arbitrary  units.    
  
4.2.2 Adult Lis1-deficient HSCs have a cell-autonomous defect in self-
renewal in vivo   
Using  our  tamoxifen-­‐‑inducible  Lis1  deletion  strategy,  we  found  that  loss  of  Lis1  
in  adult  mice  led  to  a  significant  reduction  in  the  frequency  and  absolute  number  of  
adult  HSCs  (c-­‐‑Kit+  Lin-­‐‑  Sca-­‐‑1+  Flt3-­‐‑)  (Figure  11).  
 
Figure  11:  Reduction  in  the  frequency  and  absolute  number  of  adult  HSCs  in  the  





















































Figure  11:  a,  Average  frequency  of  HSCs  (KLS  Flt3-­‐‑,  KLSF)  in  whole  bone  marrow  from  control  
(+/+)  and  (-­‐‑/-­‐‑)  mice;  n=6  for  control  (+/+),  n=5  for  (-­‐‑/-­‐‑);  *p=0.0268.  b,  Absolute  number  of  HSCs  in  
whole  bone  marrow  from  control  (+/+)  and  (-­‐‑/-­‐‑)  mice;  n=6  for  control  (+/+),  n=5  for  (-­‐‑/-­‐‑);  **p=0.0085.  
b,  Representative  FACS  plots  of  HSCs  (KLSF)  from  control  (+/+)  and  (-­‐‑/-­‐‑)  mice.  
  
  
Functionally,  self-­‐‑renewal  and  reconstitution  ability  of  adult  HSCs  was  also  
affected  by  Lis1  deletion  in  vivo.  Specifically,  while  transplantation  of  HSCs  (c-­‐‑Kit+  Lin-­‐‑  
Sca-­‐‑1+  CD150+  CD48-­‐‑)  from  tamoxifen-­‐‑treated  control  (Lis1+/+;  Rosa-­‐‑creER)  mice  led  to  
increasing  average  donor  chimerism  from  39%  to  51%  over  time,  mice  reconstituted  with  
Lis1-­‐‑deficents  cells  showed  a  gradual  loss  in  donor  chimerism  from  ~6.5%  to  0%  (Figure  
12).  These  data  suggest  that,  similar  to  Lis1’s  role  in  fetal  development,  Lis1  is  also  
required  for  the  self-­‐‑renewal  of  HSCs  during  adulthood.  
 
Figure  12:  Lis1-­‐‑deficient  cells  have  impaired  reconstitution  ability  in  vivo.  
Figure  12:  a,  Repopulation  efficiency  of  Lis1-­‐‑/-­‐‑  HSCs.  Representative  FACS  plots  shows  donor  
chimerism  (CD45.2+  cells)  in  recipients  transplanted  with  500  HSCs  (KLS  CD150+  CD48-­‐‑)  from  
control  (+/+)  or  (-­‐‑/-­‐‑)  mice.  FACS  analysis  was  performed  28  weeks  post-­‐‑transplantation.  b,  
Average  donor  chimerism  at  different  times  after  transplantation  (5-­‐‑6  mice  per  cohort).  Control  










































To  determine  whether  the  reduced  donor  chimerism  observed  in  recipients  that  
received  Lis1-­‐‑deficient  cells  was  due  to  a  failure  of  Lis1-­‐‑deficient  HSCs  to  properly  home  
to  the  bone  marrow  following  transplantation,  we  transplanted  whole  bone  marrow  
cells  from  either  tamoxifen-­‐‑treated  control  (Lis1+/+;  Rosa-­‐‑creER)  or  Lis1f/f;  Rosa-­‐‑creER  mice  
into  irradiated  recipients.  A  short  period  after  transplantation,  mice  that  received  Lis1-­‐‑
deficient  cells  displayed  similar  levels  of  donor  chimerism  compared  to  mice  that  
received  control  cells,  suggesting  that  the  observed  long-­‐‑term  renewal  defects  of  Lis1-­‐‑
deficient  HSCs  were  unlikely  to  be  a  consequence  of  impaired  homing  (Figure  13).  
  
Figure  13:  Loss  of  Lis1  does  not  affect  homing  ability  of  bone  marrow  cells.  
Figure  13:  a-­‐‑b,  Relative  homing  ability  of  control  and  Lis1-­‐‑/-­‐‑  bone  marrow  cells.  A  total  of  5  x  106  
bone  marrow  cells  from  control  (Lis1+/+;  Rosa-­‐‑creER)  and  Lis1f/f;  Rosa-­‐‑creER  mice  1  day  post-­‐‑
tamoxifen  injections  were  transplanted  into  irradiated  recipients  (n=4-­‐‑5  in  each  group),  and  the  
presence  of  donor-­‐‑derived  cells  was  analyzed  by  FACS  6  hr  post  transplant  (b).    
  












































of  the  ubiquitous  Rosa26  promoter.  Thus,  following  tamoxifen  treatment,  Lis1  is  deleted  
in  non-­‐‑hematopoietic  tissues  as  well.  In  this  regard,  non-­‐‑cell-­‐‑autonomous  defects  may  
underlie  the  impaired  self-­‐‑renewal  of  HSCs  following  Lis1  deletion.  To  address  this,  we  
initially  tested  whether  the  HSC  bone  marrow  niche  was  affected  by  the  loss  of  Lis1,  and  
find  that  the  frequency  and  extent  of  microenvironmental  elements  of  the  bone  marrow  
such  as  VE-­‐‑Cadherin+  blood  vessels  and  Osterix+  osteoblasts  are  largely  unaffected  
following  in  vivo  deletion  of  Lis1  (Figure  14).    
 
Figure  14:  Frequency  and  extent  of  bone  marrow  microenvironmental  elements  are  
unaffected  in  the  absence  of  Lis1.  
Figure  14:  a-­‐‑d,  Analysis  of  microenvironment  of  control  (Lis1+/+;  Rosa-­‐‑creER;  +/+)  and  Lis1f/f;  Rosa-­‐‑
creER  (-­‐‑/-­‐‑)  mice  that  were  administered  tamoxifen  daily  for  4  days.  a,  Bone  marrow  sections  from  




































































DAPI  in  blue).  b,  Average  fluorescence  intensity  of  Osterix  in  bone  shaft,  femur  head,  and  
trabecular  bone  regions  of  control  (+/+)  and  (-­‐‑/-­‐‑)  mice.  Data  are  compiled  from  two  independent  
experiments;  n=2-­‐‑3  mice  per  genotype.  c,  Representative  images  of  VE-­‐‑Cadherin  (white)  
expression  in  different  matched  regions  of  the  bone  marrow  in  control  (+/+)  and  (-­‐‑/-­‐‑)  mice  injected  
with  anti-­‐‑VE-­‐‑Cadherin  and  imaged.  d,  Average  fluorescence  intensity  of  VE-­‐‑Cadherin  in  two  
bone  marrow  regions  in  control  (+/+)  and  (-­‐‑/-­‐‑)  mice.  Data  are  compiled  from  two  independent  
experiments;  n=2-­‐‑3  mice  per  genotype.  
  
However,  to  exclude  the  possibility  that  unidentified  defects  in  the  
microenvironment  may  impact  HSCs  indirectly,  we  created  chimeras  in  which  only  the  
hematopoietic  system  contained  the  Lis1  floxed  allele  and  the  microenvironment  
remained  wild  type  (Figure  15a).  Thus,  isolated  HSCs  from  untreated  control  Lis1+/+;  
Rosa-­‐‑creER  or  Lis1f/f;  Rosa-­‐‑creER  mice  were  transplanted  into  lethally  irradiated  
recipients.  Eight  weeks  after  transplantation,  donor-­‐‑derived  HSCs  successfully  multi-­‐‑
lineage  repopulated  recipient  mice  (Figure  15b).  Importantly,  we  achieved  80-­‐‑90%  donor  
chimerism  regardless  of  the  genotype  of  the  donor  cells.  At  this  time,  chimeric  mice  
were  treated  with  tamoxifen  to  delete  Lis1  specifically  in  the  hematopoietic  system.  This  




Figure  15:  Significant  reduction  in  the  frequency  of  HSC-­‐‑enriched  cells  in  Lis1  
chimeric  mice.  
Figure  15:  a,  Experimental  scheme  to  generate  chimeras  with  hematopoietic-­‐‑specific  Lis1  deletion;  
1,000  HSCs  (KLS  CD150+  CD48-­‐‑)  from  control  (Lis1+/+;  Rosa-­‐‑creER)  or  Lis1f/f;  Rosa-­‐‑creER  (CD45.2+)  
mice  were  transplanted  into  CD45.1+  recipient  mice.  Two  months  post-­‐‑transplantation,  an  
average  of  ~80%  donor-­‐‑derived  chimerism  was  observed.  All  recipient  mice  were  administered  
tamoxifen  daily  for  5  days  and  analyses  and  cell  sorting  were  performed  3  days  post-­‐‑tamoxifen  
treatment.  b,  Donor  chimerism  prior  to  tamoxifen  (tam)  treatment  was  assessed  two  months  post-­‐‑
transplantation.  (+/+)  indicates  control  Lis1+/+;  Rosa-­‐‑creER  and  (f/f)  indicates    Lis1f/f;  Rosa-­‐‑creER  
transplanted  mice  (6  mice  in  each  cohort).  c,  Frequency  of  donor-­‐‑derived  KLS  cells  in  chimeric  
mice  post-­‐‑deletion.  ((+/+)  +tam)  indicates  mice  that  received  donor  cells  from  Lis1+/+;  Rosa-­‐‑creER  
and  ((f/f)  +tam)  indicates  mice  that  received  donor  cells  from  Lis1f/f;  Rosa-­‐‑creER  mice;  n=3  for  each  
cohort,  *p=0.0277.  
  
To  test  cell  autonomous  stem  cell  function  in  vivo,  donor-­‐‑derived  whole  bone  
marrow  cells  from  both  control  and  Lis1-­‐‑deficient  chimeras  were  re-­‐‑transplanted  into  
recipient  mice.  While  the  average  chimerism  from  control  cells  was  53.5%,  chimerism  
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non-­‐‑chimeric  Lis1  null  mice  (Figure  16).  These  data  suggest  that  adult  Lis1-­‐‑deficient  
HSCs  have  a  cell-­‐‑autonomous  defect  in  self-­‐‑renewal  in  vivo.    
  
Figure  16:  Lis1-­‐‑deficient  HSCs  have  a  cell-­‐‑autonomous  defect  in  self-­‐‑renewal  in  vivo.    
Figure  16:  a-­‐‑b,  Repopulation  ability  of  whole  bone  marrow  (WBM)  cells  isolated  from  Lis1  
chimera  mice.  Lis1  chimeras  that  were  generated  by  transplantation  of  HSCs  derived  from  Lis1f/f;  
Rosa-­‐‑creER  mice  (CD45.2+)  were  treated  with  corn  oil  (f/f  +vehicle)  or  tamoxifen  (f/f  +tam)  daily  
for  5  days.    3  days  post-­‐‑treatment  300,000  WBM  cells  were  transplanted  into  recipient  mice  a,  
Representative  FACS  plots  show  donor  chimerism  (CD45.2+  cells)  in  recipients  that  received  cells  
from  either  control  (f/f  +vehicle)  or  (f/f  +tam)  Lis1  chimeras.  b,  Average  donor  chimerism  at  16  
weeks  post-­‐‑transplantation  (n=3-­‐‑4  recipients  per  cohort;  *p=0.0369).  
  
4.3 Discussion 
The  hallmark  of  hematopoietic  stem  cells  (HSC)  is  their  dual  abilities  to  self-­‐‑
renew  and  to  differentiate  into  multiple  blood  cell  lineages.  Importantly,  the  remarkable  
ability  of  HSCs  to  balance  self-­‐‑renewal  to  maintain  the  HSC  pool  with  differentiation  to  
generate  mature  cells  is  why  the  mammalian  hematopoietic  system  can  generate  1011  






































Orkin  2000).  This  balance  is  critical  not  only  when  the  blood  replaces  cells  to  maintain  
homeostasis,  but  also  after  acute  injury  when  an  exponential  rise  in  HSCs  is  required  to  
quickly  replenish  the  hematopoietic  compartment.  Importantly,  improper  control  of  this  
balance  is  intimately  tied  to  the  development  of  hematological  malignancies.  While  a  
number  of  regulators  and  signaling  pathways  that  are  involved  in  the  control  of  HSC  
self-­‐‑renewal  have  been  identified  including  Notch,  Sonic  hedgehog  and  Wnt,  we  are  
only  beginning  to  understand  the  complex  mechanisms  and  the  interplay  between  cell-­‐‑
intrinsic  and  cell-­‐‑extrinsic  mechanisms  that  control  this  process  (Reya  2003).    
Here  we  show  that  Lis1,  a  facultative  regulator  of  the  minus-­‐‑end  directed  motor  
protein  dynein,  is  not  only  required  for  the  self-­‐‑renewal  activity  of  fetal  HSCs  during  
development,  but  has  a  conserved  functional  role  in  the  adult  blood  system.  By  using  an  
inducible  conditional  knockout  approach  in  adult  mice,  we  demonstrate  that  Lis1  
deletion  results  in  a  loss  of  HSCs.  Furthermore,  specific  deletion  of  Lis1  within  the  
hematopoietic  system  demonstrates  a  cell-­‐‑autonomous  requirement  for  Lis1  in  adult  
HSC  activity.  Several  genes,  including  Rae28,  Meis1  and  c-­‐‑myb  have  also  been  shown  to    
control  HSC  maintenance  in  both  fetal  and  adult  HSCs  and  thus,  events  controlled  by  
Lis1  activity  may  be  integrated  with  the  function  of  these  genes.  (Azcoitia  et  al.  2005;  
Hisa  et  al.  2004;  Kim  et  al.  2004;  Kirito  et  al.  2004;  Mucenski  et  al.  1991;  Ohta  et  al.  2002;  
Rebel  et  al.  2002;  Sandberg  et  al.  2005).      
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   During  adulthood,  HSCs  reside  in  specialized  microenvironments  created  by  
supporting  bone  marrow  cells,  primarily  endothelial  and  osteoblastic  cells,  which  
produce  factors  and  cytokines  that  influence  HSC  activity  (Calvi  et  al.  2003;  Kiel  et  al.  
2005).  Using  a  genetic  system  where  Lis1  presumably  is  deleted  in  non-­‐‑hematopoietic  
tissues,  we  show  that  the  loss  of  Lis1  does  not  significantly  affect  the  integrity  of  VE-­‐‑
Cadherin+  blood  vessels  and  Osterix+  osteoblasts,  suggesting  that  Lis1  does  not  
influence  HSC  activity  in  a  non-­‐‑cell-­‐‑autonomous  manner.  However,  further  studies  
where  Lis1  is  deleted  specifically  in  niche  cell  types  will  need  to  be  done  to  convincing  
demonstrate  whether  Lis1  can  act  in  a  non-­‐‑cell-­‐‑autonomous  manner  to  influence  HSC  
function.  Overall,  we  show  that  Lis1  is  required  for  HSC  self-­‐‑renewal  activity  both  
during  development  and  in  adulthood,  suggesting  that  certain  critical  mechanisms  that  
control  HSC  self-­‐‑renewal  are  not  always  development-­‐‑stage  specific.    
  








5. Cellular and molecular basis of HSC defects that arise 
in the absence of Lis1 
5.1 Introduction 
   Genetic  deletion  of  Lis1  both  during  development  and  in  adult  life  results  in  a  
severe  impairment  of  HSC  self-­‐‑renewal  activity.    In  the  absence  of  Lis1,  fetal  and  adult  
HSCs  exhibit  impaired  colony-­‐‑forming  ability  in  vitro  and  fail  to  effectively  reconstitute  
the  blood  compartment  of  recipient  mice  in  which  endogenous  hematopoiesis  has  been  
lethally  ablated  by  radiation.  Elucidating  the  cellular  and  molecular  basis  of  the  defects  
observed  in  the  absence  of  Lis1  will  aid  in  the  determination  of  the  mechanism(s)  by  
which  Lis1  exerts  its  biological  influence  on  HSC  function.    
     The  ability  of  HSCs  to  maintain  their  numbers  in  homeostasis  as  well  as  to  
effectively  respond  to  acute  injury  depends  on  tight  regulation  of  
quiescence/proliferation,  self-­‐‑renewal,  survival  and  differentiation.  Lis1  has  previously  
been  implicated  in  several  of  these  events.  In  cell  culture  experiments,  LIS1  
overexpression  or  depletion  by  antibody  injection  supports  a  role  for  LIS1  in  a  myriad  of  
dynein-­‐‑dependent  mitotic  functions  (Faulkner  et  al.  2000;  Tai  et  al.  2002).  Consistent  
with  this,  siRNA  knockdown  of  Lis1  in  rat  cortical  slices  results  in  defects  in  cell  division  
(Tsai  et  al.  2005).  A  role  for  Lis1  in  the  control  of  self-­‐‑renewal  and  differentiation  has  
been  demonstrated  in  spermatogenesis  and  in  the  Drosophila  ovary  (Chen  et  al.  2010;  
Nayernia  et  al.  2003).    
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   Interestingly,  a  role  for  Lis1  in  the  regulation  of  stem  cell  division  pattern  has  
been  shown  in  the  mammalian  nervous  system.  During  development,  neuroepithelial  
stem  cells  (NESC)  extensively  self-­‐‑renew  to  grow  the  neural  tube  and  thus,  
predominately  undergo  symmetric  renewal  divisions.  However,  loss  of  Lis1  in  NESCs  
leads  to  spindle  orientation  defects  that  subsequently  affect  the  ability  of  NESCs  to  
control  division  pattern.  As  a  result,  the  normal  expansion  of  the  stem  cell  compartment  
is  profoundly  disrupted  (Yingling  et  al.  2008).  In  hematopoietic  stem  cell  biology,  an  
unresolved  fundamental  question  is  how  self-­‐‑renewal  and  cell  fate  determination  may  
be  influenced  by  mechanisms  associated  with  asymmetric  division.  That  Lis1  has  been  
implicated  in  the  machinery  controlling  division  pattern  in  the  nervous  system  strongly  
suggest  that  Lis1  may  influences  HSC  function  in  this  manner.    
5.2 Results 
5.2.1 Proliferative capacity of both fetal and adult HSCs is unaffected 
in the absence of Lis1.   
In  an  effort  to  understand  the  basis  of  the  hematopoietic  stem  cell  (HSC)  defects  
observed  in  the  absence  of  Lis1,  we  first  examined  proliferation  and  apoptosis.  To  test  
whether  Lis1-­‐‑deficient  HSCs  have  a  reduced  proliferative  capacity  we  performed  in  vivo  
5-­‐‑bromo-­‐‑2'ʹ-­‐‑deoxyuridine  (BrdU)  incorporation  assays  combined  with  intracellular  
staining  for  DNA  content  (7AAD).  In  context  of  fetal  HSCs,  Lis1f/f  mice  were  bred  with  
Lis1f/+;  Vav-­‐‑Cre  mice  and  pregnant  dams  were  administered  BrdU  via  intraperitoneal  
injection.  Following  a  45-­‐‑minute  chase  period,  fetal  liver  cells  were  isolated  from  
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individual  embryos  and  analyzed  for  BrdU  incorporation.  As  shown  in  Figure  17,  BrdU  
incorporation  rates  were  similar  between  control  and  Lis1-­‐‑/-­‐‑  HSCs  (c-­‐‑Kit+  
Lin-­‐‑  AA4.1+)  from  E12.5  fetal  liver,  suggesting  proliferative  capacity  of  fetal  HSCs  is  
largely  unaffected  in  the  absence  of  Lis1.  
  
Figure  17:  Proliferation  of  fetal  HSCs  is  unaffected  in  the  absence  of  Lis1.  
Figure  17:  a-­‐‑b,  Analysis  of  cell  cycle  of  fetal  HSCs.  To  test  proliferation  in  vivo,  pregnant  females  
were  administered  BrdU  and  embryos  analyzed  45  minutes  post-­‐‑BrdU  injection.  a,  
Representative  BrdU/7AAD  cell  cycle  plot  of  fetal  HSCs  (KL  AA4.1+)  in  E12.5.  control  (Lis1f/f)  and    
Lis1-­‐‑/-­‐‑  (Lis1f/f;  Vav-­‐‑Cre)  littermates  b,  Average  frequency  of  BrdU-­‐‑positive  KL  AA4.1+  cells  from  
control  and  Lis1-­‐‑/-­‐‑  mice  at  E12.5.  Data  shown  are  from  two  independent  experiments  (n=4-­‐‑9  per  
cohort).    
  
To  examine  whether  HSC  defects  in  the  adult  blood  system  resulted  from  
impaired  proliferation  of  adult  HSCs,  control  Lis1+/+;  Rosa-­‐‑creER  and  Lis1f/f;  Rosa-­‐‑creER  
mice  were  treated  with  tamoxifen  daily  for  five  days  (D1-­‐‑D5).  On  day  6  (D6),  mice  were  
administered  BrdU  and  bone  marrow  cells  were  analyzed  after  an  18-­‐‑hour  chase  period.  














































cells  (KLS)  and  multipotent  progenitors  (KLS  CD150-­‐‑  CD48+)  incorporated  BrdU  at  a  rate  
similar  to  control  and  displayed  a  normal  cell  cycle  distribution  (G0/G1,  S  and  G2/M).  
Collectively,  these  data  suggest  that  in  both  the  fetal  and  adult,  HSC  proliferation  
proceeds  unabated  following  the  loss  of  Lis1.  
  
Figure  18:  Proliferation  of  adult  bone  marrow  HSCs  is  unaffected  in  the  absence  of  
Lis1.  
Figure  18:  Analysis  of  adult  HSC  cell  cycle  distribution.  a,  Schematic  illustrates  the  strategy  used  
to  determine  cell  cycle  status  of  hematopoietic  cells  following  Lis1  deletion.  Control  (Lis1+/+;  Rosa-­‐‑
creER)  and  Lis1f/f;  Rosa-­‐‑creER  mice  were  administered  tamoxifen  daily  for  5  days  (D1-­‐‑D5).  Mice  
were  pulsed  with  5-­‐‑bromodeoxyuridine  (BrdU)  at  1  day  post-­‐‑injection    (D6).  After  an  18  hr  chase  
period,  bone  marrow  cells  were  analyzed.  b,  Representative  BrdU/7AAD  plot  showing  cell  cycle  



















































































































KLS  (c)  KLS  CD48+  CD150-­‐‑  (d)  KLS  CD150+  CD48-­‐‑  (e)  in  G0/G1,  S,  and  G2/M  cell  cycle  phases  in  
control  (+/+)  and  (-­‐‑/-­‐‑)  mice.  Data  shown  are  from  two  independent  experiments  (n=2-­‐‑3  per  
cohort).  All  error  bars  show  the  standard  error  of  the  mean  (SEM).  
  
5.2.2 Loss of Lis1 in both fetal and adult HSCs leads to necrotic/late 
stage apoptosis.  
To  determine  whether  the  loss  of  Lis1  leads  to  cell  death  in  fetal  HSCs,  we  
stained  fetal  liver  cells  from  Vav-­‐‑Cre-­‐‑mediated  conditional  Lis1  knockout  mice  (Lis1f/f;  
Vav-­‐‑Cre)  for  AnnexinV  and  7AAD  and  found  that  loss  of  Lis1  results  in  a  slight  increase  
in  the  frequency  of  AnnexinV+  7AAD+  necrotic/late  stage  apoptotic  fetal  liver  HSCs  
compared  to  controls  (Figure  19).      
  
Figure  19:  Loss  of  Lis1  leads  to  a  marginal  increase  in  necrotic/late  apoptotic  cells.  
Figure  19:  a-­‐‑c,  Cell  death  of  fetal  HSCs.  a,  Representative  AnnexinV/7AAD  profile  of  fetal  HSCs  
(KL  AA4.1+)  from  control  (Lis1f/f)  and    Lis1-­‐‑/-­‐‑  (Lis1f/f;  Vav-­‐‑Cre)  littermates  at  E12.5.  d-­‐‑e,  Frequency  of  
KL   AA4.1+   cells   undergoing   apoptosis   (AnnexinV+   7AAD-­‐‑)   (b)   or   undergoing   necrosis/late  
apoptosis  (AnnexinV+  7AAD+)  (c)  in  control  (Lis1f/f)  and    Lis1-­‐‑/-­‐‑  (Lis1f/f;  Vav-­‐‑Cre)  littermates  at  E12.5.  
Data   compiled   from   3-­‐‑5   embryos   per   genotype.   All   error   bars   show   the   standard   error   of   the  




























































































To  examine  whether  HSC  defects  in  the  adult  blood  system  resulted  from  
increased  cell  death  of  adult  HSCs,  control  Lis1+/+;  Rosa-­‐‑creER  and  Lis1f/f;  Rosa-­‐‑creER  mice  
were  treated  with  tamoxifen  daily  for  five  days  (D1-­‐‑D5).  As  shown  in  Figure  20,  HSCs  
had  equivalent  frequencies  of  Annexin  V+  7AAD-­‐‑  early  apoptotic  cells  at  several  times  
points  after  Lis1  deletion.  However,  an  increase  in  Annexin  V+  7AAD+  necrotic/late  stage  
apoptotic  cells  was  detected  at  day  6  (D6)  (Figure  20).  
  
Figure  20:  Lis1  deletion  results  in  an  increase  in  late  onset  necrotic/late  stage  apoptotic  




































































































































































































































Figure  20:  Analysis  of  adult  HSC  cell  death.  a,  Schematic  illustrates  the  strategy  used  to  analyze  
cell  death  of  hematopoietic  cells  following  Lis1  deletion.  Control  (Lis1+/+;  Rosa-­‐‑creER)  and  
Lis1f/f;  Rosa-­‐‑creER  mice  were  administered  tamoxifen  daily  for  5  days  (D1-­‐‑D5).  Cell  death  
analysis  was  performed  on  D4,  D5,  during  tamoxifen  treatment  and  1  day  post-­‐‑tamoxifen  
injections  (D6).  b-­‐‑d,  Percentage  of  HSCs  (c-­‐‑Kit+  Lin-­‐‑  Sca1+  CD150+  CD48-­‐‑)  undergoing  apoptosis  
(AnnexinV+  7AAD-­‐‑)  or  undergoing  necrosis/late  apoptosis  (AnnexinV+  7AAD+)  in  control  (+/+)  
and  (-­‐‑/-­‐‑)  mice  on  D4  (b),  D5  (c)  and  D6  (d).  Data  shown  are  from  two  independent  experiments  
(n=2-­‐‑3  per  cohort  for  each  day  analyzed;  *p=0.0141).  All  error  bars  show  the  standard  error  of  the  
mean  (SEM).  
  
Importantly,  as  shown  in  Figure  21,  HSC  depletion  occurred  as  early  as  day  3  
(D3)  after  Lis1  deletion  when  no  change  in  survival  was  observed.  Thus,  although  it  is  
possible  that  a  late  onset  death  contributes,  in  part,  to  the  overall  phenotype  observed,  
the  fact  that  it  occurs  later  than  when  HSC  defects  are  first  observed  suggest  that  Lis1  
may  influence  hematopoietic  stem  cells  through  other  mechanisms.      
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Figure  21:  Early  reduction  in  adult  HSCs  following  the  loss  of  Lis1.    
Figure   21:   a,   Representative   FACS   profile   of   CD48/CD150   expression   within   the   KLS  
compartment  of  control  (+/+)  and  (-­‐‑/-­‐‑)  mice.  b-­‐‑c,  Average  frequency  of  HSCs  (KLS  CD48-­‐‑  CD150+)  
(b)  and  multipotent  progenitors  (MPPs;  KLS  CD48+  CD150-­‐‑)  (c)  within  the  KLS  population  from  
control  (+/+)  and  (-­‐‑/-­‐‑)  mice;  n=3  for  control  (+/+),  n=4  for  (-­‐‑/-­‐‑).  *p=0.0103  for  HSCs  and  *p=0.0211  for  
MPPs.  d-­‐‑e,  Percentage  of  HSCs   (KLS  CD48-­‐‑  CD150+)  undergoing  apoptosis   (AnnexinV+  7AAD-­‐‑)  
(d)  or  undergoing  necrosis/late  apoptosis  (Annexin  V+  7AAD+)  (e)   in  control  (+/+)  and  (-­‐‑/-­‐‑)  bone  
marrow  on  day  3  of  tamoxifen  injections;  n=3  for  control  (+/+),  n=4  for  (-­‐‑/-­‐‑).    
 
 
5.2.3 Loss of Lis1 leads to accelerated differentiation of HSCs in vitro 
and in vivo.  
The  loss  of  the  immature  cell  population  in  vivo  following  Lis1  deletion  suggested  








































































































































actual  rate  of  differentiation  of  Lis1-­‐‑deficient  cells.  To  test  this,  identical  number  of  HSC-­‐‑
enriched  cells  (c-­‐‑Kit+  Lin-­‐‑  Sca-­‐‑1+)  isolated  from  either  Lis1f/f;  Rosa-­‐‑creER  or  control  Lis1+/+;  
Rosa-­‐‑creER  mice  were  plated  in  vitro,  treated  with  4-­‐‑hydroxytamoxifen  (4-­‐‑OH  tamoxifen)  
at  t=0  and  the  generation  of  differentiated  cells  tracked  following  Lis1  deletion,  which  
was  determined  by  genomic  PCR  analysis  (Figure  22).    
  
Figure  22:  Approach  and  efficiency  of  Lis1  deletion  in  vitro.  
Figure   22:   a,   Schematic   illustrates   the   approach   used   to   delete   Lis1   in   vitro.   Briefly,   an  HSC-­‐‑
enriched  fraction  of  bone  marrow  cells  (c-­‐‑Kit+  Lin-­‐‑  Sca1+;  KLS)  was  isolated  from  control  (Lis1+/+;  
Rosa-­‐‑creER)   and   Lis1f/f;   Rosa-­‐‑creER   mice   and   treated   with   4-­‐‑OH-­‐‑tamoxifen   in   liquid   media.   b,  
Analysis  of  deletion  efficiency  by  genomic  PCR  analysis.  Genomic  DNA  from  cultured  KLS  cells  
at  different  time  points  after  4-­‐‑OH-­‐‑tamoxifen  treatment.    
     
By  tracking  the  rate  of  cell  differentiation,  we  found  that  over  a  period  of  24  
hours,  ~23%  of  Lis1-­‐‑/-­‐‑  cells  become  positive  for  lineage  markers  (Lin+)  while  in  control  
cultures  only  ~9%  of  cells  become  positive  for  lineage  markers  (Lin+)  (Figure  23a,b).  
Importantly,  as  shown  in  Figure  23c,  the  observed  increase  in  differentiated  cells  upon  
Lis1  deletion  was  not  due  to  a  preferential  death  of  immature  cells  (Lin-­‐‑).      














Figure  23:  Loss  of  Lis1  leads  to  the  accelerated  differentiation  of  adult  HSCs  in  vitro.  
Figure  23:  a-­‐‑b,  Analysis  of  rate  of  differentiation  of  Lis1-­‐‑/-­‐‑  cells.    Equal  numbers  of  KLS  cells  were  
isolated  from  control  (Lis1+/+;  Rosa-­‐‑creER)  and  Lis1f/f;  Rosa-­‐‑creER  mice  and  treated  with  4-­‐‑OH-­‐‑
tamoxifen  in  vitro.  a,  Representative  FACS  plot  shows  frequency  of  cells  expressing  lineage  
markers  in  control  (+/+;  shown  in  gray)  or  Lis1-­‐‑deficient  (-­‐‑/-­‐‑;  shown  in  black)  populations  24  
hours  post-­‐‑deletion.  b,  Average  frequency  of  cells  expressing  lineage  markers  (Lin+)  cells  in  (+/+)  
and  (-­‐‑/-­‐‑)  cells.  Data  shown  are  from  three  independent  experiments;  ***p=0.0002.  c,  Analysis  of  
apoptosis  in  Lin-­‐‑  and  Lin+  fraction  of  Lis1-­‐‑/-­‐‑  cells.    Percentage  of  Annexin  V+  cells  is  shown  24  
hours  post-­‐‑deletion.  Data  shown  are  from  two  independent  experiments.  Error  bars  show  the  
standard  error  of  mean  (SEM).        
  
Looking  in  more  detail,  we  tracked  the  specific  types  of  differentiated  cells  
generated  following  Lis1  deletion.  Using  fluorescence-­‐‑activated  cell  sorting  (FACS)  
analysis,  we  find  that  of  the  mature  lineage  positive  (Lin+)  Lis1-­‐‑deficient  cell  population,  
81.5%  of  the  Lin+  cells  are  Mac1+  Gr1-­‐‑  cells  (early  myeloid)  and  8.6%  are  Mac+  Gr1+  
(granulocytic).  In  addition,  2.8%  of  cells  are  the  B  lineage  (B220+).  Although  6.0%  
expressed  CD4  and  0.3%  expressed  CD8  neither  co-­‐‑expressed  CD3,  suggesting  either  























































Figure  24:  Accelerated  differentiation  of  Lis1  null  HSCs  into  early  myeloid  cells.  
Figure  24:  a-­‐‑c,  Identical  numbers  of  KLS  cells  were  isolated  from  control  (Lis1+/+;  Rosa-­‐‑creER)  and  
Lis1f/f;  Rosa-­‐‑creER  mice  and  treated  with  4-­‐‑OH-­‐‑tamoxifen  in  vitro.  a,  Frequency  of  cells  expressing  
lineage  markers  (Lin+)  cells  in  control  (+/+)  and  (-­‐‑/-­‐‑)  cells.  Pie  chart  indicated  composition  of  Lin+  
cells   in   (-­‐‑/-­‐‑)   cells.  b,  Representative  FACS  plot  of  Mac1/Gr1  expression   in   (+/+)  and   (-­‐‑/-­‐‑)   cells.   c,  
Frequencies  of  mature  cell  populations  in  (+/+)  and  (-­‐‑/-­‐‑)  cells.  (+/+)  is  shown  in  black  and  (-­‐‑/-­‐‑)   is  
shown  in  white.    
     
Consistent  with  this,  we  analyzed  the  hematopoietic  compartment  in  vivo  for  a  
wave  of  differentiation  that  may  accompany  the  loss  of  HSCs.  Following  three  days  of  












































































(KLS  CD150+  CD48-­‐‑)  into  multipotent  progenitors  (MPP;  KLS  CD150+  CD48+).  
Specifically,  tamoxifen  treated  Lis1f/f;  Rosa-­‐‑creER  mice  had  a  7.5%  reduction  in  HSCs  and  
a  concomitant  11.3%  rise  in  MPPs  (Figure  21a-­‐‑c).  Collectively  our  in  vitro  and  in  vivo  data  
suggest  that  the  loss  of  Lis1  leads  to  the  accelerated  differentiation  of  HSCs.    
5.2.4 Predominance of Numb asymmetry in the absence of Lis1 both 
in vitro and in vivo.   
Because  accelerated  differentiation  can  be  a  consequence  of  defects  in  
asymmetric  division  we  examined  whether  the  absence  of  Lis1  led  to  altered  
polarization  of  fate  determinants  within  the  mother  cell  or  altered  inheritance  of  these  
determinants  by  the  daughter  cells.  Numb  is  an  important  fate  determinant  whose  
expression  can  mark  differentiated  cells.  Specifically,  we  found  by  immunofluorescence  
that  Numb  is  expressed  1.8-­‐‑fold  higher  in  progenitor  cells  (KLS  CD48+)  than  HSCs  (KLS  
CD150+  CD48-­‐‑)  (Figure  25a,b).  In  addition,  PCR  analysis  revealed  a  5.2-­‐‑fold  increase  in  
Numb  mRNA  from  immature  lineage-­‐‑negative  (Lin-­‐‑)  cells  to  mature  lineage-­‐‑positive  
(Lin+)  cells.  Collectively,  these  data  suggest  that  increased  Numb  expression  increases  
with  increased  acquisition  of  the  differentiated  state  (Figure  25b).  Consistent  with  this,  
Numb  was  shown  to  be  inherited  at  higher  levels  by  daughter  cells  that  become  
differentiated  (Wu  et  al.  2007).  We  thus  specifically  tracked  the  polarization  and  
inheritance  of  this  fate  determinant.    
  76  
  
Figure  25:  Expression  of  the  cell  fate  determinant  Numb  can  mark  differentiated  
hematopoietic  cells.  
Figure  25:  a,  Expression  of  Numb  in  HSCs  and  progenitor  cells.  Representative  image  with  
zoomed  inlay  (dotted  white  box)  shows  HSCs  (KLS  CD48-­‐‑  CD150+)  and  progenitor  cells  (KLS  
CD48+)  stained  with  anti-­‐‑Numb  antibody  (green)  and  DAPI  (blue),  63X.  b,  Average  fluorescence  
intensity  of  Numb  in  individual  HSCs  and  progenitor  cells.  c,  Realtime  RT-­‐‑PCR  analysis  of  Numb  
expression  in  Lin-­‐‑  and  Lin+  cells  (n=2  each).  
  
Distribution  of  Numb  was  first  analyzed  in  HSC-­‐‑enriched  cells  (c-­‐‑Kit+  Lin-­‐‑  Sca-­‐‑
1+).  To  test  this,  KLS  cells  were  isolated  from  either  Lis1f/f;  Rosa-­‐‑creER  or  Lis1+/+;  Rosa-­‐‑creER  
control  mice,  treated  with  4-­‐‑OH  tamoxifen  in  vitro  to  delete  Lis1  and  fixed  cells  were  
stained  for  Numb.  In  63%  of  cells  Numb  was  distributed  equally  to  both  sides,  and  in  
37%  Numb  was  polarized  on  one  side  of  the  mother  cell.  As  shown  in  Figure  26c,  in  the  





















































































Figure  26:  Polarization  of  Numb  in  HSCs  is  unaffected  in  the  absence  of  Lis1    
Figure  26:  a,  Experimental  scheme  used  to  determine  Numb  polarization  and  inheritance  in  HSC-­‐‑
enriched  cells.  KLS  cells  were  isolated  from  control  (Lis1+/+;  Rosa-­‐‑creER)  and  Lis1f/f;  Rosa-­‐‑creER  
mice,  treated  with  4OH-­‐‑tamoxifen  in  vitro  and  analyzed  24  hours  post-­‐‑deletion.  b,  Representative  
images  of  individual  cells  with  polarized  or  non-­‐‑polarized  Numb  (Numb  in  red,  DAPI  in  blue,  
zoomed  63x  images).  c,  Frequency  of  control  (+/+)  or  Lis1-­‐‑deficient  (-­‐‑/-­‐‑)  cells  with  polarized  
Numb.  Frequencies  were  determined  out  of  100  tracked  cells  for  each  genotype.  
  
In  cells  in  which  the  cell  fate  determinant  Numb  is  polarized,  the  two  daughters  
depending  on  the  plane  of  division  can  inherit  Numb  equally  or  unequally  (Figure  27a).  
To  assess  whether  there  were  any  changes  in  Numb  inheritance,  we  used  HSC-­‐‑enriched  
cells  in  which  Lis1  was  deleted  in  vitro.  HSC-­‐‑enriched  cells  from  control  Lis1+/+;  Rosa-­‐‑
creER  or  Lis1f/f;  Rosa-­‐‑creER  mice  were  treated  with  4-­‐‑OH  tamoxifen.  Following  Lis1  
deletion,  the  cells  were  stained  for  Numb  and  the  ratio  of  symmetric  and  asymmetric  
cell  divisions  was  determined.  Only  cells  in  late  telophase  or  undergoing  cytokinesis  
were  tracked  to  assess  Numb  inheritance  in  incipient  daughter  cells.  Cells  either  













































top,  symmetric),  or  unequal  distribution,  i.e.  higher  levels  of  Numb  to  one  daughter  and  
lower  levels  to  the  other  (Figure  27b  bottom,  asymmetric).  As  shown  in  Figure  27c,  
control  cells  displayed  two-­‐‑fold  more  symmetric  inheritance  relative  to  asymmetric  
inheritance  of  Numb.  In  contrast,  the  absence  of  Lis1  led  to  a  complete  reversal  in  the  
pattern  of  inheritance  with  two-­‐‑fold  more  cells  undergoing  asymmetric  divisions  where  
one  daughter  inherited  higher  levels  of  Numb.  These  data  suggest  HSC  division  pattern  
is  significantly  shifted  in  the  absence  of  Lis1.  
  
Figure  27:  Absence  of  Lis1  leads  to  a  complete  reversal  in  the  pattern  of  Numb  
inheritance  in  vitro  
Figure  27:  a,  Model  illustrates  how  two  dividing  cells  may  equivalently  polarize  Numb  (shown  in  
red)  to  one  side  of  the  cell,  yet  direct  the  cleavage  plane  in  such  a  way  to  ensure  either  equal  or  
unequal  inheritance  of  Numb  into  the  incipient  daughter  cells.  b,  Representative  image  of  a  
tracked  cell  inheriting  Numb  symmetrically  (top)  or  asymmetrically  (bottom)  into  incipient  
daughter  cells  (Numb  in  red,  DAPI  in  blue,  zoomed  63x  images).  c,  Relative  ratios  of  
symmetric:asymmetric  division  in  vitro.  Data  shown  are  from  two  independent  experiments;  
n=25-­‐‑27  dividing  cells  were  assessed  for  each  experiment  per  cohort;  **p=0.0022.  





























































We  next  tested  if  this  shift  in  division  pattern  occurred  in  vivo.  To  test  this,  we  
first  generated  Lis1  chimeric  mice  (i.e.  wild  type  microenvironment)  by  transplanting  
HSCs  (c-­‐‑Kit+  Lin-­‐‑  Sca1+  CD150+  CD48-­‐‑)  from  either  control  Lis1+/+;  Rosa-­‐‑creER  or  Lis1f/f;  
Rosa-­‐‑creER  mice  into  lethally  irradiated  mice.  Following  successful  donor  repopulation,  
Lis1  chimeras  were  treated  with  tamoxifen  to  delete  Lis1  specifically  in  hematopoietic  
cells.  Due  to  the  limited  number  of  telophase  HSCs  in  vivo  we  targeted  a  less  enriched  
but  nonetheless  immature  lineage-­‐‑negative  (Lin-­‐‑)  population.  Thus,  Lis1  null  or  control  
Lineage  negative  (Lin-­‐‑)  cells  were  isolated  from  chimeric  mice  and  tracked  to  assess  
inheritance  of  the  cell  fate  determinant  Numb  in  incipient  daughter  cells  (Figure  28a).  
Consistent  with  our  in  vitro  data,  we  found  that  while  control  cells  underwent  3.5  times  
more  symmetric  division,  the  loss  of  Lis1  led  to  a  predominance  of  asymmetry  and  only  
rare  symmetric  division.  Remarkably,  this  shift  in  pattern  led  to  a  seven-­‐‑fold  difference  
in  the  ratio  of  symmetric:asymmetric  division  between  wild  type  and  Lis1-­‐‑deficient  cells  
(Figure  28b,c).  Importantly,  because  the  loss  of  Lis1  affected  the  inheritance  of  Numb  but  
not  the  polarization  of  Numb,  these  data  cumulatively  suggest  that  the  absence  of  Lis1  
affects  inheritance  by  affecting  the  cleavage  plane,  and  thus  leads  to  a  greater  frequency  






Figure  28:  Predominance  of  Numb  asymmetry  in  the  absence  of  Lis1  in  vivo.    
Figure  28:  a,  Experimental  scheme  used  to  determine  Numb  inheritance  in  vivo.  1,000  HSCs  (KLS  
CD48-­‐‑  CD150+)  from  untreated  control  (Lis1+/+;  Rosa-­‐‑creER)  and  Lis1f/f;  Rosa-­‐‑creER  mice  were  
transplanted  into  wild  type  recipients  to  generate  chimeric  mice  with  a  wild  type  
microenvironment.  Following  reconstitution,  recipients  were  treated  with  tamoxifen  and  donor-­‐‑
derived  lineage  negative  (Lin-­‐‑)  cells  were  sorted,  fixed  and  stained  to  determine  Numb  
inheritance  in  cells  undergoing  telophase/cytokinesis.  b,  Representative  image  of  symmetric  (top)  
and  asymmetric  (bottom)    inheritance  of  Numb  by  incipient  daughter  cells  (Numb  in  red,  DAPI  
in  blue,  zoomed  63x  images).  c,  Relative  ratio  of  symmetric:asymmetric  division  in  vivo  (nine  
dividing  cells  were  assessed  for  the  control  (+/+)  group;  eight  dividing  cells  were  assessed  for  the  
Lis1-­‐‑deficient  (-­‐‑/-­‐‑)  group.  Data  analyzed  using  three  independent  chimeric  mice  for  each  
genotype).  
  
5.2.5 Loss of Lis1 leads to spindle positioning defects in HSCs.   
To  directly  test  whether  the  loss  of  Lis1  led  to  differences  in  the  plane  of  division  
and  to  define  if  this  may  be  directed  by  defects  in  spindle  orientation  we  developed  a  
strategy  to  image  spindle  orientation  during  cell  division  in  real  time.  This  live  imaging  
method  was  a  modification  of  a  method  previously  used  to  visualize  the  spindle  using  
epithelial  cell  lines  (Toyoshima  and  Nishida  2007).  We  first  infected  HeLa  cells  with  the  
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and  mCherry-­‐‑α-­‐‑tubulin  to  mark  the  spindle  during  division  and  found  that  we  could  
effectively  visualize  the  spindle  during  progressive  phases  of  cell  division  (Day  et  al.  
2009;  Kanda  et  al.  1998)  (Figure  29a  and  Supplementary  Movie  1).  These  cells  were  
plated  and  imaged;  4  dimensional  movies  (x,y,z,t)  of  the  dividing  cells  were  visualized  
from  the  side  to  measure  the  spindle  angle  relative  to  the  substrate  (Figure  29b).  
  
Figure  29:  Imaging  system  permits  visualization  of  mitotic  spindle  during  progressive  
phases  of  cell  division  of  HeLa  cells    
Figure  29:  Visualization  of  a  HeLa  cell  in  progressive  phases  of  mitosis  in  real-­‐‑time.  a,  HeLa  cells  
were  retrovirally  co-­‐‑infected  with  H2B-­‐‑GFP  and  mCherry-­‐‑α-­‐‑tubulin  fusion  constructs  and  
individual  cells  tracked  during  division  (corresponding  movie  shown  in  Supplementary  Movie  1,  
which  is  described  in  Appendix  A).  b,  Representative  top  view  (left)  and  orthogonal  view  (right)  
of    a  GFP+  mCherry+  HeLa  cell  in  metaphase.  The  spindle  angle  relative  to  the  substrate  can  be  
measured  by  drawing  a  dotted  line  that  bisects  the  cell’s  centrosomes.  
  
Using  this  approach,  we  first  assessed  spindle  orientation  in  the  hematopoietic  












and  plated  on  the  adherence  cue  retronectin  and  their  spindle  angle  relative  to  the  
retronectin  base  was  measured  over  time.  Although  the  cells  had  a  range  of  spindle  
angles  in  metaphase,  the  spindle  always  positioned  parallel  (0-­‐‑10°)  to  the  substrate  as  
the  cells  entered  telophase,  consistent  with  previous  reports  (Toyoshima  and  Nishida  
2007)  (Figure  30b).  
  
Figure  30:  Retronectin  directs  re-­‐‑positioning  of  the  mitotic  spindle  of  M1  cells.  
Figure  30:  a,  Experimental  scheme  used  to  determine  the  orientation  of  the  mitotic  spindle  in  M1  
cells.   M1   cells   were   co-­‐‑infected   with   H2B-­‐‑GFP   and   mCherry-­‐‑α-­‐‑tubulin   fusion   constructs   and  
plated   on   retronectin-­‐‑coated   slides   and   their   spindle   angle   relative   to   the   retronectin   base  was  




































Appendix  A).  b,  Quantification  of  spindle  orientation  in  M1  cells  relative  to  the  retronectin  base.  
Values  are  expressed  as  a  percentage  of  M1  cells  within  each  angle   interval.  Angle   intervals   in  
which   >1%   cell   are   present   are   shaded   in   blue.   Data   are   shown   from   three   independent  
experiments;  n=20  tracked  cells.    
  
The  fact  that  retronectin  directed  re-­‐‑positioning  of  the  mitotic  spindle  allowed  us  
to  use  this  system  to  test  the  role  of  Lis1  in  spindle  orientation  in  primary  hematopoietic  
cells.  To  test  this,  HSC-­‐‑enriched  cells  (c-­‐‑Kit+  Lin-­‐‑  Sca-­‐‑1+)  were  isolated  from  either  wild  
type  control  Lis1+/+;  Rosa-­‐‑creER  or  Lis1f/f;  Rosa-­‐‑creER  mice  and  infected  with  H2B-­‐‑GFP  and  
mCherry-­‐‑alpha-­‐‑tubulin.  Re-­‐‑sorted  HSC-­‐‑enriched  cells  doubly  infected  for  H2B-­‐‑GFP  and  
mCherry-­‐‑alpha-­‐‑tubulin  were  plated  on  retronectin  and  treated  with  4-­‐‑OH  tamoxifen  to  
delete  Lis1  (Figure  31a).  Using  this  approach,  we  found  that  wild  type  HSC-­‐‑enriched  
cells  displayed  a  range  of  angles  during  metaphase  but  re-­‐‑positioned  their  spindles  by  
telophase  (Figure  31b,c).  Interestingly,  in  the  absence  of  Lis1,  cells  were  unable  to  
correctly  align  their  spindle  in  response  to  the  substrate.  These  data  suggest  that  loss  of  
Lis1  leads  to  spindle  positioning  defects  in  HSC-­‐‑enriched  cells  (Figure  31b,c).    
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Figure  31:  Loss  of  Lis1  leads  to  spindle  positioning  defects  in  HSC-­‐‑enriched  cells.  
Figure  31:  a,  Experimental  scheme  used  to  determine  spindle  orientation  in  HSC-­‐‑enriched  cells  in  
real-­‐‑time.  KLS  cells  were  isolated  from  Lis1+/+;  Rosa-­‐‑creER  (control)  and  Lis1f/f;  Rosa-­‐‑creER  mice,  
infected  with  H2B-­‐‑GFP  and  mCherry-­‐‑α-­‐‑tubulin,  resorted  and  treated  with  4OH-­‐‑tamoxifen  in  
vitro.  Following  Lis1  deletion,  cells  were  placed  on  retronectin-­‐‑coated  slides  and  imaged.  b,  
Representative  side  view  images  of  a  control  (+/+)  and  Lis1-­‐‑/-­‐‑  (-­‐‑/-­‐‑)  cell  undergoing  cell  division  and  
their  spindle  angles.  c,  Average  metaphase  and  telophase  spindle  angles  of  control  (+/+)  and  (-­‐‑/-­‐‑)  
cells  relative  to  substrate;  data  shown  are  from  three  independent  experiments;  n=7  cells  per  
genotype;  **p=0.0054.  
  
5.2.6 Spindle positioning defects drive the improper inheritance of 
Numb in the absence of Lis1.   
To  determine  whether  spindle  orientation  defects  led  to  improper  inheritance  of  
Numb  in  the  absence  of  Lis1,  we  tracked  the  orientation  of  the  spindle  coordinately  with  
Numb  inheritance  in  real  time.  To  test  this,  HSC-­‐‑enriched  cells  from  either  wild  type  
control  Lis1+/+;  Rosa-­‐‑creER  or  Lis1f/f;  Rosa-­‐‑creER  mice  were  infected  with  mCherry-­‐‑alpha-­‐‑
tubulin  and  Numb-­‐‑CFP  fusion  vectors,  re-­‐‑sorted,  plated  in  methylcellulose,  treated  with  






































































spindle  using  time  lapse  microscopy.  Of  the  cells  we  observed  entering  mitosis,  we  
focused  on  those  with  polarized  Numb  since  changes  in  the  angle  of  the  spindle  could  
have  a  consequence  of  whether  Numb  is  inherited  asymmetrically  or  symmetrically  only  
in  those  cells  (i.e.  non-­‐‑polarized  cells  should  invariably  under  undergo  symmetric  
division  regardless  of  spindle  orientation).    
An  example  of  a  cell  with  polarized  Numb  that  subsequently  aligns  its  spindle  to  
facilitate  a  symmetric  division,  whereby  Numb  is  inherited  equally  by  the  two  daughter  
cells  is  shown  in  Figure  32.  A  corresponding  time-­‐‑lapse  movie  of  this  cell  is  shown  in  
Supplementary  Movie  2  and  described  in  the  Appendix.    In  addition,  examples  of  cells  
with  polarized  Numb  that  subsequently  positions  their  spindles  in  such  a  way  to  
promote  an  asymmetric  division,  whereby  Numb  is  inherited  unequally  by  the  two  
incipient  daughter  cells  are  shown  in  Figure  33  and  Supplementary  Movie  3  and  4  and  
described  in  the  Appendix.  Importantly,  because  it  was  extremely  technically  
challenging  to  live  image  conditional  mutant  primary  stem  and  progenitor  cells  infected  
with  two  fusion  constructs,  only  a  few  cells  could  be  tracked.    
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Figure  32:  Real  time  imaging  of  a  cell  with  polarized  Numb  subsequently  undergoing  
a  symmetric  division.    
Figure  32:  Symmetric  inheritance  of  Numb.  HSC-­‐‑enriched  cells  (KLS)  were  co-­‐‑infected  with  
Numb-­‐‑CFP  and  mCherry-­‐‑α-­‐‑tubulin  fusion  construct  and  imaged  overtime.  (Numb  is  shown  in  
green  and  α-­‐‑tubulin  is  shown  in  red;  corresponding  movie  is  shown  in  Supplementary  Movie  2  
and  described  in  the  Appendix.        
  
  
Figure  33:  Real  time  imaging  of  a  cell  with  polarized  Numb  subsequently  undergoing  
an  asymmetric  division.  
Figure  33:  Asymmetric  inheritance  of  Numb.  HSC-­‐‑enriched  cells  (KLS)  were  co-­‐‑infected  with  






































green  and  α-­‐‑tubulin  is  shown  in  red;  corresponding  movie  is  shown  in  Supplementary  Movie  3  
and  described  in  the  Appendix.        
  
Using  our  time-­‐‑lapse  imaging-­‐‑based  system,  we  found  that  the  patterns  observed  
were  remarkably  different  between  wild  type  and  Lis1-­‐‑deficient  cells.  While  the  mitotic  
spindle  was  positioned  such  that  Numb  was  bisected  asymmetrically  in  56.5%  of  wild  
type  cells,  the  mitotic  spindle  bisected  Numb  asymmetrically  in  100%  of  Lis1  null  cells  
(Figure  34).  
  
Figure  34:  Defective  spindle  positioning  drives  increased  asymmetric  inheritance  of  
Numb  in  the  absence  of  Lis1.  
Figure  34:  a,  Numb  distribution  in  dividing  HSC-­‐‑enriched  cells  relative  to  mitotic  spindle  
orientation.  Representative  images  of  control  (+/+)  cells  (I  and  II)  or  Lis1-­‐‑/-­‐‑  cells  (-­‐‑/-­‐‑;  III  and  IV)  with  
examples  of  symmetric  (I)  or  asymmetric  (II,  III,  IV)  inheritance  of  Numb  by  incipient  daughter  
cells.  Numb  (green),  α-­‐‑tubulin  (magenta).  On  far  right  panel,  each  cell  is  displayed  in  spectrum  
color  format  to  facilitate  accurate  identification  of  spindle  position  (dotted  black  line  connecting  























































































































which  partitions  the  dividing  cell  into  incipient  daughter  1  (D1)  and  daughter  2  (D2).  b,  
Quantification  of  fluorescence  intensity  of  Numb  in  D1  and  D2  for  each  representative  control  
(+/+;  I  and  II)  or  Lis1-­‐‑/-­‐‑  cell  (-­‐‑/-­‐‑;  III,  IV)  shown  in  (a).  c,  Frequency  of  cells  undergoing  asymmetric  
inheritance  of  Numb  in  control  (+/+)  or  Lis1-­‐‑deficient  cells  (-­‐‑/-­‐‑);  data  are  shown  for  four  
independent  experiments;  n=23  for  (+/+)  and  n=5  for  (-­‐‑/-­‐‑).  All  error  bars  show  the  standard  error  
of  mean  (SEM).      
  
    
Thus,  the  set  of  in  vivo  and  in  vitro  imaging  experiments  collectively  suggest  that  
defective  spindle  positioning  drives  the  increased  asymmetric  inheritance  of  Numb  in  
the  absence  of  Lis1  and  identifies  a  potential  mechanism  that  may  underlie,  at  least  in  
part,  the  observed  accelerated  differentiation  and  subsequent  depletion  of  HSCs.    
5.2.7 Loss of Lis1 does not affect spindle morphology, nuclear 
envelope breakdown or mitotic duration of HSCs.   
     Although  loss  of  Lis1  affects  spindle  positioning  and  orientation,  it  may  also  
affect  other  aspects  of  stem  cell  function.  Because  Lis1  is  linked  to  spindle  assembly,  we  
tested  if  Lis1  deficiency  affected  bipolar  spindle  formation,  spindle  morphology  and  
nuclear  envelope  breakdown.  To  determine  whether  spindle  morphology  was  
compromised  in  the  absence  of  Lis1,  we  stained  Lis1-­‐‑deficient  HSCs  (c-­‐‑Kit+  Lin-­‐‑  Sca-­‐‑1+  
CD48-­‐‑)  for  alpha-­‐‑tubulin  and  found  that  bipolar  spindle  formation  and  spindle  
morphology  was  unaffected  in  the  absence  of  Lis1  (Figure  35).    
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Figure  35:  Formation  of  bipolar  spindles  and  spindle  morphology  is  unaffected  in  the  
absence  of  Lis1.  
Figure  35:  Bipolar  spindle  formation  and  spindle  morphology  of  Lis1-­‐‑/-­‐‑  cells.  HSCs  (KLS  CD48-­‐‑)  
were  isolated  from  control  (Lis1+/+;  Rosa-­‐‑creER)  and  Lis1f/f;  Rosa-­‐‑creER  mice  and  treated  with  4-­‐‑OH-­‐‑
tamoxifen  in  vitro.  Representative  images  of  control  (+/+)  and  Lis1-­‐‑/-­‐‑  (-­‐‑/-­‐‑)  cells  immunostained  for  
anti-­‐‑α-­‐‑tubulin  antibody  (green)  and  4′,  6-­‐‑diamidino-­‐‑2-­‐‑phenylindole  (DAPI,  blue).  
  
  
Further,  we  tracked  mitotic  events  in  HSC-­‐‑enriched  cells  (c-­‐‑Kit+  Lin-­‐‑  Sca-­‐‑1+;  KLS)  
through  dynamic  real  time  imaging.  Specifically,  KLS  cells  were  isolated  from  either  
control  Lis1+/+;  Rosa-­‐‑creER  or  Lis1f/f;  Rosa-­‐‑creER  mice  and  co-­‐‑infected  with  H2B-­‐‑GFP  and  
mCherry-­‐‑alpha-­‐‑tubulin.  Sorted  KLS  GFP+  mCherry+  cells  were  treated  with  4OH-­‐‑
tamoxifen  to  delete  Lis1  and  subsequently  tracked  to  determine  if  nuclear  envelope  
disassembly  was  intact  (Figure  36a).  Using  H2B-­‐‑GFP  to  label  chromatin,  we  found  that  
in  all  Lis1-­‐‑deficient  cells  tested,  nuclear  shrinking/chromosome  condensation  occurred  
normally  (Figure  36b),  which  has  previously  been  reported  to  coincide  with  and/or  
occur  rapidly  after  nuclear  envelope  breakdown  (NEBD)  (Beaudouin  et  al.  2002),  
















Figure  36:  Nuclear  envelope  breakdown  is  intact  in  the  absence  of  Lis1.  
Figure  36:  a, Schematic illustrates the strategy used to visualize cell division in real-time. KLS cells were 
isolated from Lis1+/+; Rosa-creER (control) and Lis1f/f; Rosa-creER mice, retrovirally infected with H2B-
GFP and mCherry-α-tubulin, resorted and treated with 4-OH-tamoxifen in vitro. Following Lis1 deletion, 
cells were placed on retronectin-coated slides or in methylcellulose and imaged. b, Representative images 
of a control (+/+) and Lis1-/- (-/-) cell undergoing nuclear envelope breakdown/chromosome condensation. 
H2B (green), α-tubulin (magenta). White arrows indicate NEB; n=18 for +/+ and n=14 for -/-. 
 
To  determine  whether  loss  of  Lis1  affected  the  length  of  mitosis,  we  quantified  
mitotic  duration  of  dividing  cells  identified  in  movie  replay  by  measuring  the  average  
time  spent  between  NEBD  and  chromosome  condensation  until  the  beginning  of  
telophase  and  found  that  duration  of  mitosis  was  relatively  similar  between  Lis1-­‐‑
deficient  cells  and  wild  type  control  cells.  However,  there  was  a  marginal  rise  in  mitosis  


































Figure  37:  Loss  of  Lis1  does  not  affect  the  mitotic  length  of  HSCs.  
Figure  37:  Duration  of  mitosis  of  Lis1-­‐‑/-­‐‑  cells.  Representative  images  of  a  Lis1-­‐‑/-­‐‑  cell  at  the  onset  of  
NEB  and  at  early  telophase.  H2B  (green)  and  α-­‐‑tubulin  (magenta).  Graph  on  right  shows  
quantification  of  duration  of  mitosis  (time  in  seconds  from  NEB  to  early  telophase);  n=18  tracked  
control  (+/+)  cells  and  n=14  tracked  Lis1-­‐‑/-­‐‑  (-­‐‑/-­‐‑)  cells.  
 
5.2.8 Marginal increases in the frequency of polyploidy and cells 
undergoing abnormal mitosis in the absence of Lis1.   
To  determine  whether  the  loss  of  Lis1  leads  to  abnormal  mitoses,  we  scored  the  
frequency  of  cells  that  underwent  an  incomplete  mitosis,  defined  by  a  cell  that  
compacted  its  chromatin  but  failed  to  complete  division,  and  found  that  over  an  initial  
48  hour  period,  ~3%  (2/66)  of  wild  type  cells  and  ~1.5%  (1/67)  of  Lis1-­‐‑deficient  cells  
underwent  incomplete  mitosis,  and  during  the  next  24  hours,  8.7%  (2/23)  of  Lis1-­‐‑
deficient  cells  underwent  incomplete  mitosis  (Figure  38).  Multipolar  cell  division  








































subsequent  generation  of  three  aneuploid  daughter  cells)  were  also  scored:  while  no  
apparent  multipolar  cell  divisions  were  observed  in  control,  ~3%  (2/67)  and  8.7%  (2/23)  
of  Lis1-­‐‑deficient  cells  underwent  multipolar  cell  division  at  48  and  72  hours  respectfully  
(Figure  38).    
  
Figure  38:  Loss  of  Lis1  in  HSCs  leads  to  a  rise  in  the  number  of  cells  with  abnormal  
mitosis.  
Figure  38:  Percentage  of  control  (+/+)  and  Lis1-­‐‑/-­‐‑  (-­‐‑/-­‐‑)  cells  that  underwent  a  multipolar  cell  
division  or  an  incomplete  mitosis.  (n=67  cells  per  genotype  tracked  between  24-­‐‑72  hrs  and  n=23  
cells  per  genotype  tracked  between  72-­‐‑96  hrs).  
  
We  also  carried  out  a  cytogenetic  analysis  on  G-­‐‑banded  HSC-­‐‑enriched  (c-­‐‑Kit+  Lin-­‐‑  
Sca-­‐‑1+)  metaphase  cells  after  in  vitro  deletion  of  Lis1  and  found  that  Lis1-­‐‑deficient  cells  
demonstrated  an  apparent  normal  karyotype.  However,  whereas  ~6%  (3/50)  of  wild  type  















Collectively,  these  data  suggest  that  a  potential  consequence  of  loss  of  Lis1  in  cultured  
HSCs  may  be  the  acquisition  of  polyploidy  or  aneuploidy  Although  compared  to  wild  
type  control  cells,  Lis1-­‐‑deficient  cells  display  more  mitotic  defects,  these  events  are  not  
very  dominant.  However,  they  could  cumulatively  be  compounding  the  
differentiation/spindle  orientation  defects  and  thus,  contribute  to  the  overall  blood  
phenotype  observed.    
  
Figure  39:  Elevated  frequency  of  polyploidy  in  HSCs  in  the  absence  of  Lis1.  
Figure  39:  Karyotype  of  Lis1-­‐‑/-­‐‑   cells.  Representative  G-­‐‑banded  karyogram  of   a   control   (+/+)   and  
Lis1-­‐‑/-­‐‑  (-­‐‑/-­‐‑)  cell  (top)  and  table  showing  the  percent  of  (+/+)  and  (-­‐‑/-­‐‑)  cells  with  normal  karyotypes  
and  the  frequency  of  polyploidy  (bottom).            
  
5.2.9 Loss of the “stem cell signature” is a key downstream 
consequence of Lis1 deletion.  
To  provide  molecular  insight  into  how  Lis1  operates  and  in  particular  to  examine  
genes  that  have  been  identified  to  affect  HSC  self-­‐‑renewal,  we  carried  out  a  genome  
wide  expression  analysis  on  wild  type  and  Lis1-­‐‑deficient  HSC-­‐‑enriched  cells.    
!"! #"#
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Specifically,  wild  type  control  Lis1+/+;  Rosa-­‐‑creER  and  Lis1f/f;  Rosa-­‐‑creER  mice  were  
administered  tamoxifen  daily  for  five  consecutive  days  and  three  days  post-­‐‑tamoxifen  
treatment,  HSC-­‐‑enriched  cells  (c-­‐‑kit+  Lin-­‐‑  Sca-­‐‑1+)  were  FACS-­‐‑sorted  and  total  cellular  
RNA  were  purified.  Comparison  of  transcriptional  profiles  of  the  wild  type  and  Lis1-­‐‑
deficient  cells  led  to  the  identification  of  746  down-­‐‑regulated  and  622  up-­‐‑regulated  gene  
sets  at  significance  level  (false  discovery  rate)  of  0.01  as  affected  by  the  loss  of  Lis1  
(Figure  40a).  While  some  stem  cell-­‐‑related  genes  such  as  Runx1,  Msi2  and  Bmi1  do  not  
appear  to  be  changed  significantly  other  genes  known  to  play  important  regulatory  roles  
in  hematopoietic  stem/progenitor  cell  maintenance  and  differentiation  such  as  Pim1,  
Socs3,  Trib2  and  Pml  are  altered  and  may  mediate  downstream  effects  of  Lis1  (Figure  
38e).      
Interestingly,  the  differentially  expressed  gene  sets  that  were  affected  by  the  loss  
of  Lis1  revealed  significant  enrichment  of  multiple  stem-­‐‑associated  gene  expression  
profiles  identified  (Figure  40b-­‐‑d)  (Wong  et  al.  2008)  (Venezia  et  al.  2004)  (Eppert  et  al.  
2011).  That  loss  of  the  stem  cell  signature  is  a  key  downstream  consequence  of  Lis1  
deletion  confirms,  through  an  independent  molecular  strategy,  that  Lis1  is  critical  to  




Figure  40:  Loss  of  the  “stem  cell  gene  signature”  is  a  key  consequence  of  Lis1  deletion.  
Figure  40:  a-­‐‑e,  Genome  wide  expression  analysis  of  Lis1-­‐‑deficient  HSC-­‐‑enriched  cells.  Control  
(Lis1+/+;  Rosa-­‐‑creER)  and  Lis1f/f;  Rosa-­‐‑creER  mice  were  treated  with  tamoxifen  daily  for  5  days.  KLS  
cells  were  isolated  from  control  and  Lis1  null  mice  3  days  post-­‐‑tamoxifen  treatment  and  
microarray  analysis  was  performed  (3  independent  RNA  samples  were  used  for  each  genotype,  











































































































Comparative  gene  set  enrichment  analysis  identified  5.5%  of  genes  as  changed  with  a  false  
discovery  rate  of    <0.01;  746  probe  sets  were  down-­‐‑regulated  and  622  probe  sets  were  up-­‐‑
regulated.  b-­‐‑d,  Significant  differential  expression  of  mRNAs  identified  previously  as  part  of  a  
stem  cell-­‐‑associated  gene  signature.  Heat  map  showing  expression  changes  in  mRNAs  highly  
enriched  in  (b),  Adult  Tissue  Stem  Cell  Module  (FDR  <-­‐‑0.01)  (Wong  et  al.  2008);  Bonferroni  p-­‐‑
value=1.25E-­‐‑25,  (c),  HSC-­‐‑Common  quiescence  signature  (Venezia  et  al.  2004);  Bonferroni  p-­‐‑
value=9.08E-­‐‑11,  (d),  HSC-­‐‑R  expression  profile  (Eppert  et  al.  2011);  Bonferroni  p-­‐‑value=5.61E-­‐‑05  in  
the  Lis1-­‐‑deficient  HSC-­‐‑enriched  cells.  e,  Heat  map  of  known  regulators  of  stem  cell  and  
progenitor  cell  activity  significantly  affected    by  the  loss  of  Lis1.  
  
5.3 Discussion 
  Using  two  independent  strategies  to  direct  the  genetic  deletion  of  Lis1  in  the  
hematopoietic  system,  we  showed  that  the  dynein-­‐‑binding  protein  Lis1  not  only  has  a  
broad  impact  on  HSC  function  at  multiple  sites  during  embryogenesis,  but  also  has  a  
conserved  functional  role  in  the  adult  blood  system.  We  report  here  that  the  basis  of  the  
HSC  defects  (i.e.  HSC  depletion  and  impaired  self-­‐‑renewal  ability  in  vitro  and  in  vivo)  
that  arise  following  Lis1  deletion  is  largely  due  to  a  loss  of  cell  fate  control.  Specifically,  
by  tracking  the  rate  of  differentiation  in  vitro,  we  found  that  Lis1-­‐‑deficient  HSCs  fail  to  
maintain  the  undifferentiated  state  and  prematurely  differentiate  predominantly  into  
early  myeloid  progenitor  cells.    This  accelerated  differentiation  phenotype  was  also  
apparent  in  vivo,  where  we  found  that  the  loss  of  Lis1  initially  leads  to  a  drop  in  HSCs  
with  a  concomitant  rise  in  multipotent  progenitor  cells.  Importantly,  we  show  that  the  
loss  of  HSCs  that  occurs  immediately  following  Lis1  deletion  was  not  due  to  elevated  
apoptosis  or  alterations  in  cell  cycle.  Although  at  later  time  points  we  did  find  some  
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increase  in  AnnexinV+  7AAD+  necrotic/late  stage  apoptotic  cells,  it  is  difficult  to  know  if  
this  may  be  a  consequence  of  increased  differentiation,  or  an  independent  event.      
Interestingly,  we  found  that  the  inability  of  Lis1-­‐‑deficient  HSCs  to  maintain  the  
undifferentiated  state  is  due  to  an  underlying  defect  in  the  regulation  of  HSC  division  
pattern.    In  previous  studies  where  we  used  transgenic  notch  reporter  mice  and  time-­‐‑
lapse  microscopy  to  trace  cell  division,  we  showed  that  HSCs  have  the  ability  to  
undergo  both  symmetric  and  asymmetric  cell  division  (Wu  et  al.  2007).  Importantly,  we  
found  that  during  an  asymmetric  division,  the  cell  fate  determinant  Numb  is  selectively  
partitioned  into  the  differentiated  hematopoietic  daughter  cell  and  thus,  the  pattern  of  
Numb  inheritance  could  be  used  to  code  a  division  as  either  symmetric  or  asymmetric.    
With  this  approach,  we  found  that  HSCs  preferentially  undergo  symmetric  
renewal  division.  Although  it  is  more  commonly  thought  that  under  homeostatic  
conditions,  HSCs  predominantly  undergo  asymmetric  division;  a  division  mode  that  
favors  maintenance  over  expansion,  the  observation  that  HSCs  underwent  more  
symmetric  renewal  divisions  suggest  that  experimental  conditions  (i.e.  culturing  
conditions)  could  have  unintentionally  shifted  the  balance.  Interestingly,  we  found  that  
both  in  vitro  and  in  vivo  loss  of  Lis1  leads  to  a  predominance  of  asymmetry  and  only  rare  
symmetric  renewal  divisions.  Since  perpetual  asymmetric  divisions  compared  to  either  a  
balance  of  asymmetric  and  symmetric  division  or  perpetual  symmetric  renewal  
divisions  would  generate  more  differentiated  cells  overtime,  the  increase  in  asymmetric  
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division  observed  following  the  loss  of  Lis1  provides  a  possible  explanation  for  the  
accelerated  differentiation  of  HSCs  that  occurs  in  the  absence  of  Lis1.    
Previous  studies  demonstrated  that  the  cell  fate  determinant  Numb  induces  
differentiation  by  inhibiting  Notch  signaling,  most  likely  by  controlling  the  intracellular  
trafficking  of  Notch  intermediates  (Berdnik  et  al.  2002).  Interestingly,  we  found  that  
changes  in  Numb  inheritance  following  Lis1  deletion  affected  Notch  signaling.  
Specifically,  genome  wide  expression  and  gene  set  enrichment  analysis  on  RNA  samples  
isolated  from  wild  type  or  Lis1-­‐‑deficient  HSC-­‐‑enriched  cells  indicated  a  marked  
downregulation  of  the  Notch  receptor  Notch1  and  the  Notch1  target  gene  Trib2,  
suggesting  potential  repression  of  Notch  signaling  in  the  absence  of  Lis1.  In  addition  to  
changes  in  Trib2  expression,  the  promyelocytic  leukemia  gene  Pml  was  also  significantly  
downregulated  following  Lis1  deletion.  Loss  of  both  of  these  genes  have  been  linked  to  
increased  differentiation  and  may  be  part  of  the  downstream  mechanisms  that  sets  into  
motion  the  accelerated  differentiation  we  observe  (Ito  et  al.  2012;  Keeshan  et  al.  2006).    
In  Drosophila  neuroblasts,  vertebrate  skin  progenitor  cells  and  mammalian  
neuroepithelial  stem  cells,  it  has  been  documented  that  precise  positioning  of  the  mitotic  
spindle  is  one  of  several  mechanisms,  which  concur  to  facilitate  the  regulation  of  cell  fate  
(reviewed  in  (Morin  and  Bellaiche  2011)).  The  fact  that  upon  Lis1  deletion,  Numb  
inheritance  is  altered  and  not  polarization,  suggest  that  the  spindle-­‐‑directed  cleavage  
plane  is  affected  in  the  absence  of  Lis1.  Using  a  sophisticated  real  time  imaging  system,  
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we  were  able  to  visualize  the  mitotic  spindle  in  HSCs  during  progressive  phases  of  cell  
division  and  show  that  in  the  absence  of  Lis1,  HSCs  fail  to  undergo  rectronectin-­‐‑directed  
spindle  positioning,  suggesting  an  inability  of  Lis1-­‐‑deficient  HSCs  to  properly  regulate  
spindle  orientation  in  response  to  either  cell-­‐‑extrinsic  or  cell-­‐‑intrinsic  cues.    In  the  
hematopoietic  system,  and  in  several  other  systems,  whether  spindle  orientation  has  a  
direct  instructive  role  on  cell  fate  specification  is  still  unclear,  because  none  of  the  
reports  in  which  spindle  orientation  is  misoriented  has  adequately  addressed  the  
distribution  of  fate  determinants.  In  this  study,  using  a  live  imaging  approach,  we  were  
able  to  track  spindle  orientation  coordinately  with  Numb  inheritance  and  show  that  
changes  in  spindle  orientation  triggered  by  Lis1  loss  ultimately  affected  how  the  pool  of  
polarized  Numb  was  fractioned  and  subsequently  inherited  by  the  incipient  daughter  
cells.  These  data  convincingly  demonstrate  Lis1  influences  HSC  function  by  regulating  
HSC  division  pattern  at  the  level  of  controlling  spindle  orientation.      
A  role  for  Lis1  in  spindle  orientation  and  positioning  has  been  demonstrated  in  
the  budding  yeast  Saccharomyces  cerevisiae  (Lee  et  al.  2003),  C.  elegans  (Cockell  et  al.  2004),  
Drosophila  neuroblasts  (Siller  and  Doe  2008a),  in  cultured  epithelial  cells  (Faulkner  et  al.  
2000)  and  in  the  mammalian  neuroepithelium  (Yingling  et  al.  2008).  Studies  primarily  in  
invertebrate  systems  have  elucidated  a  model  in  which  a  cascade  of  protein  interactions  
involving  heterotrimeric  G  proteins,  Pins/AGS3  and  Mud/NuMA  establish  a  docking  
site  for  astral  microtubules  to  orient  the  mitotic  spindle.  The  Lis1/dynein  complex  
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facilitates  the  interaction  between  proteins  concentrated  at  the  cell  cortex  and  astral  
microtubules  (reviewed  in  (Knoblich  2008).  Future  work  will  need  to  be  done  to  
determine  whether  this  established  framework  on  how  spindle  orientation  is  regulated  















6. Lis1 is a key regulator of malignant hematopoietic 
development. 
6.1 Introduction 
While  properly  controlled  self-­‐‑renewal  is  a  key  feature  of  normal  stem  cell  
maintenance,  aberrant  and  uncontrolled  self-­‐‑renewal  can  be  a  hallmark  of  oncogenesis.  
One  important  question  that  remains  unaddressed  is  whether  regulators  of  spindle  
orientation  and  division  plane  can  drive  aberrant  self-­‐‑renewal  in  cancer.  This  may  be  
particular  relevant  for  understanding  cancers  that  become  increasingly  undifferentiated  
during  progression,  since  division  can  shift  towards  symmetric  renewal  in  order  to  
generate  immature  daughters,  and  contribute  to  the  failure  of  differentiation.    
In  the  hematopoietic  system,  acute  phase  myeloid  leukemias  such  as  blast  crisis  
chronic  myelogenous  leukemia  (bcCML)  and  de  novo  acute  myelogenous  leukemia  
(AML)  display  a  severe  differentiation  blockade.  In  context  of  bCML  progression,  
recently  we  showed  that  NUP98-­‐‑HOXA9,  a  chromosomal  translocation  product  
implicated  in  bcCML  and  de  novo  AML,  promotes  leukemia  by  shifting  the  normal  
balance  of  asymmetric  and  symmetric  cell  division  towards  more  symmetric  renewal  
divisions.  Since  Lis1  may  control  normal  HSC  activity  by  regulating  division  pattern,  the  
ability  of  NUP98-­‐‑HOXA9  to  subvert  the  normal  balance  of  asymmetric  and  symmetric  
division  may  depend  on  Lis1  function.    Thus  using  bcCML  and  AML  as  models  we  
tested  if  Lis1  plays  a  role  in  cancer.      
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6.2 Results 
6.2.1 Lis1 is required for the establishment, maintenance and 
propagation of blast crisis chronic myelogenous leukemia (bcCML). 
To  determine  if  Lis1  plays  a  role  in  bcCML,  we  modeled  the  disease  in  the  mouse  
by  employing  a  “2-­‐‑hit”  retroviral-­‐‑based  system.  Previous  studies  showed  that  the  
delivery  of  the  translocation  product  NUP98-­‐‑HOXA9  together  with  BCR-­‐‑ABL  leads  to  
the  development  of  a  disease  characterized  by  arrested  differentiation  and  accumulation  
of  immature  myeloid  cells  and  thus,  faithfully  recapitulates  human  bcCML  (Dash  et  al.  
2002;  Mayotte  et  al.  2002;  Neering  et  al.  2007).  Thus,  to  generate  bcCML,  HSC-­‐‑enriched  
cells  (c-­‐‑Kit+  Lin-­‐‑  Sca-­‐‑1+)  from  Lis1+/+;  Rosa-­‐‑creER  or  Lis1f/f;  Rosa-­‐‑creER  mice  were  co-­‐‑infected  
with  BCR-­‐‑ABL  and  NUP98-­‐‑HOXA9  and  transplanted  into  sub-­‐‑lethally  irradiated  mice.  
Three  days  post-­‐‑transplantation,  recipients  were  given  tamoxifen  or  corn  oil  daily  for  5  
days  to  delete  Lis1  specifically  in  the  cells  driving  leukemia  development  in  vivo.  
Whereas  tamoxifen-­‐‑treated  mice  transplanted  with  control  BCR-­‐‑ABL/NUP98-­‐‑HOXA9-­‐‑
infeced  cells  all  succumbed  to  bcCML,  only  22%  of  the  tamoxifen  treated  mice  
transplanted  with  Lis1f/f;  Rosa-­‐‑creER  BCR-­‐‑ABL/NUP98-­‐‑HOXA9-­‐‑infected  cells  developed  
leukemia.  (Figure  41).  These  data  suggest  that  Lis1  is  required  for  the  propagation  of  
bcCML  in  vivo.  
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Figure  41:  Lis1  is  required  for  the  propagation  of  bcCML  in  vivo.  
Figure  41:  Impact  of  loss  of  Lis1  on  bcCML  initiation.    KLS  cells  were  isolated  from  control  
(Lis1+/+;  Rosa-­‐‑creER)  and  Lis1f/f;  Rosa-­‐‑creER  mice  and  co-­‐‑transduced  with  BCR-­‐‑ABL-­‐‑YFP  and  
NUP98-­‐‑HOXA9-­‐‑GFP;  500  double  positive  cells  transplanted  into  recipients.  Three  days  post-­‐‑
transplantation,  recipients  were  administered  tamoxifen  or  vehicle  (corn  oil)  daily  for  5  days  and  
survival  monitored.  Data  shown  are  from  three  independent  experiments  (n=10  for  Lis1f/f  
+tamoxifen  (black),  n=9  for  Lis1f/f  +vehicle  (corn  oil)  (blue)  and  n=7  for  Lis1+/+  +tamoxifen  (green)).  
  
The  ability  to  temporally  control  Lis1  deletion  allowed  us  to  delete  Lis1  after  
disease  establishment  and  thus  test  whether  Lis1  is  required  for  the  continual  
maintenance  of  bcCML.  We  first  tested  whether  colony-­‐‑forming  ability  of  established  
leukemia  cells  was  impaired  in  the  absence  of  Lis1.  To  do  this,  established  bcCML  cells  
negative  for  lineage  markers  (bcCML-­‐‑propagating  cells)  and  harboring  a  Lis1f/f  allele  
were  plated  in  methylcellulose  and  treated  with  4OH-­‐‑tamoxifen  to  delete  Lis1.  Whereas  
control  cells  successfully  formed  colonies,  deletion  of  Lis1  lead  to  a  5.5  fold  reduction  in  
colony  formation  (Figure  42a).    




















To  determine  whether  the  loss  of  Lis1  affects  the  propagation  and  maintenance  
of  bcCML  in  vivo,  established  bcCML-­‐‑propagating  cells  with  a  Lis1f/f  allele  were  
transplanted  into  sub-­‐‑lethally  irradiated  mice.    Seven  days  post-­‐‑transplantation,  
recipient  mice  were  treated  with  tamoxifen.  Whereas  all  the  mice  transplanted  with  
control  leukemia-­‐‑propagating  cells  succumbed  to  leukemia,  none  of  the  mice  
transplanted  with  floxed  Lis1  cells  developed  leukemia  (Figure  42b).  
  
  
Figure  42:  Lis1  is  important  for  the  maintenance  and  propagation  of  bcCML.  
Figure  42:  a,  Impact  of  loss  of  Lis1  on  colony-­‐‑forming  ability  of  established  bcCML  cells.  3-­‐‑5,000  
lineage-­‐‑negative  (Lin-­‐‑)  cells  from  control  Lis1+/+;  Rosa-­‐‑creER  or  Lis1f/f;  Rosa-­‐‑creER  bcCML  were  
plated  in  methylcellulose  and  treated  with  either  4-­‐‑OH-­‐‑tamoxifen  or  ethanol  (EtOH)  in  vitro  and  
total  colonies  generated  were  scored,  ***p<0.001.  b,  Impact  of  loss  of  Lis1  on  propagation  of  
established  bcCML.  1,000  Lin-­‐‑negative  cells  from  established  control  Lis1+/+creER  or  Lis1f/fcreER  
bcCML  were  transplanted  into  secondary  recipients.  Seven  days  post-­‐‑transplantation,  recipients  
were  administered  tamoxifen  daily  for  5  days  and  survival  monitored  (n=4  for  Lis1+/+,  green  and  

























































Interestingly,  detailed  tracking  of  tumor  growth  in  vivo  indicated  that  deletion  of  
Lis1  well  after  the  tumor  burden  had  begun  to  climb  allowed  complete  reversion  to  
normal  cell  counts.    Specifically,  whereas  tumor  burden  on  average  increased  4.7-­‐‑fold  in  
control  mice,  tumor  burden  in  mice  that  received  Lis1  floxed  leukemia  cells  decreased  
3.4-­‐‑fold  during  a  10  day  period  following  the  start  of  tamoxifen  injections  (Figure  43a).  
Important,  this  reversion  to  normal  cell  counts  was  accompanied  by  a  resolution  of  
splenomegaly  (Figure  43b).    
  
Figure  43:  Resolution  of  disease  following  Lis1  deletion.  
Figure  43:  a,  Average  tumor  burden  was  tracked  before  and  after  tamoxifen  delivery.  40,000  
lineage-­‐‑negative  (Lin-­‐‑)  cells  from  control  Lis1+/+;  Rosa-­‐‑creER  or  Lis1f/f;  Rosa-­‐‑creER  established  
bcCML  were  transplanted  into  secondary  recipients.  Tumor  burden  was  assessed  in  the  
peripheral  blood  at  day  14  (D14)  post-­‐‑transplantation  before  the  start  of  tamoxifen  injections  
(daily  for  5  days;  D14  to  D18)  and  again  5  days  post-­‐‑tamoxifen  injections  on  day  23  (D23)  in  the  
spleen  of  mice  that  received  wild  type  control  bcCML  (+/+)  or  Lis1f/f    bcCML  (-­‐‑/-­‐‑);  n=4  for  control  
(+/+)  and  n=3  for  (-­‐‑/-­‐‑)  mice;  **p=0.0065.  b,  Representative  image  shows  control  (+/+)  and  (-­‐‑/-­‐‑)  



































Collectively,  these  data  strongly  indicate  that  Lis1  is  critically  important  not  only  
for  the  establishment  but  also  for  the  continual  maintenance  and  propagation  of  bcCML  
in  vivo.      
6.2.2 Lis1 is required for the establishment of de novo acute 
myelogenous leukemia (AML) in vivo. 
Both  blast  crisis  phase  CML  and  the  majority  of  de  novo  AML  share  similar  
disease  characteristics  such  as  an  aggressive  growth  of  immature  cells  and  reduced  
differentiation.  Therefore,  it  is  possible  that  de  novo  AML  also  depends  on  Lis1  function.  
To  determine  whether  Lis1  is  required  for  the  development  of  AML,  we  took  advantage  
of  a  previously  established  mouse  model  of  AML  induced  by  co-­‐‑expression  of  human  
mixed-­‐‑lineage  leukemia  fusion  gene  (MLL-­‐‑AF9;  also  known  as  MLLT3)  and  
constitutively  active  NRAS  (NRASG12V)  (Zuber  et  al.  2009).  HSC-­‐‑enriched  cells  isolated  
from  either  untreated  Lis1f/f;  Rosa-­‐‑creER  or  Lis1+/+;  Rosa-­‐‑creER  control  mice  were  
retrovirally  co-­‐‑infected  with  MLL-­‐‑AF9  and  NRASG12V  and  subsequently  transplanted  
into  sub-­‐‑lethally  irradiated  recipients.  Seven  days  post-­‐‑transplantation,  recipient  mice  
were  administered  tamoxifen  or  corn  oil  daily  for  5  days.  While  all  control  mice  died  of  
leukemia  within  3  weeks,  only  ~40%  of  mice  transplanted  with  floxed  Lis1  cells  
developed  AML,  and  those  that  did  exhibited  a  longer  disease  latency  (Figure  44).  These  




Figure  44:  Loss  of  Lis1  impairs  establishment  of  de  novo  AML  in  vivo.  
Figure  44:  Impact  of  loss  of  Lis1  on  de  novo  AML.    KLS  cells  were  isolated  from  control  (Lis1+/+;  
Rosa-­‐‑creER)  and  Lis1f/f;  Rosa-­‐‑creER  mice  and  co-­‐‑transduced  with  MLL-­‐‑AF9-­‐‑GFP  and  NRASG12V-­‐‑
YFP  and  120,000  cells  were  transplanted  into  recipients.  Seven  days  post-­‐‑transplantation,  
recipients  were  administered  either  tamoxifen  or  corn  oil  daily  for  5  days  and  survival  was  
monitored.  Data  shown  are  from  two  experiments  (n=5  for  Lis1f/f  +tamoxifen  (black),  n=4  for  Lis1f/f  
+vehicle  (corn  oil)  (blue)  and  n=3  for  Lis1+/+  +tamoxifen  (green)).  
  
6.2.3 Lis1 plays a critical role in maintaining the undifferentiated state 
of leukemia cells. 
To  understand  the  cellular  and  molecular  impact  of  Lis1  deletion  on  
leukemogenesis,  we  used  the  bcCML  model  and  specifically  determined  if  the  in  vivo  
loss  of  Lis1  leads  to  accelerated  differentiation,  impairs  proliferation  and/or  triggers  cell  
death  of  leukemia  cells.  To  test  this,  established  bcCML  cells  with  Lis1f/f  alleles  were  
transplanted  into  secondary  recipients.  Fourteen  days  post-­‐‑transplantation,  recipient  
mice  were  given  tamoxifen  daily  for  5  days.  Interestingly,  one  day  post-­‐‑tamoxifen  
treatment,  the  most  notable  and  immediate  impact  of  Lis1  deletion  was  a  5-­‐‑fold  increase  
in  differentiated  leukemic  cells  (Figure  45a,b).    This  accelerated  differentiation  of  




















leukemia  cells  following  Lis1  deletion  was  accompanied  by  a  rise  in  Numb  levels  (Figure  
45c,d).  Thus,  similar  to  Lis1’s  role  in  normal  HSC  activity,  Lis1  plays  a  critical  role  in  
maintaining  the  undifferentiated  state  of  leukemia  cells.    
  
  
Figure  45:  Accelerated  differentiation  of  leukemia  cells  and  enhanced  Numb  levels  
following  Lis1  deletion.  
Figure  45:  a,  Representative  FACS  plots  show  frequency  of  bcCML  cells  expressing  lineage  
markers  in  control  (+/+)  or  Lis1-­‐‑deficient  (-­‐‑/-­‐‑)  populations  1  day  post-­‐‑tamoxifen  treatment.  b,  
Average  frequency  of  bcCML  cells  expressing  lineage  markers  (Lin+).  Data  shown  are  from  two  
independent  experiments  (n=4  for  +/+  and  n=6  for  -­‐‑/-­‐‑,  *p=0.0204).  c,  Representative  image  shows  
control  (+/+)  and  (-­‐‑/-­‐‑)  leukemia  cells  stained  with  anti-­‐‑Numb  antibody  (red)  and  DAPI  (blue),  63X.  
d,  Average  fluorescence  intensity  of  Numb  in  individual  bcCML  cells  (n=67  cells  each,  













































6.2.4 Impaired proliferation and late onset death of Lis1-deficient 
leukemia cells.  
To  determine  whether  Lis1-­‐‑deficient  leukemia  cells  not  only  prematurely  
differentiate  but  also  have  an  impaired  proliferative  ability,  we  performed  in  vivo  BrdU  
incorporation  assays.  Specifically,  established  bcCML  cells  carrying  Lis1  floxed  alleles  
were  transplanted  into  recipient  mice.  Fourteen  days  post-­‐‑transplantation,  recipient  
mice  were  given  tamoxifen  daily  for  5  days.  On  the  last  day  of  tamoxifen  treatment,  mice  
were  administered  BrdU  and  following  an  18-­‐‑hour  chase  period  leukemia  cells  were  
analyzed.  No  difference  in  proliferation  was  observed  between  the  immature  (lineage  
negative;  Lin-­‐‑)  and  mature  (lineage  positive;  Lin+)  compartments  (Figure  46b-­‐‑d).  These  
data  suggest  that  the  increase  in  differentiated  leukemia  cells  observed  following  Lis1  
deletion  is  not  due  to  a  preferential  proliferation  defect  of  immature  cells.  However,  as  
shown  in  Figure  46a-­‐‑c,  Lis1  loss  led  to  a  slight  1.5-­‐‑fold  reduction  in  proliferation  in  both  
cell  compartments;  thus  the  differentiation  and  proliferation  defect  may  act  in  concert  to  
lead  to  the  deep  defects  observed  in  leukemogenesis.    
To  determine  whether  the  loss  of  Lis1  in  bCML  cells  resulted  in  an  increase  in  
cell  death  we  stained  cells  for  AnnexinV  and  found  that  consistent  with  what  was  
observed  in  normal  hematopoiesis,  the  loss  of  Lis1  did  not  lead  to  any  significant  defects  
in  apoptosis  at  early  time  points  (Figure  46e).  However,  the  loss  of  Lis1  did  lead  to  a  
two-­‐‑fold  increase  in  apoptosis  in  conjugation  with  a  more  pronounced  impairment  of  
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proliferation  at  later  time  points.  Specifically,  when  cell  death  and  BrdU  incorporation  
assays  were  conducted  5  days  post-­‐‑tamoxifen,  we  found  that  Lis1-­‐‑deficient  bcCML  
lineage  negative  cells  display  an  ~3-­‐‑fold  reduction  in  BrdU  incorporation  and  a  
concomitant  ~2-­‐‑fold  increase  in  the  percentage  of  cells  positive  for  AnnexinV  (Figure  
46f-­‐‑h).  Collectively,  these  data  suggest  that  the  loss  of  Lis1  prevents  bcCML-­‐‑propagating  
cells  from  establishing  and  maintaining  the  disease  state  initially  by  triggering  their  
premature  differentiation  and  subsequently  halting  their  robust  proliferative  capacity  
and  inducing  their  late-­‐‑onset  death.  
  
































































































































































































Figure  46:  Impact  of  loss  of  Lis1  on  the  growth  and  survival  of  bcCML  cells.  40,000  lineage-­‐‑
negative  (Lin-­‐‑)  cells  from  established  control  Lis1+/+;  Rosa-­‐‑creER  or  Lis1f/f  ;  Rosa-­‐‑creER  bcCML  were  
transplanted  into  secondary  recipients.  Fourteen  days  post-­‐‑transplantation,  recipients  were  
administered  tamoxifen  daily  for  5  days.  On  the  last  day  of  treatment  or  5  days  post-­‐‑tamoxifen,  
mice  were  pulsed  with  5-­‐‑bromodeoxyuridine  (BrdU).    After  an  18  hr  chase  period,  bcCML  cells  
were  analyzed.  a,  Representative  BrdU/7AAD  plot  showing  cell  cycle  distribution  of  lineage-­‐‑
negative  (Lin-­‐‑)  bcCML  cells  1  day  post-­‐‑tamoxifen  treatment.  b,  Average  frequency  of  BrdU+  
lineage-­‐‑negative  (Lin-­‐‑)  bcCML  cells  1  day  post-­‐‑tamoxifen  treatment  (n=3  for  +/+  and  n=6  for  -­‐‑/-­‐‑,  
*p=0.0154).    c,  Average  frequency  of  BrdU+  lineage-­‐‑positive  (Lin+)  bcCML  cells  1  day  post-­‐‑
tamoxifen  treatment  (n=3  for  +/+  and  n=6  for  -­‐‑/-­‐‑,  *p=0.0171).  d,  The  relative  fold  change  ((+/+)/(-­‐‑/-­‐‑))  
of  the  percentage  of  BrdU+  cells  from  lineage-­‐‑negative  (Lin-­‐‑)  or  lineage-­‐‑positive  (Lin+)  bcCML  
cells  1  day  post-­‐‑tamoxifen  treatment.  e,  Average  frequency  of  AnnexinV+  lineage-­‐‑negative  (Lin-­‐‑)  
bcCML  cells  1  day  post-­‐‑tamoxifen  treatment  (n=4  for  +/+  and  n=6  for  -­‐‑/-­‐‑).  f,  Representative  
BrdU/7AAD  plot  showing  cell  cycle  status  of  lineage-­‐‑negative  (Lin-­‐‑)  bcCML  cells  5  days  post-­‐‑
tamoxifen  treatment.  g,  Percentage  of  BrdU+  lineage-­‐‑negative  (Lin-­‐‑)  bcCML  cells  5  day  post-­‐‑
tamoxifen  treatment  (n=7  for  +/+  and  n=4  for  -­‐‑/-­‐‑,  **p=0.0040).  h,  Percentage  of  AnnexinV+  lineage-­‐‑
negative  (Lin-­‐‑)  bcCML  cells  5  days  post-­‐‑tamoxifen  treatment  (n=7  for  +/+  and  n=4  for  -­‐‑/-­‐‑,  
*p=0.0309).  Error  bars  represent  the  standard  error  of  mean  (SEM).  
 
6.2.5 Loss of Lis1 alters the expression of  genes implicated in 
regulating leukemic development.  
To  gain  molecular  insight  into  how  Lis1  loss  may  lead  to  defects  in  leukemia  
formation  we  focused  on  genes  that  were  altered  in  the  normal  stem  cell-­‐‑enriched  
fraction  but  have  also  been  implicated  in  regulating  leukemogenesis.  Of  these,  Pml  and  
Msi2  were  significantly  downregulated,  and  Socs3  was  upregulated  based  on  
quantitative  PCR  analysis  (Figure  47).  These  data  suggest  that  these  downstream  players  
may  in  part,  mediate  the  defects  observed.    
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Figure  47:  Loss  of  Lis1  leads  to  altered  expression  of  genes  implicated  in  leukemia  
maintenance  and  propagation.  
Figure  47:  Gene  expression  changes  in  Lis1-­‐‑deficient  established  blast  crisis  CML  cells.  40,000  
lineage-­‐‑negative  (Lin-­‐‑)  cells  from  established  control  Lis1+/+;  Rosa-­‐‑creER  or  Lis1f/f;  Rosa-­‐‑creER  
bcCML  were  transplanted  into  recipient  mice.  Fourteen  days  post-­‐‑transplantation,  recipients  
were  administered  tamoxifen  daily  for  5  days  and  5  days  post-­‐‑tamoxifen  treatment,  RNA  
samples  were  isolated  from  lineage-­‐‑negative  (Lin-­‐‑)  leukemia  cells  of  recipient  mice.  Lis1,  Msi2,  
Pml,  and  Socs3  expression  in  Lin-­‐‑  control  (+/+)  and  (-­‐‑/-­‐‑)  leukemia  cells;  n=2,  *p=0.020  for  Lis1,  
*p=0.205  for  Msi2  and  *p=0.0415  for  Pml.    For  realtime  PCR,  expression  levels  were  normalized  to  
the  level  of  beta-­‐‑2  microglobulin  and  displayed  relative  to  the  control.  Error  bars  represent  the  
standard  error  of  the  mean  (SEM).    
6.2.6 LIS1 plays a critical role in sustaining human leukemic growth. 
To  test  whether  Lis1  was  also  required  for  human  myeloid  leukemia,  we  deleted  
Lis1  in  both  cell  lines  and  primary  patient  samples.  Both  K562,  a  bcCML  cell  line,  and  
MV411,  a  de  novo  AML  cell  line,  were  infected  with  shRNA  targeting  LIS1  and  colony-­‐‑
forming  ability  was  measured.  As  shown  in  Figure  48,  we  confirmed  effective  





























































































Figure  48:  Efficient  shRNA  knockdown  of  LIS1  in  human  leukemia  cell  lines.  
Figure  48:  a-­‐‑b,    Realtime  RT-­‐‑PCR  analysis  of  LIS1  mRNA  expression  in    a,  K562  blast  crisis  CML  
cells  b,  MV4-­‐‑11  AML  cells  following  transduction  with  either  firefly  luciferase  shRNA  as  a  
control  (shLuc)  or  LIS1  shRNA  (shLIS1).  Expression  levels  were  normalized  to  beta-­‐‑2-­‐‑
microglobulin  and  displayed  relative  to  the  control  arbitrarily  set  at  1.  Error  bars  represent  
standard  error  of  the  mean  (SEM)  of  triplicate  PCRs.  c,  Resorted  K562  blast  crisis  CML  cells  were  
analyzed  by  western  blot;  shLIS1-­‐‑(592)  and  shLIS1-­‐‑(1191)  represent  two  independent  hairpin  
shRNA  targeting  LIS1.  
  
Effective  knockdown  of  LIS1  lead  to  a  significant  reduction  in  colony-­‐‑forming  
ability  of  both  cell  lines  (Figure  49).    
  
Figure  49:  shRNA-­‐‑mediated  knockdown  of  LIS1  impairs  colony-­‐‑forming  ability  of  








































































































































Figure  49:  Influence  of  Lis1  on  human  leukemia  growth.  Human  leukemia  cells  were  infected  
with  either  control  (shLuc)  or  lentiviral  shRNA  targeting  human  LIS1  (shLIS1).    Subsequently  
infected  cells  were  sorted  and  plated  in  methylcellulose.  Colony  formation  was  assessed  in  K562  
blast  crisis  CML  cells  (a),  MV4-­‐‑11  AML  cells  (b);  *p<0.05,  **p<0.01,  ***p<0.001.  Error  bars  represent  
standard  error  of  the  mean  (SEM).    
  
To  demonstrate  that  the  observed  effects  of  the  shLIS1  are  not  the  result  of  off-­‐‑
target  effects,  we  used  an  independent  LIS1  shRNA  and  show  a  similar  response  (Figure  
50a-­‐‑d).  In  addition,  shLIS1-­‐‑mediated  reduction  in  colony  formation  was  completely  
rescued  by  introducing  a  shRNA-­‐‑resistant  mutant  LIS1,  further  suggesting  the  observed  
effects  of  the  shLIS1  were  not  the  result  of  off-­‐‑target  effects  (Figure  50e,f).      
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Figure  50:  LIS1  inhibition  via  an  independent  shRNA  construct.  
Figure  50:  a-­‐‑d,  Human  leukemia  cells  were  infected  with  either  control  (shLuc)  or  lentiviral  
shRNA  targeting  human  LIS1  (shLIS1):  shLIS1-­‐‑(1191)  represent  an  independent  hairpin  shRNA  
targeting  LIS1.  a-­‐‑b,  Resorted  K562  blast  crisis  CML  cells  (a)  and  MV4-­‐‑11  AML  cells  (b)  were  
analyzed  by  realtime  RT-­‐‑PCR  for  LIS1  expression.  Error  bars  represent  the  standard  error  of  the  
mean  (SEM)  of  triplicate  PCRs.  c-­‐‑d,  Reduction  of  colony  formation  of  K562  cells  (c)  and  MV4-­‐‑11  
(d)  by  shLIS1-­‐‑(1191)  (n=2  for  each  cell  type;  ****p<0.0001.  e,  LIS1  expression  levels  in  samples  
expressing  the  indicated  constructs.  LIS1  mut:  shLIS1-­‐‑resistant  LIS1  mutant  cDNA.  Error  bars  
represent  SEM  of  triplicate  PCRs.  ***p=0.0002.  f,  Rescue  of  shLIS1-­‐‑mediated  reduction  of  colony-­‐‑
forming  ability  with  expression  of  shLIS1-­‐‑resistant  LIS1  mutant  cDNA.  K562  blast  crisis  CML  
cells  were  transduced  retrovirally  with  either  Vector  control  or  LIS1  mutant  together  with  the  
indicated  shRNA  constructs,  sorted  and  plated  in  methylcellulose  media  for  colony  formation.  





























































































































































































To  test  if  LIS1  function  may  be  relevant  for  primary  human  leukemia  growth,  
primary  patient-­‐‑derived  CD34+  bcCML  cells  that  were  triple  resistant  to  the  tyrosine  
kinase  inhibitors  imatinib,  nilotinib  and  dasatinib  as  we  as  primary  CD34+  AML  patient  
cells  harboring  the  frequently  therapy-­‐‑resistant  MLL-­‐‑AF9  translocation  were  infected  
with  shLIS1,  and  colony-­‐‑forming  ability  was  assessed.  As  shown  in  Figure  51,  inhibition  
of  LIS1  expression  led  to  a  significant  blockade  of  colony-­‐‑forming  ability  suggesting  that  
LIS1  plays  a  critical  role  in  sustaining  human  leukemic  growth.      
  
Figure  51:  Impaired  colony-­‐‑forming  ability  of  primary  human  leukemia  cells  in  the  
absence  of  LIS1.  
Figure  51:  a-­‐‑b,  Efficiency  of  shRNA  knockdown  of  LIS1  in  primary  human  leukemia.  a-­‐‑b,  
Realtime  RT-­‐‑PCR  analysis  of  LIS1  mRNA  expression  in  a,  human  primary  CD34+  bcCML  and  b,  
human  primary  CD34+  AML  following  transduction  with  either  firefly  luciferase  shRNA  as  a  
control  (shLuc)  or  LIS1  shRNA  (shLIS1).  Expression  levels  were  normalized  to  beta-­‐‑2-­‐‑
microglobulin  and  displayed  relative  to  the  control  arbitrarily  set  at  1.  c-­‐‑d,  Influence  of  LIS1  on  
human  leukemia  growth.  Colony  formation  was  assessed  in  Imatinib,  Nilotinib  and  Dastinib-­‐‑
resistant  human  primary  CD34+  bcCML  (c)  and  human  primary  CD34+  AML  (d);  *p<0.05,  **p<0.01,  



















































































































We  report  here  that  the  asymmetric  division  regulator  Lis1  is  critical  for  the  
aberrant  cell  growth  that  occurs  in  myeloid  leukemia.  Using  a  mouse  model  of  blast-­‐‑
crisis  CML  (bcCML),  we  show  that  deletion  of  Lis1  prevents  disease  initiation  and  
progression.  In  the  context  of  bcCML,  it  has  been  shown  that  only  the  immature  fraction  
(cells  bereft  of  mature  lineage  markers;  Lin-­‐‑  cells)  of  the  leukemia  cell  population  can  
successfully  establish  and  propagate  the  disease  in  secondary  recipients  (Dash  et  al.  
2002;  Mayotte  et  al.  2002;  Neering  et  al.  2007).  Interestingly,  Lis1-­‐‑deficient  bcCML-­‐‑
propagating  cells  (Lin-­‐‑)  fail  to  establish  and  propagate  the  disease  in  secondary  
recipients;  even  deletion  of  Lis1  at  later  stages  of  myeloid  leukemia,  when  tumor  burden  
is  at  ~25%  of  the  peripheral  blood  population,  results  in  complete  reversion  to  normal  
cell  counts  and  resolution  of  disease.  Since  in  the  clinical  setting,  most  cancers  are  
discovered  only  when  the  tumor  is  either  palpable  or  at  a  size  amendable  to  detection,  
treatments  are  usually  initiated  at  a  time  when  the  disease  is  already  well  advanced.  The  
finding  that  Lis1  loss  even  at  later  stages  of  the  disease  nearly  eradicates  the  cancer,  
underscores  Lis1  as  an  attractive  therapeutic  target.    
The  essential  requirement  for  Lis1  in  disease  initiation  extends  to  de  novo  AMLs  
as  well.  Cells  transformed  with  MLL-­‐‑AF9  and  constitutively  active  NRAS  give  rise  to  an  
aggressive  AML-­‐‑like  disease  state  (Zuber  et  al.  2009),  which  fails  to  occur  in  the  absence  
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of  Lis1.  These  data  suggest  that  Lis1  is  broadly  required  for  the  development  of  
aggressive  undifferentiated  myeloid  leukemias.    
  Both  blast  crisis  phase  CML  and  the  majority  of  de  novo  AML  share  similar  
disease  characteristics  such  as  an  aggressive  growth  of  immature  cells  and  reduced  
differentiation.  Progression  and  continually  propagation  of  the  disease,  therefore,  may  
require  maintenance  of  the  undifferentiated  state.  Indeed,  the  most  notable  and  
immediate  impact  of  Lis1  deletion  is  a  significant  increase  in  differentiated  leukemia  
cells.  These  data  suggest  that  the  forced  differentiation  of  leukemic  cells  following  the  
loss  of  Lis1  may  be  the  underlying  reason  the  disease  fails  to  establish  or  propagate  in  
the  absence  of  Lis1.  In  addition  to  differentiation  defects,  we  found  that  loss  of  Lis1  also  
lead  to  reduced  proliferative  capacity  and  an  increase  in  cell  death  of  leukemia  cells,  
suggesting  that  the  differentiation,  proliferation  and  death  defects  may  act  in  concert  to  
lead  to  the  deep  defects  observed  in  leukemogenesis.    
Importantly,  a  role  for  Lis1  in  leukemia  is  not  limited  to  our  mouse  model  
systems.  We  found  that  inhibition  of  LIS1  expression  lead  to  a  significant  blockade  of  
colony-­‐‑forming  ability  of  both  human  leukemia  cell  lines  and  primary,  therapy-­‐‑resistant  
human  patient  samples,  suggesting  that  LIS1  plays  an  important  role  in  sustaining  
human  leukemic  growth.      
Signals  that  are  important  in  development  are  often  critical  in  cancer.  This  has  
been  demonstrated  for  genes  such  as  PML  and  Foxo3a  (Ito  et  al.  2008;  Miyamoto  et  al.  
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2007;  Naka  et  al.  2010).  Here  we  show  that,  in  addition  to  a  requirement  of  Lis1  in  
normal  hematopoietic  stem  cell  self-­‐‑renewal,  Lis1  is  also  required  for  aberrant  self-­‐‑
renewal  in  cancer.            
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7. Conclusions and perspectives  
7.1 Lis1 plays a critical role in blood development and in HSC 
self-renewal in both fetal and adult life by regulating asymmetric 
cell division. 
During  embryonic  development,  hematopoietic  stem  cells  (HSCs)  are  generated  
de  novo  in  numerous  anatomical  sites  including  the  yolk  sac  and  placenta  but  primarily  
self-­‐‑renewal  and  differentiate  within  the  fetal  liver.  Late  in  development,  hematopoietic  
activity  moves  to  the  bone  marrow,  where  HSCs  reside  in  specialized  
microenvironments  (Mikkola  and  Orkin  2006).    During  embryogenesis  and  adult  life,  an  
elaborate  interplay  of  extrinsic  and  intrinsic  mechanisms  controls  the  balance  between  
HSC  self-­‐‑renewal  and  differentiation.  Proper  control  of  this  balance  is  critical  during  
development  to  ensure  that  enough  stem  cells  are  generated  for  postnatal  life  and  for  the  
production  of  differentiated  cells  immediately  required  for  growth  and  development.  
Furthermore,  in  adult  life,  tight  regulation  of  this  balance  is  important  not  only  when  the  
body  replaces  cells  to  maintain  homeostasis,  but  also  after  hematopoietic  insult  when  a  
precipitous  rise  in  HSCs  is  required  for  effective  regeneration.    
Here  we  show  that  the  cell  fate  regulator  Lis1  plays  an  important  role  in  blood  
development  and  in  HSC  self-­‐‑renewal  in  both  fetal  and  adult  life.  Genetic  deletion  of  
Lis1  causes  a  significant  suppression  of  fetal  HSC  expansion  and  thus  leads  to  a  near  
bloodless  embryo  and  lethality  before  birth.  Such  an  impact  on  fetal  hematopoiesis  has  
been  previously  reported  mainly  for  key  transcription  factors  such  Runx1/Aml1,  Scl/Tal-­‐‑
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1  and  Gata2  (Okuda  et  al.  1996;  Porcher  et  al.  1996;  Tsai  et  al.  1994;  Wang  et  al.  1996).  The  
similarities  in  phenotype  suggest  the  possibility  that  cellular  and  molecular  events  
controlled  by  Lis1  activity  may  be  integrated  with  the  function  of  these  transcription  
factors.  It  is  also  important  to  note  that  the  drastic  impact  to  the  fetal  HSC  compartment  
following  Lis1  deletion  is  consistent  with  the  phenotype  previously  reported  in  neuronal  
development,  where  following  neural-­‐‑specific  deletion  of  Lis1,  there  is  a  profound  
disruption  of  stem  cell  expansion,  resulting  in  a  catastrophic  phenotype  (Yingling  et  al.  
2008).  That  loss  of  Lis1  has  such  an  affect  on  the  stem  cell  compartments  in  a  variety  of  
tissues,  suggest  that  Lis1  may  have  a  broad  role  in  stem  cell  renewal  during  
development.        
  The  identification  of  numerous  developmental-­‐‑stage  specific  regulators  of  HSC  
self-­‐‑renewal,  such  as  Sox17,  Meis1  and  Rae28  suggest  that  self-­‐‑renewal  mechanisms  
employed  by  HSCs  might  be  distinct  or  shared  between  HSCs  derived  from  the  fetal  
liver  and  from  that  of  the  adult  bone  marrow  (Kim  et  al.  2007).  While  an  understanding  
of  how  HSC  self-­‐‑renewal  is  regulated  during  development  is  important,  the  
identification  of  regulators  and  mechanisms  that  specifically  control  (or  also  control)  
adult  HSC  self-­‐‑renewal  may  be  more  relevant  and  critical  for  the  development  of  novel  
regenerative  therapies  and  treatments  aimed  at  reigning  in  leukemia  stem  cells.    
Using  a  tamoxifen-­‐‑inducible  cre  system,  we  deleted  Lis1  in  the  adult  blood  
system  and  found  that  loss  of  Lis1  in  adult  life  led  to  a  significant  reduction  in  the  
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frequency  and  absolute  number  of  HSCs.  In  addition,  in  a  transplantation-­‐‑based  assay,  
Lis1-­‐‑deficient  adult  HSCs  failed  to  effectively  repopulate  the  blood  compartment  of  
lethally  irradiated  recipient  mice,  suggesting  a  critical  role  for  Lis1  in  adult  HSC  self-­‐‑
renewal  activity  in  vivo.  To  determine  whether  Lis1  was  cell-­‐‑autonomously  required  for  
adult  HSC  function,  we  generated  Lis1  chimera  mice  (i.e.  wild-­‐‑type  microenvironment)  
and  found  that  blood-­‐‑specific  deletion  of  Lis1  led  to  a  significant  reduction  in  HSC-­‐‑
enriched  cells,  suggesting  Lis1  plays  a  role  in  HSC  self-­‐‑renewal  activity  in  a  cell-­‐‑
autonomous  manner.    Collectively,  these  data  underscores  Lis1’s  critical  role  in  HSC  
activity  in  both  fetal  and  adult  life.    
What  is  the  mechanism  by  which  Lis1  influences  HSC  self-­‐‑renewal?  A  well-­‐‑
characterized  functional  role  of  Lis1  is  being  a  facultative  regulator  of  the  minus-­‐‑end  
directed  motor  protein  dynein  (Lee  et  al.  2003;  Lei  and  Warrior  2000).  In  this  context,  
Lis1  has  been  linked  to  several  cell  division  events  that  require  dynein  function.  In  a  
variety  of  cell  types  including  neural  progenitor  cells  and  cultured  epithelial  cells,  
perturbations  in  Lis1  expression  results  in  mitotic  defects  and  impaired  cell  cycle  
progression  that  in  some  instances  subsequently  leads  to  increased  apoptotic  death  
(Faulkner  et  al.  2000;  Tsai  et  al.  2005;  Yingling  et  al.  2008).  Here  we  show  that  cell  cycle  
status  and  survival  of  HSCs  are  largely  unaffected  in  the  absence  of  Lis1.  However,  we  
do  see  an  increase  in  the  frequency  of  late  apoptotic/necrotic  cells  in  the  absence  of  Lis1.  
Furthermore,  we  find  that  loss  of  Lis1  in  cultured  HSCs  results  in  a  slight  increase  in  the  
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frequencies  of  aneuploid  and  polyploid  cells.  These  data  suggest  that  both  elevated  HSC  
death  and  increased  acquisition  of  polyploidy  and/or  aneuploidy  may  contribute  to  the  
deep  phenotype  that  manifest  following  Lis1  deletion.    
The  profound  loss  of  the  immature  cell  population  in  both  fetal  and  adult  blood,  
suggested  a  potential  defect  in  maintenance  of  the  undifferentiated  state.  Intriguingly,  
by  tracking  the  actual  rate  of  differentiation  of  cultured  HSCs,  we  found  that  loss  of  Lis1  
led  to  accelerated  differentiation  of  these  cells  in  vitro.  In  support  of  this,  a  wave  of  
premature  HSC  differentiation  accompanied  the  loss  of  Lis1  in  vivo.  These  data  suggest  
that  mechanisms  that  control  HSC  self-­‐‑renewal  and  maintain  the  stem  cell  state  may  be  
dysfunctional  or  ineffective  in  the  absence  of  Lis1.  Interestingly,  genome  wide  
expression  analysis  of  wild  type  and  Lis1-­‐‑deficient  HSC-­‐‑enriched  cells  demonstrated  a  
significant  loss  of  core  genes  that  form  the  stem  cell  signature,  as  well  as  elevated  levels  
of  pro-­‐‑differentiation  genes  such  as  Socs3  and  CD48.  These  data  further  confirm,  through  
an  independent  molecular  approach,  that  Lis1  function  is  important  to  maintain  the  
stem  cell  state.  
In  other  stem  cell  systems,  including  those  of  Caenorhabditis  elegan  and  Drosophila  
melanogaster,  asymmetric  cell  division  represents  one  of  the  critical  mechanisms  of  self-­‐‑
renewal  regulation.  Intriguingly,  Lis1  has  been  implicated  in  the  machinery  controlling  
division  pattern  in  these  systems  (Siller  and  Doe  2009).  Whether  HSCs  undergo  
asymmetric  division  to  facilitate  the  balance  between  self-­‐‑renewal  and  differentiation  
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has  been  difficult  to  address  largely  due  to  the  absence  of  a  marker  that  unambiguously  
distinguishes  HSCs  from  differentiating  daughter  cells.    Recently,  using  a  transgenic  
reporter-­‐‑based  system,  where  GFP  marks  stem  cells  and  is  lost  as  cells  differentiate,  we  
showed  that  HSCs  have  the  capacity  to  undergo  both  asymmetric  and  symmetric  
division  (Wu  et  al.  2007).  These  data  suggest  that,  similar  to  other  stem  cell  systems,  
asymmetric  division  may  serve  as  an  important  mechanism  of  self-­‐‑renewal  regulation  in  
the  hematopoietic  system.    
Because  accelerated  differentiation  can  be  a  consequence  of  defects  in  
asymmetric  division,  we  tested  whether  the  loss  of  Lis1  had  an  impact  on  this  specific  
renewal  mechanism.  Previously,  we  found  that  differential  cell  fate  of  paired  daughter  
cells  correlated  with  the  asymmetric  acquisition  of  the  Numb  protein,  a  known  
asymmetric  cell  fate  determinant  in  other  cell  types  (Wu  et  al.  2007).  We  thus  specifically  
tracked  the  polarization  and  inheritance  of  Numb  and  found  that  while  the  polarization  
of  Numb  was  unaffected  in  the  absence  of  Lis1,  the  loss  of  Lis1  led  to  a  complete  reversal  
of  the  pattern  of  Numb  inheritance  both  in  vitro  and  in  vivo.  In  contrast  to  wild  type  cells,  
which  preferentially  undergo  symmetric  renewal  division,  Lis1-­‐‑deficient  cells  
predominately  undergo  asymmetric  cell  division,  and  only  rarely  symmetrically  divide.  
Since  an  increase  in  asymmetric  division  would  generate  more  differentiated  cells  over  
time,  the  predominance  of  asymmetry  in  the  absence  of  Lis1  may  explain  the  observed  
accelerated  differentiation  defect.    
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As  a  potential  mechanism  that  may  underlie  the  increased  inheritance  of  Numb  
and  a  marked  imbalance  of  asymmetric  and  symmetric  divisions,  we  show  that  loss  of  
Lis1  leads  to  defective  spindle  positioning  during  HSC  division.  Specifically,  while  wild  
type  cells  effectively  direct  the  position  of  their  spindles  in  such  a  way  to  facilitate  equal  
inheritance  of  Numb  by  the  two  incipient  daughter  cells,  Lis1-­‐‑deficient  cells  ineffectively  
direct  the  position  of  their  spindles,  thus  causing  changes  in  the  cleavage  plane.  These  
changes  in  cleavage  plane  undoubtedly  increases  the  likelihood  that  Numb  will  be  
differentially  inherited  by  the  two  daughter  cells.  Collectively,  these  data  suggest  that  
the  premature  differentiation  and  HSC  loss  observed  in  the  absence  of  Lis1  is  primarily  
due  to  spindle  orientation  defects  that  drive  increased  asymmetric  inheritance  of  Numb.  
In  this  context,  our  findings  identify  Lis1  as  a  key  component  of  the  molecular  
machinery  that  directs  asymmetric  division  in  hematopoietic  stem  cells  and  provides  the  
first  genetic  proof  for  the  requirement  of  a  proper  balance  of  asymmetric  division  and  its  
regulators  for  hematopoiesis  in  vivo.  These  data  raise  the  possibility  that  the  position  and  
orientation  of  the  immature  hematopoietic  cells  within  its  microenvironment  may  be  
critically  important  in  directing  self-­‐‑renewal  and  differentiation  and  indicates  that  
environmental  cues  may  specify  the  plane  of  division  of  hematopoietic  cells  through  
Lis1.      
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7.2 The asymmetric division regulator Lis1 is critically required 
for malignant hematopoietic development.  
Elucidating  the  basis  of  maintenance  of  the  undifferentiated  state  in  normal  
HSCs  is  important  because  it  may  allow  an  understanding  of  mechanisms  that  underlie  
the  blockade  of  differentiation,  a  hallmark  of  many  cancers  such  as  glioblastoma,  breast  
cancer  and  leukemias  (Calabretta  and  Perrotti  2004;  Maher  et  al.  2001;  Stingl  and  Caldas  
2007).  Under  normal  conditions,  the  ability  of  HSCs  to  undergo  different  modes  of  
division  (symmetric  or  asymmetric  cell  division)  allows  for  effective  modulation  of  the  
balance  between  HSC  self-­‐‑renewal  and  differentiation.    Thus,  asymmetric  cell  division  
represents  one  of  the  critical  mechanisms  of  self-­‐‑renewal  regulation  in  normal  HSCs.  
Interestingly,  in  the  context  of  oncogenesis,  we  recently  showed  that  certain  oncogenes  
promote  leukemia  development  by  subverting  the  normal  balance  of  asymmetric  and  
symmetric  division.  Specifically,  whereas  BCR-­‐‑ABL,  the  hallmark  genetic  abnormality  in  
CML,  cannot  affect  the  choice  between  asymmetric  and  symmetric  division,  NUP98-­‐‑
HOXA9,  an  oncogene  associated  with  aggressive,  undifferentiated  blast  crisis  CML,  
shifts  the  normal  balance  of  asymmetric  and  symmetric  division  towards  symmetric  
renewal  divisions  (Wu  et  al.  2007).  These  data  suggest  that  dysregulation  of  HSC  
division  pattern  may,  in  part,  be  responsible  for  the  failure  of  differentiation  that  occurs  
during  disease  progression      
Intriguingly,  emerging  studies  indicate  that  the  presence  and  dysregulated  
expression  of  fate  determinants  and  asymmetric  division  regulators  may  be  important  
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elements  of  the  induction  and/or  propagation  of  cancers  that  become  increasingly  
undifferentiated  during  progression.  In  the  context  of  leukemia,  the  cell  fate  
determinants  Musashi  (Msi2)  and  Numb  have  been  implicated  in  CML  disease  
progression  (Ito  et  al.  2010;  Kharas  et  al.  2010),  Prox1  (Drosophila  Prospero)  mutations  
have  been  reported  in  several  primary  leukemia  samples  and  cell  lines  (Nagai  et  al.  
2003),  and  repression  of  the  polarity  protein  Llgl1  has  been  shown  to  be  associated  with  
human  leukemia  development  (Heidel  et  al.  2013).    
We  now  show,  using  mouse  models  of  blast  crisis  CML  and  de  novo  AML,  that  
the  asymmetric  division  regulator  Lis1  is  critically  required  for  the  initiation  and  
maintenance  of  these  hematopoietic  malignancies.  For  both  diseases,  only  ~30%  of  mice  
(compared  to  100%  in  control  groups)  developed  leukemia  when  Lis1  was  deleted  
during  initiation.  Importantly,  those  that  did  succumb  to  leukemia  exhibited  longer  
disease  latency.  Remarkably,  deletion  of  Lis1  at  late  stages  of  blast  crisis  CML  results  in  
complete  reversion  to  normal  blood  cell  counts  and  resolution  of  disease.  These  data  
strongly  imply  that  Lis1  inhibitors  may  be  attractive  candidates  for  a  novel  molecular  
target  therapy  in  hematological  malignancies.  In  support  of  this,  inhibition  of  LIS1  
expression  in  primary  human  leukemias  that  are  resistant  to  current  and  conventional  
therapy  led  to  a  significant  blockade  of  colony-­‐‑forming  ability,  highlighting  a  critical  
requirement  for  LIS1  in  the  growth  of  human  leukemias.      
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Similar  to  the  basis  of  the  defects  observed  in  normal  HSCs  in  the  absence  of  
Lis1,  we  find  that  the  immediate  impact  of  loss  of  Lis1  in  leukemia  is  increased  
differentiation  of  immature  lineage  negative  cells,  a  population  that  harbors  leukemia  
stem  cells  (Neering  et  al.  2007).  This  increase  in  differentiation  is  not  due  to  changes  in  
viability  or  proliferation  within  the  immature  population.  However,  overtime,  the  loss  of  
Lis1  does  lead  to  defects  in  proliferation  and  apoptosis.  Thus,  these  late-­‐‑onset  defects  in  
conjunction  with  increases  in  differentiation  may  act  together  to  lead  to  the  deep  defect  
observed  in  leukemogenesis.  Importantly  though,  the  increased  propensity  for  Lis1-­‐‑
deficient  leukemia  stem  cells  to  differentiate  is  suggestive  that  the  observed  defects  in  
disease  propagation  and  sustainability  may  be  due,  at  least  in  part,  to  a  shift  toward  pro-­‐‑
differentiation  divisions,  as  opposed  to  perpetual  self-­‐‑renewal  divisions.      
Fate  determinants,  such  as  Numb  and  Msi2  have  recently  been  shown  to  play  a  
role  in  the  onset  and  or/propagation  of  several  cancers,  including  leukemia  (Ito  et  al.  
2010;  Pece  et  al.  2004).  Our  work  now  shows  that  regulatory  mechanisms  that  direct  the  
inheritance  of  these  determinants  are  equally  important  for  the  establishment  and  
continued  propagation  of  malignancies.  Previous  studies  have  shown  that  loss  of  
asymmetric  division  proteins  including  Brat,  Prospero  and  Numb  can  trigger  tumor  
formation  in  Drosophila  neuroblasts  (Bello  et  al.  2006;  Betschinger  et  al.  2006;  Caussinus  
and  Gonzalez  2005;  Lee  et  al.  2006a;  Lee  et  al.  2006b;  Wang  et  al.  2006).  Using  mouse  
models  and  patient  samples  of  leukemias  that  are  resistant  to  therapy  in  the  clinic,  our  
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data  is  the  first  to  link  Lis1  and  the  machinery  regulating  determinant  inheritance  with  
mammalian  oncogenesis  and  thus  provide  an  important  complement  to  studies  in  
Drosophila.  This  raises  the  possibility  that  modulators  of  determinant  inheritance  could  
serve  as  a  powerful  new  class  of  regulators  of  cancer  growth  and  that  further  work  in  

















Supplementary  Movie  1:  Imaging  Cell  Division  in  Real  Time.  Cells  were  co-­‐‑infected  
with  H2B-­‐‑GFP  and  mCherry-­‐‑α-­‐‑tubulin  fusion  constructs  and  imaged  over  time.  
Representative  movies  showing  A.  HeLa  cell,  B.  M1  Cell,  and  C.  Primary  Hematopoietic  
Stem  &  Progenitor  Cells  undergoing  cell  division  (H2B-­‐‑GFP  is  shown  in  green  and  α-­‐‑
tubulin  is  shown  in  magenta).    
  
Supplementary  Movie  2:  Symmetric  inheritance  of  Numb  
HSC-­‐‑enriched   cells   (KLS)   were   co-­‐‑infected   with   Numb-­‐‑CFP   and   mCherry-­‐‑α-­‐‑tubulin  
fusion   constructs   and   imaged   overtime.   Representative   movie   showing   a   KLS   cell  
undergoing  a  symmetric  division   (Numb  is  shown  in  green  and  α-­‐‑tubulin   is  shown  in  
red).    
  
Supplementary  Movie  3:  Asymmetric  inheritance  of  Numb  
HSC-­‐‑enriched   cells   (KLS)   were   co-­‐‑infected   with   Numb-­‐‑CFP   and   mCherry-­‐‑α-­‐‑tubulin  
fusion   constructs   and   imaged   overtime.   Representative   movie   showing   a   KLS   cell  
undergoing  an  asymmetric  division  (Numb  is  shown  in  green  and  α-­‐‑tubulin  is  shown  in  
red).    
  
Supplementary  Movie  4:  Asymmetric  inheritance  of  Numb  
HSC-­‐‑enriched   cells   (KLS)   were   co-­‐‑infected   with   Numb-­‐‑YFP   and   mCherry-­‐‑α-­‐‑tubulin  
fusion   constructs   and   imaged   overtime.   Representative   movie   showing   a   KLS   cell  
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